

San Francisco

Spring Group Meeting



Three+ Glorious Days in San Francisco

Welcome to SWOG's spring 2025 group meeting!

As you are no doubt aware, we have consolidated our meeting schedule this spring into three days – Thursday through Saturday afternoon (plus a few business meetings late Wednesday). But this consolidation has not reduced the number of opportunities for learning about and contributing to our trials, both current and planned, or for professional development.

We've combined our former plenary I and plenary II into a unified general session on Friday afternoon, which will include two translational medicine speakers and two speakers on how we can better engage our community oncology practices and practitioners. In my plenary update, I'll also address how SWOG is facing up to some of the new challenges 2025 has brought to biomedical research.


As older patients are chronically underrepresented in cancer trials, we are hosting a Geriatric Oncology Symposium on Thursday which tackles that issue head on, with a focus on designing practical, evidence-driven trials for this population. Adolescents and young adults (AYAs) are at the other end of the age

spectrum, and our Take Action Symposium is dedicated to strategies for engaging these patients in our trials.

Other special sessions in San Francisco will include three devoted to new NCORP trials – a kickoff for the recently activated S2408 palliative care trial and information sessions for the soon-to-be-activated S2417CD and S2424CD cancer care delivery trials.

We'll also host the second Meyskens Lecture in cancer prevention, delivered this spring by Dr. Ian Thompson, Jr., our genitourinary committee chair emeritus. And this spring's CTP Update Forum will be a particularly exciting one, as it will highlight, among other opportunities, our activation of 21CTP.Leuk01, our first CTP study.

I hope you enjoy the meeting!



Charles D. Blanke, MD
SWOG Chair



Group Meeting Index

Chair's Welcome Message	2
Schedule of Events	4-6
Plenary Session	7
Top Accruers & Top Performing Sites	8-9
Funding & Career Development Opportunities	10
S2408 Kick-Off Session	11
Take Action Symposium	12
S2424CD Information Session	15
Geriatric Oncology Symposium	16
SWOG Clinical Trials Partnerships (CTP) Update Forum	17
S2417CD Information Session	18
ESITC Poster Session	19
Nicholas J. Vogelzang, MD GU Symposium	20
Frank and Linda Meyskens & Robert Livingston Lectures	21
Group Meeting App & CME Credit Information	22-24
SWOG Administrative & Research Support Committees	25
Future Meeting Dates	25
Adolescent and Young Adults Committee	26
Bone Marrow & Stem Cell Transplantation Committee	27
Clinical Trials Training Course	28
Digital Engagement Committee	29
Jeri & Noboru Oishi Symposium	30
Pharmaceutical Sciences & Drug Information Joint Meeting	31
Surgery Committee	32
SWOG Latin America Initiative Symposium	33
VA Committee	34-35
Committee Agendas and Accrual Reports	
Barlogie-Salmon Myeloma Committee	36-39
Breast Committee	40-46
Cancer Control & Prevention Committee Leadership	47-48
Cancer Care Delivery Committee	49-51
Early Therapeutics & Rare Cancers Committee	63-66
Gastrointestinal Committee	67-76
Genitourinary Committee	77-88
Immunotherapeutics Committee	89-90
Leukemia Committee	91-94
Lung Committee	95-104
Lymphoma Committee	105-108
Melanoma Committee	109-111
Palliative Care Committee	52-53
Prevention, Screening, and Surveillance Committee	54-56
Radiation Oncology Committee	112
Symptom Management and Survivorship Committee	57-62
SWOG Publications	113-119

SWOG 2025 Spring Programs

Atrium Level | Bay Level | Street Level | Pacific Concourse Level

SPRING PROGRAM-AT-A-GLANCE

REGISTRATION & INFORMATION DESK: GRAND BALLROOM FOYER, STREET LEVEL

WEDNESDAY: 4:00 PM - 6:00 PM

THURSDAY-FRIDAY: 6:30 AM - 5:00 PM

SATURDAY: 7:00 AM - 12:30 PM

HOPE FOUNDATION INFORMATION DESK: GRAND BALLROOM FOYER, STREET LEVEL

THURSDAY-FRIDAY: 8:00 AM - 5:00 PM

SATURDAY: 8:00 AM - 11:00 AM



EXHIBITS GRAND BALLROOM FOYER, STREET LEVEL

THURSDAY-FRIDAY:
8:00 AM - 5:00 PM

◀ GO TO THE MEETING APP ONLINE
swog.org/meetingappS25

WEDNESDAY, APRIL 30, 2025

		ROOM
4:30 PM–6:00 PM	Hope Foundation Board Meeting (Board Members Only)	PACIFIC F
6:00 PM–8:00 PM	Quality Initiative Meeting (Closed Business Meeting)	WATERFRONT AB
6:00 PM–8:30 PM	NCORP Research Base Executive Committee (Committee Members Only)	PACIFIC JK

THURSDAY, MAY 1, 2025

7:00 AM–7:20 AM	CRA Clinical Trials Training Course Check-In	GRAND BALLROOM FOYER
-----------------	--	----------------------

7:00 AM–7:50 AM	Leadership Council on Representation (Closed Business Meeting)	PACIFIC F
7:20 AM–12:00 PM	CRA Clinical Trials Training Course	GRAND BALLROOM A
7:55 AM–8:30 AM	Leadership Council on Representation Open Forum (All members welcome)	PACIFIC F
8:00 AM–10:00 AM	Palliative Care Committee	BAYVIEW ROOM
9:00 AM–11:00 AM	Early Therapeutics and Rare Cancers Committee	SEACLIFF AB
10:30 AM–12:30 PM	Cancer Care Delivery Committee	BAYVIEW ROOM
11:00 AM–12:30 PM	Digital Engagement Committee	PACIFIC HI
12:30 PM–2:00 PM	Site Operations	GARDEN ROOM
12:45 PM–1:45 PM	Geriatric Oncology Symposium: Enhancing Clinical Trials for Older Adults with Cancer	SEACLIFF AB
1:00 PM–3:00 PM	Leukemia Working Group (Working Group Members Only)	PACIFIC JK
1:30 PM–2:30 PM	S2424CD Information Session	PACIFIC HI
2:00 PM–3:30 PM	SWOG Tissue Banking Meeting (Closed Business Meeting)	WATERFRONT AB
2:00 PM–4:00 PM	Sarcoma Working Group of the Early Therapeutics Committee	PACIFIC F
2:00 PM–4:00 PM	Symptom Management and Survivorship Committee	BAYVIEW ROOM
2:00 PM–4:30 PM	Take Action Symposium	GRAND BALLROOM A
2:00 PM–5:00 PM	CRA Clinical Trials Training Course Practicum	GRAND BALLROOM BC

SWOG 2025 Spring Programs

THURSDAY, MAY 1, 2025 CONTINUED

2:30 PM–4:00 PM	Professional Review Committee (Closed Business Meeting)	PACIFIC D
3:00 PM–4:30 PM	Bone Marrow & Stem Cell Transplantation Committee	GARDEN ROOM
3:00 PM–5:00 PM	Radiation Oncology Committee	SEACLIFF CD
4:00 PM–6:00 PM	Immunotherapeutics Committee	SEACLIFF AB
4:30 PM–6:00 PM	VA Committee	PACIFIC HI
4:30 PM–6:30 PM	Prevention, Screening, and Surveillance Committee	BAYVIEW ROOM
5:00 PM–6:00 PM	Conflict Management Committee (Closed Business Meeting)	PACIFIC F
5:15 PM–7:15 PM	Leukemia Committee	GARDEN ROOM
5:30 PM–6:30 PM	Clinical Trials Partnerships Update Forum	GRAND BALLROOM A
5:30 PM–6:30 PM	S2408 Kick-Off	SEACLIFF CD
6:30 PM–8:00 PM	Early Therapeutics and Rare Cancers Committee Working Group Dinner Retreat (Invitation Only)	PACIFIC D
7:00 PM–9:00 PM	Breast Committee Social (Invitation Only)	WATERFRONT DE

FRIDAY, MAY 2, 2025











7:00 AM–8:00 AM	NCORP/MU-NCORP Site PI Meeting	GARDEN ROOM
7:00 AM–8:00 AM	Clinical Trials Partnerships Scientific Advisory Board (Closed Business Meeting)	PACIFIC D
7:00 AM–8:00 AM	Imaging Committee (Committee Mmbrs Only)	PACIFIC F

7:00 AM–8:30 AM	Lung-MAP Site Coordinators Meeting (Committee Mmbrs Only)	PACIFIC JK
7:30 AM–8:00 AM	Jeri & Noboru Oishi Symposium Check-In	BAYVIEW A FOYER
7:30 AM–10:30 AM	GU Working Group (Committee Mmbrs Only)	GRAND BALLROOM A
8:00 AM–10:30 AM	Jeri & Noboru Oishi Symposium	BAYVIEW ROOM
8:00 AM–11:30 AM	Breast Committee and TM Working Group (Working Group Members Only)	SEACLIFF AB
8:45 AM–9:45 AM	Lung-MAP Administrative Meeting (Committee Mmbrs Only)	PACIFIC JK
8:45 AM–12:15 PM	GI Committee and TM Working Group (Working Group Members Only)	GARDEN ROOM
9:00 AM–11:00 AM	Myeloma Working Group (Committee Members Only)	WATERFRONT AB
9:00 AM–11:00 AM	Pharmaceutical Sciences Committee and Drug Information Subcommittee	PACIFIC F
11:00 AM–12:30 PM	ORP Open Forum	PACIFIC L-0
11:30 AM–1:30 PM	Lung Working Group (Working Group Members Only)	SEACLIFF CD
11:30 AM–1:30 PM	Nursing Research and Advanced Practice Provider Subcommittee (Invitation Only)	PACIFIC F
11:30 AM–1:30 PM	Advocates Committee (Committee Mmbrs Only)	PACIFIC JK
11:45 AM–1:45 PM	Surgery Committee	PACIFIC HI
12:00 PM–1:30 PM	SWOG Latin America Initiative Symposium	BAYVIEW ROOM
12:30 PM–1:30 PM	S2417CD Information Session	SEACLIFF AB






SWOG 2025 Spring Programs







Atrium Level | Bay Level | Street Level | Pacific Concourse Level

FRIDAY, MAY 2, 2025 CONTINUED

1:00 PM–2:00 PM	25 Years of ESITC Poster Session	GRAND BALLROOM FOYER 
1:00 PM–2:00 PM	Plenary Reception	GRAND FOYER 
2:00 PM–4:00 PM	Plenary Session	GRAND BALLROOM 
4:15 PM–5:15 PM	Lung Community Engagement Subcommittee (Committee Members Only)	PACIFIC F 
4:15 PM–6:15 PM	Nicholas J. Vogelzang, MD GU Symposium	BAYVIEW ROOM 
4:15 PM–6:15 PM	Lung Radiation/Surgery Subcommittee (Committee Mmbrs Only)	PACIFIC JK 
4:30 PM–6:30 PM	GI Committee	GARDEN ROOM 
4:30 PM–6:30 PM	Barlogie-Salmon Myeloma Committee	PACIFIC HI 
4:30 PM–6:30 PM	Breast Committee	SEACLIFF BCD 
6:00 PM–7:00 PM	Executive Reception (Invitation Only)	
6:45 PM–8:30 PM	Group Reception	ATRIUM 

SATURDAY, MAY 3, 2025

7:00 AM–7:45 AM	Board of Governors (Board Members Only)	GRAND BALLROOM B 
8:00 AM–9:00 AM	Committee Chairs (Committee Chairs Only)	GRAND BALLROOM B 
8:00 AM–10:00 AM	Mentoring APPs (Invitation Only)	PACIFIC F 
9:00 AM–10:30 AM	Quality Assurance Committee (Committee Members Only)	PACIFIC D 
9:15 AM–10:45 AM	Adolescent and Young Adult (AYA) Committee	GARDEN ROOM 

9:30 AM–11:30 AM	GU Committee	GRAND BALLROOM A 
9:30 AM–11:30 AM	Lymphoma Working Group (Working Group Members Only)	PACIFIC JK 
9:30 AM–12:30 PM	Lung Committee	SEACLIFF BCD 
10:00 AM–12:00 PM	Melanoma Working Group (Working Group Members Only)	PACIFIC HI 
12:00 PM–2:00 PM	Lymphoma Committee	GARDEN ROOM 
12:30 PM–2:30 PM	Melanoma Committee	GRAND BALLROOM B 

We've Supported SWOG
for a Generation.
**Let's Make a Plan
for the Next.**

You can plant a seed for future generations of cancer researchers when you leave a gift in your will for The Hope Foundation.



SCAN THE
QR CODE
TO LEARN
MORE

THE HOPE
FOUNDATION
FOR CANCER RESEARCH

PLENARY

Enhancing Engagement: Bench, Bedside, and Beyond

FRIDAY, MAY 2 • 2 – 4 PM PT • GRAND BALLROOM / HYBRID



Chair's Welcome and Update

Charles D. Blanke, MD, FASCO, FAWM

SWOG Group Chair

Knight Cancer Institute, Oregon Health & Science University



Translational Medicine: Introduction

Lee M. Ellis, MD, FASCO, FACS

SWOG Vice-Chair for Translational Medicine

MD Anderson Cancer Center



Working Towards Personalized Treatment in Advanced Prostate Cancer: HOPE for the FUTURE

Paul G. Corn, MD, PhD

MD Anderson Cancer Center



TM at the SWOG Stat Center: A Peek Under the Hood

Michael C. Wu, PhD, FASA

Fred Hutch Cancer Center



Community Engagement: Introduction

Charles D. Blanke, MD, FASCO, FAWM

SWOG Group Chair

Knight Cancer Institute, Oregon Health & Science University



Engaging community practice oncologists and defining community oncology

Raymond U. Osarogiagbon, MD

Baptist Cancer Center



Increasing participation of oncologists and other research professionals at community care sites in the design and conduct of SWOG clinical trials

Banu Symington, MD

Memorial Hospital of Sweetwater County

Q & A with presenters

THANKS TO

Our Top Accruers

Patient volunteers power our trials —
and SWOG members connect us to them.

**SWOG-Credited Registrations to SWOG-Managed Trials
July 1 through December 31, 2024.**



- Moffitt Cancer Center
- Yale University - Yale Cancer Center LAPS
- University of Michigan Comprehensive Cancer Center LAPS
- Instituto Nacional de Cancerologia de Mexico
- UC Irvine Health/Chao Family Comprehensive Cancer Center



- Heartland Cancer Research NCORP
- University of Kansas Cancer Center - MCA Rural MU NCORP
- Michigan Cancer Research Consortium NCORP
- Cancer Research of Wisconsin and Northern Michigan Consortium
- Southeast Clinical Oncology Research Consortium NCORP
- Kaiser Permanente NCORP



THANKS TO

Our Top Performing Sites

To help our data management sites track their performance relative to that of others, we have developed a new metric based on the quality and timeliness of data and biospecimen submissions. Data management institutions with at least 10 SWOG accruals in the prior 13 months are scored on this scale.

The members below are SWOG's top-performing sites for the period of July 1, 2024 to December 31, 2024.



The Don and Sybil Harrington Cancer Center
Universidad de la Republica - Facultad de Medicina
Baylor College of Medicine/Dan L Duncan Comp Cancer Center
Lahey Hospital and Medical Center
STCC at DHR Health Institute for Research & Development
Audie L Murphy VA Hospital
Cancer Research for the Ozarks NCORP
Carle Cancer Center NCORP
Case Western Reserve University
Instituto Nacional de Enfermedades Neoplasicas
Michigan Cancer Research Consortium NCORP
Sutter Cancer Research Consortium
University of Alabama at Birmingham Cancer Center
University of Kansas Cancer Center – MCA Rural MU NCORP
Yale University

Upcoming Funding & Career Development Opportunities

- John Crowley, PhD Award:
May 31
- ESI Training Course:
June 3
- SEED Fund:
July 1
- CRA/Nurse Travel Support:
July 7
- Meyskens Lectureship:
November 1

See all Hope Foundation programs at
thehopefoundation.org/funding-opportunities

THE **HOPE**
FOUNDATION
FOR CANCER RESEARCH

S2408 Kick-Off Meeting

S2408: A Randomized Phase III Blinded Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula

THURSDAY, MAY 1 • 5:30 – 6:30 PM PT • SEACLIFF CD (BAY LEVEL)

S2408 is evaluating whether a single dose of the somatostatin analogue *lanreotide* may prevent the “Achilles Heel” of pancreatic surgery – postoperative pancreatic fistula (POPF) – in patients undergoing distal pancreatectomy for cancer or a pre-malignant pancreatic lesion.

POPF delays chemotherapy, increases healthcare costs, and decreases survival times.

STUDY CHAIR



Jonathan Sham, MD, MBEE

STUDY CO-CHAIR



Venu Pillarisetty, MD

SPONSORING COMMITTEE CHAIR



Robert Krouse, MD

LEAD BIOSTATISTICIANS




Katherine Guthrie, PhD



Kathryn Arnold, MS

PATIENT ADVOCATE



Valerie Fraser

BIostatistician: Amy Darke, MS • **DATA COORDINATOR:** Roxanne Topacio, CCRP • **DATA COORDINATOR:** Kim Carvalho
ORP LIAISON: Shirley Siu • **PROTOCOL PROJECT MANAGER:** Andrea Garcia

The S2408 kick-off meeting will provide:

- An overview of the study design of this newly activated phase III multicenter trial
 - Considerations for site feasibility assessments and local activation
- An opportunity for interactive discussion with the study team

INCLUDING KEY INFORMATION ABOUT



Eligibility



Single-dose treatment



Surveillance



Blinding procedures



Specimen collection



Patient-reported outcomes

SURGEONS, MEDICAL ONCOLOGISTS, AND ONCOLOGY RESEARCH PROFESSIONALS ARE ENCOURAGED TO ATTEND!

Hybrid session: IN-PERSON & VIRTUAL attendance options

S2408 activated on 2/14/2025. All study documents are now accessible via [CTSU.org](https://www.ctsu.org).

TAKE ACTION SYMPOSIUM:

Adolescent and Young Adult (AYA): Engaging AYAs in Clinical Research

*Presented by SWOG Recruitment
& Retention Committee*

*Join us for an interactive discussion
with subject matter experts in
the Adolescent and Young Adult
(AYA) population.*

Objectives:

- 1** REVIEW AND APPRECIATE CHALLENGES THAT AFFECT AYAS DURING TREATMENT AND SURVIVORSHIP
- 2** UNDERSTAND BARRIERS TO AYA CLINICAL TRIAL PARTICIPATION
- 3** DISCUSS STRATEGIES FOR ENROLLING, ENGAGING, AND RETAINING AYA POPULATIONS IN CLINICAL TRIALS

TARGET AUDIENCE:

Investigators, research professionals, and patient advocates, NCORP and LAPS sites


PRESENTERS



**Paula Aristizabal,
MD, MAS**
Rady Children's
Hospital –
UC San Diego



Lauren Fryzel
SWOG AYA
community
advocate



**Tim JD Ohlsen,
MD, MS**
Seattle Children's



Allison Rosen
SWOG AYA
research
advocate



**Kirk Wyatt,
MD, MAS**
Sanford Health



1040 U.S.

Filing Status

Check only one box.

Your first name

If joint return

Home address

City

State

Zip

Signature

Date

Another tax season has passed, but it's never too early to start planning for next year

As a reminder, you can make a tax-free gift from your IRA if you are 70½ or older

Here are a few reasons to direct this gift to The Hope Foundation:

- It helps provide immediate support for SWOG's work
- IRA gifts can reduce a future tax burden and satisfy a Required Minimum Distribution (RMD)
- These gifts allow you to give and save while building a legacy of generosity in cancer care

We encourage you to share this information with an eligible loved one or consider how your family can use an IRA to support Hope this year.
Thank you so much for your ongoing support.

THE HOPE
FOUNDATION
FOR CANCER RESEARCH

thehopefoundation.org/donate/other-ways-to-give/



Give to Support SWOG's Work

Advance Research, Education, and Group Meetings!



Thank you for improving and lengthening lives
through your work with SWOG.

Make an impact for our members and patients when you
donate to The Hope Foundation, SWOG's public charity.

Join in giving today, making a planned gift,
or establishing a monthly gift.

thehopefoundation.org/donate

THE HOPE
FOUNDATION
FOR CANCER RESEARCH

S2424CD Information Session

S2424CD: Lay Health Worker Navigation to Promote Goals of Care Communication among Patients with Advanced Cancer: A Randomized Controlled Trial

THURSDAY, MAY 1 • 1:30 – 2:30 PM PT • PACIFIC HI (PACIFIC CONCOURSE LEVEL) / HYBRID

All NCORP-based staff and investigators are invited!

We invite members from NCORP sites to learn about this new cancer care delivery trial focused on improving goals of care communication between patients with cancer and their clinical care team.

S2424CD features an automated screening tool to reduce the workload for each site and make trial enrollment much easier. The protocol will activate in Fall 2025 and **we are recruiting sites to set up the screening tool** in preparation for launch.

THIS SESSION WILL DISCUSS:



Trial objectives and design



The intervention and goals of care



Benefit of lay health navigators & education for practices and patients



Use of EHR-integrated participant screening processes to reduce staff effort



Financial support for the trial and IT setup



Logistics for site participation

RESEARCH TEAM



Ravi B. Parikh,
MD, MPP, FACP
Study Chair
Emory University



Manali I. Patel,
MD, MPH
Study Chair
Stanford University



Christopher
Manz, MD
Study Chair
Dana-Farber Cancer
Institute

Geriatric Oncology Symposium

Enhancing Clinical Trials for Older Adults with Cancer: Integrating Geriatric Principles into Design and Implementation

THURSDAY, MAY 1ST • 12:45 – 1:45 PM PT • SEACLIFF AB (BAY LEVEL)

Older adults represent most patients with cancer, yet they remain significantly underrepresented in clinical trials. Designing practical, inclusive, and evidence-driven trials for this population is critical to improving care.

This symposium will provide attendees with actionable strategies for successfully incorporating older adults into cancer research. Experts in geriatric oncology will offer practical guidance on geriatric assessment measures, study design innovations, and overcoming enrollment barriers.

The session will conclude with **key takeaways and an interactive Q&A** to help attendees implement **age-inclusive trial strategies** in their own research.

Join us to advance the future of clinical trials for older adults!



Incorporating geriatric measures
into clinical trials: which and how?

Enrique Soto Pérez de Celis, MD, PhD

PANEL: Designing meaningful clinical trials for older adults:
insights from cooperative groups

MODERATOR:



Virginia Sun,
PhD, MSN, RN



Efrat Dotan,
MD




David B. Zhen,
MD



Mina S. Sedrak,
MD, MS



Jyotsana
Parajuli, PhD,
MGS, RN



Enrique Soto
Pérez de Celis,
MD, PhD

PANELISTS:

SWOG Clinical Trials Partnerships (CTP)

HOW SWOG PARTNERS WITH INDUSTRY TO CONDUCT CANCER CLINICAL TRIALS

SWOG CTP Update Forum

THURSDAY, MAY 1 • 5:30 PM – 6:30 PM PT • GRAND BALLROOM A (STREET LEVEL) / HYBRID

How do we work together in SWOG CTP?

- **SWOG CTP overview**
 - Joint study development process
 - Scientific areas of interest
 - Types of trials
- **Accrual completed: TROPION-Breast03 FDA registration trial**
- **SWOG CTP trials in protocol development:**
 - **21CTP.HN01:** Phase II study in recurrent metastatic head and neck cancer with cohorts defined by type of and/or response to prior systemic therapies
 - **21CTP.BREAST01 (MONITOR):** Phase II platform trial using circulating tumor DNA to monitor treatment response in HR+, HER2- metastatic breast cancer

- **SWOG CTP active trial**
 - **21CTP.LEUK01:** Phase II trial for patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia
 - **21CTP.LEUK01 will activate May 15th** – *To apply to open the study, complete the feasibility questionnaire by May 16th – linked from:*



swogctp.org/trials/21CTPLEUK01

- **Site logistics: operations & data management**
 - Feasibility survey outreach and site selection
 - Site funding and contracts
- **Other projects in the works**
- **Novel CTP collaborative opportunities**

All are invited!

Learn more: swogctp.org

Email us: CTP@swog.org

S2417CD Information Session

S2417CD: A Pragmatic Randomized Controlled Trial to Evaluate the Effectiveness of an Intervention Called *Current Together After Cancer (CTAC)* to Promote Guideline-Concordant Colorectal Cancer Surveillance

FRIDAY, MAY 2 • 12:30 – 1:30 PM PT • SEACLIFF AB (BAY LEVEL) / HYBRID



All NCORP and MU NCORP sites are invited to learn about this new cancer care delivery trial aimed at improving follow-up care for colorectal cancer survivors. Your input will help us successfully implement this trial across different NCORP sites.

This trial is under development and plans to activate in summer 2025.

THIS SESSION WILL DISCUSS:



Trial objectives and design



The intervention



Patient screening and recruitment



Patient-reported outcomes (PROs)



Logistics for site participation

RESEARCH TEAM

Christine Veenstra, M.D.
Study Chair
University of Michigan
Rogel Comprehensive Cancer Center



Sarah Hawley, Ph.D.
Study Chair
University of Michigan
Rogel Comprehensive Cancer Center


GOAL 1

Improve survivor's knowledge about surveillance and self-efficacy for navigating surveillance



GOAL 2

Elicit survivors' preference for supporter engagement in surveillance



GOAL 3

Promote effective supporter engagement in surveillance



All NCORP-based staff and investigators are invited




SWOG Early Stage Investigator Training Course

A POSTER SESSION

THURSDAY & FRIDAY, MAY 1 & 2 • GRAND BALLROOM FOYER (STREET LEVEL)


Presenters will appear with their posters **Friday, May 2, 1 – 2 pm PT** (during Plenary reception)

To mark the 25th anniversary of this flagship course, a special poster session will feature six recent Early Stage Investigator Training Course graduates now leading SWOG studies.



Ask
Me
About:

Please be sure to ask presenters about their experiences navigating the SWOG network, engaging with mentors, and working with The Hope Foundation!



Nicholas J. Vogelzang, MD, GU Symposium

“Moving into the 21st Century in Urologic Tumors: The Role of AI”

FRIDAY, MAY 2 • 4:15 PM – 6:15 PM PT • BAYVIEW ROOM (BAY LEVEL) / HYBRID

Honoring the many valuable contributions Dr. Vogelzang made in support of his colleagues and patients throughout his career within SWOG’s research network.



4:15 – 4:20

Introduction
David McConkey, PhD
Johns Hopkins University



4:20 – 4:40

Integrating Multimodal Data and AI to Build Digital Twins for Bladder Cancer
Bishoy M. Faltas, MD
Weill Cornell Medicine



4:40 – 5:00

Accelerating the Generation of Real Knowledge with Artificial Intelligence
Kristian Stensland, MD, MPH, MS
University of Michigan



5:00 – 5:20

Harnessing Digital Pathology in Prostate and Bladder Cancer: Applications of Context-Specific Models
Michael C. Haffner, MD, PhD
Fred Hutch Cancer Center



5:20 – 5:40

Computational Histology AI (CHAI) Biomarkers to Prognosticate and Predict Response to Treatment in Non-Muscle Invasive Bladder Cancer
Anirudh Joshi, MS
Valar Labs



5:40 – 6:15

Panel Discussion
All Speakers

THE FRANK AND LINDA MEYSKENS ANNUAL ENDOWED LECTURESHIP ON ADVANCES IN CANCER PREVENTION

“A Third of a Century Experience in Design, Execution, Analysis, Reporting, and Long-Term Follow-up of Pivotal Cancer Prevention Trials”



by Ian M. Thompson, Jr., MD

Children's Hospital of San Antonio

Presented within the prevention, screening, and surveillance committee session

Thursday, May 1 • 4:30 – 6:30 pm PT • Bayview (Bay Level)

Since the early 1980's, Dr. Frank Meyskens has been a leader in the recognition, development, and clinical usage of prevention in the management of cancer. Frank and Linda have directed the development of this lectureship to advance the explosion of knowledge that is expanding opportunities to engage prevention in personalized medicine, including early detection and genetically focused treatment options.

THE ROBERT B. LIVINGSTON TRANSLATIONAL CANCER LECTURE

Presented as part of the lung committee session

Saturday, May 3 • 9:30 am - 12:30 pm PT • Seacliff BCD (Bay Level)



“Liquid Biopsy in the Assessment of Minimal Residual Disease”

by Christian Rolfo, MD, PhD

The James Comprehensive Cancer Center,
The Ohio State University

Dr. Robert Boyd Livingston was a superb clinician and clinical trialist who greatly impacted the field of cancer research. Within SWOG, he served as chair of both the lung cancer committee (1974-1997) and the breast cancer committee (2000-2008). In his honor, SWOG established the Dr. Robert B. Livingston Translational Breast and Lung Cancer Lectureship.

SWOG Group Meeting App

The SWOG group meeting mobile app is your pocket guide to the meeting.

With key features in an easily accessible format, the app not only replaces the agenda book as your on-site companion, it contains the agenda book – as a PDF you can flip through on your phone.

WITH THE APP, YOU CAN

1 **create** your schedule, annotate sessions, and add them to your calendar

3 **claim** continuing medical education (CME) credits for sessions you attend

2 **access** a directory of presenters and session leaders, along with other attendees who have opted in

The app also offers a single go-to source for speakers and presenters:

- find travel and lodging information and links
- submit conflict-of-interest disclosure forms

4 **access** most of the key resources you've found in the agenda book

5 **access** the full agenda book itself as a PDF



swog.org/appleapps25



swog.org/googleapps25

DON'T HAVE THE APP YET?

Download the app with the appropriate QR code or URL at left

DON'T WANT TO INSTALL YET ANOTHER APP?

Access the web browser version with the QR code or URL at right.



swog.org/meetingapps25



Claim your CME credits using our Confex meeting app

(this is the 4th meeting with CME in Confex)

To claim credit, you must either create a **Confex user account** or use the one you created previously. You may use the account to navigate the meeting through the mobile app — or alternatively, via the browser-based version online.

To navigate the meeting and claim CME credit online, go here: swog.org/meetingapps25

To download the meeting app, find it in the Apple Store or via Google Play:



The screenshot displays the Confex meeting app interface with five numbered steps for claiming CME credits:

- 1** Use the **Meeting Calendar** or **Search** options to navigate to the session you attended and click on the session title.
- 2** **CLAIM CME CREDIT**
Click on the **Claim CME** button and complete the form for the session. Repeat this process for each session that you attended.
- 3** **Claim CME Credit**
Credit Claiming Instructions
CME Meeting Evaluation
- 4** At the conclusion of the group meeting, you will need to complete the **CME Meeting Evaluation**, which is linked from the **Claim CME Credit** page.
- 5** Once you have submitted the CME Meeting Evaluation, click the **Review Credit Hours and Certificates** link on the **Claim CME Credit** page to view and print your certificate(s).

Credits Evaluation List for Courtney Wille

Overall Certificates

SENT	CERTIFICATE
<input type="checkbox"/>	ATTENDEE CERTIFICATE - PDF
<input type="checkbox"/>	CREDIT TRANSCRIPT - PDF

Thursday, May 1, 2025
Palliative Care Committee (Hybrid)
Max Credit Allowed: 2.00
May 1, 2025 8:00 AM - 12:00 AM
Bayview Room (Hyatt Regency San Francisco)

Credit Claimed: 2.00

3 If a **Claim CME** button does not appear on the page, the session was not approved to offer CME credit.

The deadline for claiming credit hours is June 6th at 11:59 pm CT

Procedures for CME Credit

Group Meeting Target Audience and Educational Objectives

SWOG meets semi-annually to keep its members abreast of group science. The target audience for these meetings are physicians, nurse oncologists, and clinical research associates.

The educational objectives of these meetings are: to educate attendees about active and proposed studies so that they may implement the studies at their local institutions; to educate attendees about new treatments and prevention strategies that are available; to identify areas that can be improved in cancer research and study implementation and educate attendees on the best ways to implement the solutions at the local level.

These objectives apply to the following sessions: Adolescent and Young Adult Committee; Cancer Control and Prevention, including Cancer Care Delivery Committee, Symptom Management & Survivorship Committee, and Palliative Care Committee; Genitourinary Committee; Early Therapeutics & Rare Cancers Committee; Melanoma Committee; Surgery Committee; Radiation Oncology Committee; Translational Medicine Plenary Session; Leukemia Committee; Breast Committee; Gastrointestinal Committee; Lung Committee; Lymphoma Committee; Immunotherapeutics Committee; Bone Marrow & Stem Cell Transplantation Committee.

Continuing Medical Education Credit

The Hope Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. In addition, nurses, CRAs, and other researchers may be able to claim credits through their respective credentialing bodies.

The Hope Foundation designates this live activity for a maximum of 19.75 AMA PRA Category 1 Credits™. Learners should only claim credit commensurate with the extent of their participation in the activity.

Speaker and Planner CME Disclosure Information

Each speaker and planner for The Hope Foundation CME courses has been requested to complete a Faculty Disclosure Form prior to the activity in accordance with ACCME standards. THF strives to provide accurate and up-to-date information regarding affiliations or interests that might be perceived as a potential conflict of interest for those who control CME content. Best attempts will also be made to provide up to date information on introductory slides at each CME session.

Committees

Administrative Committees

Board of Governors

Charles D. Blanke, MD

Publications

Hagen F. Kennecke, MD

Conflict Management

Paul Okunieff, MD

Professional Review

Paul Hesketh, MD

Research Support Committees

Adolescent and Young Adult

Rebecca Johnson, MD

Patient Advocates

Anne Marie Mercurio

Barbara Segarra-Vazquez, DHSc

Bone Marrow and Stem Cell Transplantation

Patrick J. Stiff, MD

Pharmaceutical Sciences

Siu-Fun Wong, PharmD

Joyce Lee, PharmD

Digital Engagement

Mark Lewis, MD

Radiation Oncology

Chul Ha, MD

Imaging

Lawrence H. Schwartz, MD

Recruitment and Retention

Allison Caban-Holt, PhD

Oncology Research Professionals

*Connie Szczepanek,
RN, BSN, CCRP*

Surgery

Syed A. Ahmad, MD

Veterans Affairs

Stephen D. Bartlett, RPh

Future Meeting Dates

2025	2026	2027
FALL	SPRING	SPRING
September 17-20 Chicago, IL	April 29-May 2 San Francisco, CA	April 14-17 San Francisco, CA
	FALL	FALL
	October 7-10 Chicago, IL	October 13-16 Chicago, IL

Adolescent and Young Adult Committee

Saturday, May 3 • 9:15 AM – 10:45 AM PT • Garden Room

Agenda

- A. Welcome**
Becky Johnson, MD
- B. EA4241: A Two Cohort Risk-Based Randomized Study for First Relapse of Classical Hodgkin Lymphoma**
Adam Duvall, MD (Virtual)
- C. Results of AYA Sexual Health Survey**
Adam Duvall, MD (Virtual)
- D. Acute Leukemia in AYAs: current and planned NCTN trials**
Kristen O'Dwyer, MD
- E. AYA Breast Cancer**
Erin Roesch, MD
- F. Study Concept: The Use of Memantine for the Prevention of Cancer-Related Cognitive Impairment (CRCI) in Young Adult (YA) Patients with Colorectal Cancer**
Christopher Cann, MD
- G. Advancing and Sustaining AYA Oncology Research in Challenging Times**
Christabel Cheung, PhD, MSW
- H. Q&A and discussion**

Bone Marrow & Stem Cell Transplantation Committee

Thursday, May 1 • 3:00 – 4:30 PM PT
Garden Room (Atrium Lobby Level)

Agenda

- A. Welcome**
Patrick Stiff, MD
- B. New Guidelines for VMAT-TBI for Potential NCTN Trial Use**
Austin Sim, MD & Nicholas Figura, MD
- C. New Proposal TMLI vs TBI as Allograft Source for Acute Lymphoblastic Leukemia**
Monzir Al Malki, MD
- D. S2114: CAR-T Consolidation Trial**
Brian Hess, MD
- E. Report on the ECOG Mantel Cell Transplant Trial**
Brian Till, MD
- F. Update on the Amyloidosis Transplant Trial**
Patrick Hagen, MD
- G. Update on the MyeloMATCH Transplant Trial**
Stephanie Tsai, MD
- H. Update on the ECOG T-NHL Autotransplant Trial**
Marc Hoffman, MD
- I. Update on the ECOG Hodgkin's Lymphoma Autotransplant Trial**
Sairah Ahmed, MD

SWOG Clinical Trials Training Course (CTTC)

Agenda for Oncology Research Professionals

Thursday, May 1 • 7:00 AM – 5:00 PM CT

Morning Session	(Hybrid – On Site and Remote Attendees)	Location: Grand Ballroom A
7:00 – 7:20	Registration (continental breakfast provided)	
7:20 – 7:30	Introduction	Rodney Sutter, CCRP
7:30 – 7:55	Clinical Trials and Protocol Development	Dana Sparks, MAT
7:55 – 8:20	Data Submission	Alex Rangel, BA
8:20 – 8:30	Patient Reported Outcomes	Monica Yee, BA, CCRP
8:30 – 8:55	Reports to Support Quality Data	Cathy Rankin, MS
8:55 – 9:10	BREAK	
9:10 – 9:35	Long Term Follow-Up	Lisa Stoppenhagen, BS,CCRP
9:35 – 10:00	Adverse Event Reporting	Pasarlai Ahmadzai, MD, MPH
10:00 – 10:25	Serious Adverse Events	Maggie Spillers, BSN, RN
10:25 – 10:40	BREAK	
10:40 – 11:05	Audits/Quality Assurance	Laura Gonzales, BSN, MA, RN, OCN
11:05 – 11:30	Specimen Tracking System	Amy Johnson, BA, CCRP
11:30 – 11:40	Tips for Specimen Submission	Hannah Brown, BS
11:40 – 12:00	Scientific Impact of the CRA	Michael LeBlanc, PhD
12:00 – 2:00	LUNCH (on your own)	
Afternoon Session	(On-Site Attendees Only)	Location: Grand Ballroom BC
2:00 – 2:35	(Don't let your data end up in) JEOPARDY!it's a Game!	Christine Magner
2:35 – 2:40	Introduction to the Practicum	Christine Magner
2:40 – 5:00	Practicum Session	Data Operations Center Staff and SWOG CRAs

Digital Engagement Committee

Thursday, May 1 • 11:00 AM – 12:30 PM PT • Pacific HI

Agenda

- A. Welcome**
Mark Lewis, MD
- B. Keynote Speaker: cookforyourlife.org**
Heather Greenlee, ND, PhD
- C. Wearables & Stupid Cancer Liaison Opportunity**
Mark Lewis, MD
- D. Survey Updates**
Mark Lewis, MD
- E. Platform Discussion & Miscellany**
Mark Lewis, MD

ORP Jeri & Noboru Oishi Symposium

Friday, May 2 • 8:00 AM – 10:30 AM PT • Bayview Room (Bay Level)

Agenda

Topic	Time	Speaker(s)
Opening & Announcements	8:00 am – 8:10 am	Connie Szczepanek, RN, BSN Joyce Nancarrow Tull, RN, MSN
CTSU	8:10 am – 8:40 am	Rachel Albershardt Cancer Trials Support Unit (CTSU)
Cytogenetics	8:40 am – 9:10 am	Min Feng, MD, PhD Professor, Translational Science & Therapeutics Division Fred Hutchinson Cancer Center University of Washington
Deciphering Chromosomes: Cracking the Code	9:10 am – 9:40 am	Rose Ermete, RN, BSN, OCN CNR-BC, CCRP Senior Quality Assurance Nurse Auditor, SWOG
Quality Assurance in Cytogenetics – Lessons Learned	9:40 am – 10:10 am	Laura Gonzales, RN, BSN Manager, SWOG Quality Assurance
Cytogenetics lightning Round Q & A	10:10 am – 10:30 am	Christine Magner Data Operations Supervisor SWOG Statistics & Data Management Center

PLEASE KEEP THIS AGENDA AND USE THE FILLABLE STATEMENT BELOW TO DOCUMENT YOUR EDUCATIONAL CREDITS.

I certify that I attended ____ hours of this meeting. The topics of the meeting contribute to my education and professional advancement in clinical research.

Signature _____ Date _____

Oishi Education Sub-Committee Co-Chairs:

Kira Pavlik, MPH, CCRP – kira.pavlik@yale.edu

Joyce Nancarrow Tull, MSN, RN – jntull@health.ucsd.edu

Pharmaceutical Sciences Committee and Drug Information Subcommittee Joint Meeting (Hybrid)

Friday, May 2 • 9:00 AM – 11:00 AM PT • Pacific F

Agenda

Committee Reports:

1. Committee Administrative reports –*Joyce Lee/Siu Fun Wong*

- Introduction of new members
- Review of PSC Member Roster
- Summary report of committee activities
 - NCI CTEP Policy Advanced Practice Providers (APP) Task Force
 - Pharmaceutical-related events and inquiries
 - NCTN grant renewal
 - PSC Website and Audit Checklist – *Rivka Siden*
 - SWOG PSC New Member Manual – *Siu Fun Wong*

2. Drug Information Sub-Committee Report – *Vy Bui*

- Updates from the Chair – *Vy Bui*
 - Workload Summary of drug section requests and acknowledgment of writers and reviewers
 - Introduction of resident and fellow writers for 2024-2025 academic year
 - Updates on Section 3 development process and participants
- Protocol Review activities – *Holly Chan/Jorge Avila*
- Aurora roll-out updates – *Matt Boron*

3. APP Initial Order Build Focus Group – *Siu Fun Wong/Joyce Lee*

Members: *Holly Chan, Safae Chouraichi, Dawud Ellayan, Joyce Lee, Jane Rogers, Christa Braun-Inglis, Maggie Ryan, Dana Reeves*

- Program development updates
- Pilot project
- Roles of Pharmacist Liaisons

4. Pharmacist Liaison Reports – *All*

- Review of Pharmacist Liaison Assignment List
- Disease Committee Liaison Pharmacist Reports – *Open*

5. Open agenda – *All*

Surgery Committee

Friday, May 2 • 11:45 AM – 1:45 PM PT • Pacific HI

Update on the Landscape Of Rectal Cancer Trials

J. Joshua Smith, MD, PhD

Memorial Sloan Kettering Cancer Center, New York, New York

Trials and Projects in Development and Ongoing Trials

S2408: A Randomized Phase III Blinded Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula

Jonathan Sham, MD

University of Washington, Seattle WA

Prophylactic or Symptomatic Surgery in Small Bowel NETs: A Pragmatic Trial (POSS-i-BOWEL)

Alexander Gangi, MD

Cedars Sinai Medical Center, Los Angeles CA

Neoadjuvant Chemotherapy Switch for Pancreas Cancer

Flavio Rocha, MD

Knight Cancer Institute, OHSU , Portland OR

A randomized phase II study to optimize organ preservation for esophageal adenocarcinoma

Russel Palm, MD

The Ohio State University, Columbus OH

SWOG Latin America Initiative Symposium

Friday, May 2 • 12:00 PM – 1:30 PM PT • Bayview Room

Agenda

Introductory Remarks, *Drs. Erika Ruiz and Bettina Müller*

Part 1: Gastric Intestinal Cancer Collaborations

*Landscape of GI Malignancies in Latin America and the US, **Drs. Erika Ruiz and Bettina Müller***

*Colon cancer research and the NCTN network, **Dr. Philip Gold***

*Anorectal cancer research and the NCTN network, **Dr. Lisa Kachnic***

Part 2: Round Table Discussion about Collaborations

*De-escalation trial for elderly patients with resectable gastric cancer: protocol development experience and trial overview, **Dr. Iván Lyra***

Open discussion about areas of current and future GI collaborations

Part 3: Site Focus: SLAI Activities and GI Patient Overview by Country

*Focus: SWOG and scaling up in Mexico, **Dr. Paula Cabrera***

*SLAI activities and GI patient overview by country, **all SLAI sites***

Closing Remarks, *Drs. Erika Ruiz and Bettina Müller*

VA Committee

Thursday, May 1 • 4:30 PM – 6:00 PM PT • Pacific HI

Agenda

A. Introductions and Opening Comments

- *Stephen Bartlett, RPh, MSPH*

B. Studies for VA Consideration from SWOG

1. **SN2426**, “A Randomized Phase II Study of Amivantamab versus Cetuximab in Immunocompromised Participants with Recurrent Inoperable or Metastatic Cutaneous Squamous Cell Carcinoma”

Slated to activate May 15, 2025

- Dr. Jimmy Ruiz, Wake Forest University HSC/ WG Hefner VA Medical Ctr
VA Liaison on Early Therapeutics & Rare Cancers Committee

2. **S2409**, “PRISM: PReclision in SCLC via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)”

Slated to activate August 4, 2025

- Dr. Chao Hui Huang, VAMC Kansas City
VA Liaison on Lung Cancer Committee

3. **S2414**, “A Randomized Phase III Trial INcorporating Pathologic Complete ReSponse in Participants with Early StaGe Non Small Cell Lung Cancer to Optimize ImmunotHerapy in the AdjuvanT Setting (INSIGHT)”

Slated to activate in February 2025, officially activated on March 14, 2025

- Dr. Chao Hui Huang, VAMC Kansas City
VA Liaison on Lung Cancer Committee

C. VA Disease Committee Liaisons

1. Updates, ongoing goals

- Dr. Jessica D. McDermott, Rocky Mountain Regional VA Medical Ctr

2. Open Committee Roles:

Cancer Care Delivery	Immunotherapeutics	Lung
Melanoma	Palliative Care	Prevention, Screening & Surveillance

How to Apply – vamember@swog.org

VA Committee

D. Current VA Stats

Accrual/sites – SWOG Report

E. Other

1. VA and NIH - Future directions and considerations

2. AVAHO September 12-14, 2025

30th anniversary – Phoenix, AZ

F. Future Meetings

3rd Qtr. Virtual VA Committee Meeting – July 8, 2025, 2:00-3:00 CT

SWOG Fall Group Meeting September 18-20, 2025 – Chicago, IL

Barlogie-Salmon Myeloma Committee

Leadership

Chair: Robert Z. Orlowski, MD, PhD
 Vice-Chair: Sikander Ailawadhi, MD
 Vice-Chair: Jing Christine Ye, MD, MSc
 Executive Officer: Susan M. O'Brien, MD
 Statisticians: Antje Hoering, PhD
 Rachael Sexton, MS
 Adam Rosenthal, MS
 Sara Threlkel, BS

Scientific Leadership

Translational Medicine: Brian A. Walker, BSc, PhD
 Radiation: Chelsea Camille Pinnix, MD, PhD
 Surgery: TBD
 Imaging: Eric M. Rohren, MD, PhD
 Pathology: Pei Lin, MD
 Early Therapeutics: Frits van Rhee, MD, PhD

Designates

Digital Engagement: TBD
 NCORP Representative: Charles S. Kuzma, MD
 Veterans Affairs: Thomas R. Chauncey, MD, PhD
 Data Coordinators: Aubrey Gilmore, BA
 Daria Chugina, MD, CCRPS
 Pasarlai Ahmadzai, MD, MPH
 Oncology Research Professionals:
 CRA: Brandon Richard Labadie, CCRP
 Nurse: Teresa Witcher, BSN, RN
 Patient Advocate: Paul Gater, MPhil
 Pharmaceutical Science: Craig Elg, PharmD
 Ila M. Saunders, PharmD
 Protocol Project Manager: Amy Doyle
 Clinical Trials Program Manager: Sharon Palmer

Time/Location

Friday, May 2, 2025 4:30 p.m. - 6:30 p.m.
 Room: Pacific HI (Pacific Concourse Level)

Active Studies

S2005, "A Phase II Randomized Study Comparing Ibrutinib and Rituximab vs. Venetoclax and Rituximab in Previously Untreated Waldenström's Macroglobulinemia (WM) /Lymphoplasmacytic Lymphoma (LPL)" Drs. S. Ailawadhi and D. Bhutani. Activated: 6/24/21; Closed: 4/08/2022; Re-activated: 2/15/2024.

S2209, "A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or Ineligible for Stem Cell Transplant Comparing Upfront Bortezomib-Lenalidomide-Dexamethasone-Lite (VRd-Lite) with Daratumumab-Lenalidomide-Dexamethasone (DRd)." Drs. S. Ailawadhi, J.C. Ye, B. Lipe, T. Chauncey, and K. Gowin. Activated 05/30/23.

S2213, "Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (D-VCD) Induction Followed by Autologous Stem Cell Transplant or D-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis." Drs. P. Hagen, T. Parker, and S. Sidana. Activated 12/01/2023

A062102, "Randomized Phase II Study of Ixerdomide Maintenance Therapy Following Idecabtagene Vicleucel CAR-T in Multiple Myeloma Patients." Dr. R. Banerjee. Activated: 04/04/2024

EEA173, "Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma." Dr. E. Manasanch. Activated: 4/30/19.

EEA181, "Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial." Dr. K. Gowin. Activated: 10/27/20.

Developing Studies

S2508, "A Phase II Study of Optimal Induction and MRD Driven Maintenance Therapy for Patients with Newly Diagnosed High-Risk Multiple Myeloma (HRMM)." Drs. B. Lipe and J.C. Ye.

Closed Studies

S1803, "Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)." Drs. A. Krishnan and S. Chhabra. Activated: 6/27/19. Registration Step 1 Closed to Accrual: 1/15/25.

S1211, "A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)." Drs. S. Usmani, S. Ailawadhi, and B. Lipe. Activated: 11/9/12. Closed: 6/2/16.

S1702, "A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis." Drs. T. Parker and V. Sanchowala. Activated: 3/08/18; Closed: 9/30/19.

Barlogie-Salmon Myeloma Committee

S1304, "A Phase II Randomized Study Comparing Two Doses of Carfilzomib with Dexamethasone for Relapse/Refractory Multiple Myeloma." Dr. S. Ailawadhi. Activated: 10/18/13. Closed: 11/6/15.

S0777, "Frontline Phase III Rev/Dex +/- Vel, no upfront transplant." Dr. B. Durie. Activated: 4/1/18. Closed: 2/2/12.

S0120, "A prospective Observational Biologic Study of Asymptomatic Patients with Monoclonal Gammopathy and Plasmaproliferative Disorders." Dr. M. Dhodapkar. Activated: 6/1/02. Closed: 4/1/11.

CTN 0702, "Single Autologous Transplant with or without RVD Consolidation versus Tandem Transplant and Maintenance Therapy." Dr. G. Somlo. Activated: 2/15/11. Closed: 11/15/13.

A061402, "Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone after Radiation Therapy in Treating Patients with Solitary Plasmacytoma of Bone." Dr. A. Kuman Mahindra. Activated: 12/23/15. Closed: 8/15/19.

E1A11, "Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURATION Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)." Drs. S. Kumar, A. Cohen, and J. Zonder. Activated: 11/22/13. Closed: 1/29/19.

E3A06 (was S0909), "High-risk AMM – Revlimid." Dr. M. Dhodopkar. Activated: 1/17/11. Closed: 7/14/17.

A061402, "Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone after Radiation Therapy in Treating Patients with Solitary Plasmacytoma of Bone." Dr. A. Kumar Mahindra. Activated: 12/23/15. Closed: 8/15/19.

E1A11, "Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURATION Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)." Drs. S. Kumar, A. Cohen and J. Zonder. Activated: 11/22/13. Closed: 1/29/19.

EAA171, "Optimizing Prolonged Treatment in Myeloma Using MRD Assessment (OPTIMUM)." Dr. S. Kumar. Activated: 6/1/21. Closed: 03/03/23.

Proposed Studies-Pre-Triage/On Hold

SXXXX, "A Phase III Study for Evaluation of Maintenance Cessation in Patients with Standard Risk Myeloma Achieving Minimal Residual Disease Negativity." Dr. M. Mohyuddin.

SXXXX, "A Phase II Trial of BCMA Bi-Specific T-Cell Engager (BiTE) Teclistamab in Patients with Systemic Light Chain (AL) Amyloidosis." Drs. D. Bhutani and K. Dorritie.

SXXXX, "An Open-Label Randomized Phase 2 Trial to Incorporate Venetoclax in Early Relapsed t(11;14) Multiple Myeloma." Dr. R. Chakraborty.

SXXXX, Developing Smoldering Multiple Myeloma Concept. Drs. P. Hagen and A. Cowan.

Barlogie-Salmon Myeloma Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	<i>S1803</i>	<i>S2005</i>	<i>S2209</i>	<i>S2213</i>	<i>EAA173</i>	<i>EAA181</i>
Banner University Medical Center - Tucson	11	-	-	-	-	5
Boston Medical Center	5	-	-	2	-	-
CWRU Case Comprehensive Cancer Center LAPS	27	-	-	-	8	-
Cancer Research for the Ozarks NCORP	2	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	5	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	1	-	-	-
Cedars-Sinai Medical Center	6	-	-	-	-	-
City of Hope Comprehensive Cancer Center	118	-	3	-	-	-
Columbia University Minority Underserved NCORP	-	-	1	3	-	-
Columbus NCI Community Oncology Research Program	5	-	-	-	-	-
CommonSpirit Health Research Institute	1	-	3	-	-	-
Dayton NCI Community Oncology Research Program	5	-	-	-	-	-
Duke University - Duke Cancer Institute LAPS	3	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	5	-	-	-	8	-
Froedtert and the Medical College of Wisconsin LAPS	12	-	-	-	-	-
Georgia NCI Community Oncology Research Program	19	-	-	-	-	-
Gulf South Minority Underserved NCORP	4	-	-	-	-	-
Heartland Cancer Research NCORP	11	-	3	-	-	-
Henry Ford Health Providence Southfield Hospital	2	-	-	-	1	1
Henry Ford Hospital	-	-	-	-	2	-
Houston Methodist Hospital	10	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	58	-	5	-	-	-
Kansas City Veterans Affairs Medical Center	-	-	2	-	-	-
Lahey Hospital and Medical Center	3	-	-	-	-	-
Loyola University Medical Center	26	-	-	-	3	1
MU Health Care Goldschmidt Cancer Center	3	-	-	-	-	-
Massachusetts Veterans Epidemiology Research and Information Cntr	-	-	1	-	-	2
Medical University of South Carolina Minority Underserved NCORP	54	-	-	-	1	1
Mercy Medical Center - Des Moines	1	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	9	-	1	-	-	-
Moffitt Cancer Center	45	-	-	-	-	-
Montana Cancer Consortium NCORP	4	-	-	-	-	-

Barlogie-Salmon Myeloma Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	<i>S1803</i>	<i>S2005</i>	<i>S2209</i>	<i>S2213</i>	<i>EAA173</i>	<i>EAA181</i>
NCORP of the Carolinas (Prisma Health NCORP)	-	-	2	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	1	-
New Mexico Minority Underserved NCORP	15	-	4	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	5	-	-	-	-	-
Oregon Health and Science University	33	-	1	-	3	9
Pacific Cancer Research Consortium NCORP	16	-	6	-	-	-
Parker Adventist Hospital	2	-	-	-	-	-
Riverside Methodist Hospital	3	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	3	-	-	-	-	-
Stanford Cancer Institute Palo Alto	-	-	1	-	-	-
Tulane University School of Medicine	-	-	-	-	2	-
UC Davis Comprehensive Cancer Center LAPS	27	-	5	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	18	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	3	-	-	3
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	2
University of Kansas Cancer Center - MCA Rural MU NCORP	35	-	-	1	-	-
University of Kentucky/Markey Cancer Center	4	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	16	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	3	-	-	-	-	-
University of Rochester LAPS	15	2	2	-	-	3
University of Texas Health Science Center at San Antonio	22	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	27	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	16	-	-	-	4	2
Upstate Carolina NCORP	4	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	18	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	22	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	2	-	4	8
ALLIANCE	219	1	5	1	-	-
CCTG	20	-	-	-	-	-
ECOG-ACRIN	184	8	3	-	-	-
NRG	112	1	4	-	-	-
Total	1,293	12	58	7	37	37

Breast Committee

Leadership

Chair: Lajos Pusztai, MD, PhD
 Vice-Chair: Priyanka Sharma, MD
 Executive Officer: Anne Chiang, MD, PhD
 Statisticians: Allison Meisner, PhD
 Danika Lew, MA
 Shay Bellasea, MS
 Allison Hayes, BS

Scientific Leadership

Translational Medicine: Alastair M. Thompson, MD
 Andrew K. Godwin, PhD
 Radiation Oncology: Reshma Jagsi, MD
 Surgery: Joshua M.V. Mammen, MD, PhD
 Imaging: TBD
 Pathology: David L. Rimm, MD, PhD
 Early Therapeutics: Stephanie L. Graff, MD

Designates

Cancer Control Liaisons: Mariya Rozenblit, MD (Survivorship)
 Dawn L. Hershman, MD (Cancer Care Delivery)
 Banu Arun, MD (Prevention)
 Helen K. Chew, MD (Symptom Management)
 Digital Engagement: TBD
 NCORP Representative: Philip E. Lammers, MD
 Veterans Affairs: Sarah V. Colonna, MD
 Data Coordinators: Aubrey Gilmore, BA
 Gabi Herbert, MS, BS
 Kevin Moralda, BS
 Larry G. Kaye
 Oncology Research Professionals:
 CRAs: Karyn N. Hart, CCRP
 Nurse: Cameo Windham, BSN, RN
 Patient Advocates: Roberta A. Albany
 Ginny Mason, RN, BSN
 Pharmaceutical Science: Jorge G. Avila, PharmD
 Dawud Nael Dawud Ellayan, Pharm D
 Protocol Project Manager: TBD
 Clinical Trials Program Manager: Sharon Palmer

Time/Location

Friday, May 2, 2025 4:30 p.m. - 6:30 p.m.
 Room: Seaclyff BCD (Bay Level)

Agenda

4:30 - 4:35 pm Welcome and Introductions - Lajos Pusztai, MD, DPhil (Chair) and Priyanka Sharma, MD (Vice-chair)

Educational Session

"Emerging Novel Predictors for Treatment Optimization in Breast Cancer"

4:35 - 4:50 pm AI Predictor in Early-Stage Hormone Positive Breast Cancer - George Sledge, MD, Caris Life Sciences

4:50 - 5:05 pm Optimizing Patient Selection in Clinical Trials Using a CLIA-Based RPPA Assay for Functional Protein Drug Target Activation Mapping - Chip Petricoin, PhD, George Mason University

5:05 - 5:20 pm Q&A

Committee Business and Updates

5:20 - 5:30 pm Publication update – Allison Meisner, PhD

5:30 - 5:40 pm Patient Advocate update – Ginny Mason and Roberta Albany

5:40 - 5:50 pm Translational Medicine Sub-Committee update - Alastair Thompson, MD and Andrew K. Godwin, PhD

5:50 - 6:20 pm Review of open CTSU trials

6:30 - 6:30 pm Reports from Committee Liaisons

Radiotherapy: Reshma Jagsi, MD
 Surgery: Joshua Mammen, MD
 Survivorship: Mariya Rozenblit, MD
 Cancer Care Delivery: Dawn Hershman, MD
 Prevention: Banu Arun, MD
 Symptom Management: Helen K. Chew, MD
 NCORP: Philip Lammers, MD

6:30 pm Closing Comments and Adjourn

Active Studies

S2206, "Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer." Drs. Cobain and Pusztai. Activated: 10/30/23.

Breast Committee

S2212, "Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study." Drs. Sharma and Mitri. Activated: 07/21/23.

S2007, "A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases." Drs. Brenner and Kaklamani. Activated: 12/15/20.

CTSU/A011801, "The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSESSment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib." Dr. O'Sullivan. SWOG Champion: Dr. Murthy. Activated: 01/06/21.

CTSU/CCTG MA.39, "Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer." Dr. Whelan. SWOG Champion: Dr. Jagsi. Activated: 05/30/18.

CTSU/NRG-BR007, "A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)." Dr. White. SWOG Champion: Dr. Shumway. Activated: 06/07/21.

Closed Studies

S1418, "A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥ 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) after Neoadjuvant Chemotherapy." Drs. Puztai and Mammen. Activated: 11/15/16; Permanently closed: 06/30/21.

S1207, "Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e^3 Breast Cancer Study-Evaluating Everolimus with Endocrine Therapy." Drs. Chavez-MacGregor and Puztai. Activated: 09/04/13; Permanently closed: 05/01/19.

S1706, "A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer." Drs. Jagsi and Chalasani. Activated: 09/12/18. Permanently closed: 07/01/24.

CTSU/A011202, "A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (CT1-3

N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy." Dr. Boughey. SWOG Champion: Dr. Mammen. Activated: 02/07/14; Permanently closed: 07/01/22.

CTSU/EA1181, "(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSESSment to Optimize Therapy in HER2-Positive Breast Cancer)" Dr. Tung. SWOG Champions: Breast Committee: Dr. Tang, Imaging Committee: Dr. Lu. Activated: 02/11/20; Permanently closed: 10/19/23.

CTSU/EA1183, "FDG PET to Assess Therapeutic Response in Patients with Bone-Dominant Metastatic Breast Cancer, FEATURE." Dr. Specht. SWOG Champions: Breast Committee: Dr. Linden, Imaging Committee: Dr. Wright. Activated: 04/02/20; Permanently closed: 12/22/23.

CTSU/NRG-BR002, "A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer." Drs. Chmura and White. SWOG Champion: Dr. Jagsi. Activated: 12/24/14; Permanently closed: 05/27/22.

CTSU/NRG-BR003, "A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer." Dr. Valero. SWOG Champion: Dr. Makhoul. Activated: 06/26/15; Permanently closed: 04/22/22.

CTSU/NRG-BR004, "A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer." Dr. Geyer. SWOG Champion: Dr. Cobain. Activated: 03/12/19; Permanently closed: 07/01/22.

CTSU/NRG-BR005, "A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without Surgery." Dr. Basik. SWOG Champion: Dr. Thompson. Activated: 04/13/17; Permanently closed: 12/02/22.

Active Palliative Care Study

S1501, "Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III." Drs. Floyd and Leja. Activated: 09/15/17. Arms 1 and 2 permanently closed to accrual: 11/01/2024.

Breast Committee

Closed Symptom Management and Survivorship Studies

S1614, "A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors." Drs. Hwang and Lok. Activated: 02/21/19; Permanently closed: 11/15/22.

S1714, "A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients." Drs. Trivedi and Hershman. Activated 03/01/19; Permanently closed: 11/15/21.

Active Cancer Care Delivery Study

S1703, "Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer." Drs. Accordini and Hershman. Activated: 07/16/18.

Closed Prevention, Screening & Surveillance Studies

S1904, "Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ – Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)." Drs. Crew, and Kukafka. Activated: 09/01/20. Permanently closed: 06/14/2024.

CTSU/EA1151, "Tomosynthesis Mammographic Imaging Screening Trial (TMIST)." Dr. Pisano. SWOG Champion: Dr. Arun. Activated: 07/06/17. Closed to accrual: 12/20/2024.

Closed Early Therapeutics and Rare Cancers Studies

S1609, "DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors." Drs. Patel and Chae. Activated 01/13/17; Permanently closed: 03/15/23.

CTSU/EAY131, "Molecular Analysis for Therapy Choice (MATCH)". Dr. Flaherty. Activated 08/12/15; Permanently closed: 12/30/22.

Breast Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	S1706	S2007	S2206	S2212	A011801	A012103	EA1181	EA1183	EA1211	MA39
Banner MD Anderson Cancer Center	-	-	-	-	12	-	-	-	-	-
Banner University Medical Center - Tucson	1	-	-	-	-	-	10	-	-	-
Baptist Mem Health Care/Mid South Minority Underserved NCORP	3	-	2	5	-	-	1	-	2	-
Baylor College of Medicine/Duncan Comprehensive Cancer Center	-	-	-	2	-	-	-	-	-	3
Boston Medical Center	-	-	-	-	6	-	15	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	1	-	-	-	-	4	-	-	2
Cancer Research Consortium of West Michigan NCORP	1	-	-	8	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	3	-	-	3	1	-	-	-	-	-
Cancer Research of Wisconsin & Northern Michigan Consortium	-	-	1	4	-	-	-	-	-	-
Carle Cancer Center NCI Comm Oncology Research Program	-	2	2	12	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	4	1	1	1	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	9	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	4	-	1	-	-	-	3	-	-	-
CommonSpirit Health Research Institute	2	-	-	7	-	-	-	-	-	2
Dayton NCI Comm Oncology Research Program	-	1	-	-	-	-	6	2	-	-
Desert Regional Medical Center	1	-	-	-	-	-	2	-	-	1
Essentia Health NCI Comm Oncology Research Program	-	-	1	-	1	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	5	-	-	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	1	-	-	-	-	-	-
Georgia NCI Comm Oncology Research Program	2	-	2	3	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	1	-	3	6	-	-	2	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	1	-	-	-	-	-	-
Heartland Cancer Research NCORP	4	-	3	17	1	-	-	-	-	-
Henry Ford Health Providence Southfield Hospital	2	-	-	-	2	2	5	-	-	1
Henry Ford Hospital	-	-	1	2	-	3	-	-	-	-
Houston Methodist Hospital	-	-	-	-	1	-	-	-	-	3
Lahey Hospital & Medical Center	-	-	1	2	1	-	6	-	-	-
Loma Linda University Medical Center	-	-	-	4	-	-	-	-	-	-
Loyola University Medical Center	-	-	-	-	-	-	1	-	-	-
Medical University of South Carolina Minority Underserved NCORP	1	-	1	-	-	1	-	3	-	4
Michigan Cancer Research Consortium NCORP	2	-	2	8	-	-	-	-	-	-
Montana Cancer Consortium NCORP	3	-	-	4	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	-	1	-	-	-
MultiCare Tacoma General Hospital	-	-	4	-	-	-	-	-	-	-
NCORP of the Carolinas	-	-	1	3	-	-	-	-	-	-

Breast Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	S1706	S2007	S2206	S2212	A011801	A012103	EA1181	EA1183	EA1211	MA39
New Mexico Minority Underserved NCORP	6	1	-	-	-	1	-	-	-	-
Northwell Health NCORP	-	1	1	-	-	-	-	-	-	-
Northwestern University LAPS	1	2	-	14	1	-	4	1	-	-
Ohio State University Comprehensive Cancer Center LAPS	3	-	-	4	-	-	1	-	-	-
Oregon Health & Science University	-	-	1	-	-	-	-	3	-	-
Pacific Cancer Research Consortium NCORP	2	-	5	12	-	-	-	-	-	2
Rhode Island Hospital	-	-	-	1	-	-	-	-	-	-
Saint Joseph Hospital - Cancer Centers of Colorado	-	-	-	6	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	1	2	26	1	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	1	2	3	-	5	-	-	-
The Don & Sybil Harrington Cancer Center	3	-	-	-	3	-	-	-	-	-
The West Clinic - Wolf River	-	-	-	11	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	7	-	-	-	-	2	4	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	1	2	-	2	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	1	-	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-	1	-	-	-	-	2
U of Alabama at Birmingham / Deep S. Research Consortium LAPS	-	2	-	5	-	-	-	-	-	-
University of Arkansas for Medical Sciences	2	-	-	1	2	3	-	-	-	-
University of Colorado Cancer Center LAPS	1	-	1	1	1	-	11	-	-	2
University of Kansas Cancer Center - MCA Rural MU NCORP	4	-	4	8	1	-	-	-	-	3
University of Michigan Comprehensive Cancer Center LAPS	3	-	2	1	2	2	1	-	-	14
University of Mississippi Medical Center	-	-	-	-	-	-	1	-	-	-
University of Oklahoma Health Sciences Center LAPS	1	-	2	2	-	-	-	-	1	-
University of Rochester LAPS	1	-	-	-	-	-	1	-	-	-
University of Texas Health Science Center at San Antonio	-	1	3	-	-	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	1	2	-	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	5	-	-	-	1	-	7	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	2	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	1	5	2	-	14	4	3	3
Western States Cancer Research NCORP	-	-	-	-	-	-	2	-	-	-
Wisconsin NCI Comm Oncology Research Program	1	-	-	3	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	2	16	3	-	13	-	-	-
ALLIANCE	18	7	14	87	-	-	-	-	-	-
CCTG	6	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	11	3	15	70	-	-	-	-	-	-
NRG	48	-	7	54	-	-	-	-	-	-
Total	160	25	92	431	51	15	120	13	6	42

Breast Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	NRGBR007	NRGBR009
Banner MD Anderson Cancer Center	-	-
Banner University Medical Center - Tucson	-	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-
Boston Medical Center	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-
Cancer Research Consortium of West Michigan NCORP	-	-
Cancer Research for the Ozarks NCORP	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-
Cedars-Sinai Medical Center	-	-
City of Hope Comprehensive Cancer Center	-	-
Columbia University Minority Underserved NCORP	-	-
CommonSpirit Health Research Institute	-	-
Dayton NCI Community Oncology Research Program	-	-
Desert Regional Medical Center	-	-
Essentia Health NCI Community Oncology Research Program	-	-
Fred Hutchinson Cancer Research Center LAPS	-	1
Georgia Cares Minority Underserved NCORP	-	-
Georgia NCI Community Oncology Research Program	-	-
Gulf South Minority Underserved NCORP	-	-
Hawaii Minority Underserved NCORP	-	-
Heartland Cancer Research NCORP	-	1
Henry Ford Health Providence Southfield Hospital	-	2
Henry Ford Hospital	-	-
Houston Methodist Hospital	-	-
Lahey Hospital and Medical Center	-	-
Loma Linda University Medical Center	-	-
Loyola University Medical Center	-	1
Medical University of South Carolina Minority Underserved NCORP	-	-
Michigan Cancer Research Consortium NCORP	-	-
Montana Cancer Consortium NCORP	-	-
Mount Sinai Hospital	-	-
MultiCare Tacoma General Hospital	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-

Breast Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	NRGBR007	NRGBR009
New Mexico Minority Underserved NCORP	-	-
Northwell Health NCORP	2	-
Northwestern University LAPS	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-
Oregon Health and Science University	1	-
Pacific Cancer Research Consortium NCORP	-	-
Rhode Island Hospital	-	-
Saint Joseph Hospital - Cancer Centers of Colorado	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-
Sutter Cancer Research Consortium	2	1
The Don and Sybil Harrington Cancer Center	-	-
The West Clinic - Wolf River	-	2
UC Davis Comprehensive Cancer Center LAPS	1	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-
UPMC Hillman Cancer Center LAPS	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-
University of Arkansas for Medical Sciences	-	-
University of Colorado Cancer Center LAPS	3	-
University of Kansas Cancer Center - MCA Rural MU NCORP	2	-
University of Michigan Comprehensive Cancer Center LAPS	-	-
University of Mississippi Medical Center	-	-
University of Oklahoma Health Sciences Center LAPS	-	-
University of Rochester LAPS	1	-
University of Texas Health Science Center at San Antonio	4	-
University of Texas MD Anderson Cancer Center LAPS	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-
Western States Cancer Research NCORP	-	-
Wisconsin NCI Community Oncology Research Program	-	-
Yale University - Yale Cancer Center LAPS	-	-
ALLIANCE	-	-
CCTG	-	-
ECOG-ACRIN	-	-
NRG	-	-
Total	16	8

Cancer Control & Prevention Committees

Leadership

Vice-Chair NCORP: Dawn L. Hershman, MD, MS
 Cancer Care Delivery Committee Co-Chairs: Veena Shankaran, MD
 Scott D. Ramsey, MD, PhD
 Palliative Care Committee Co-Chairs: Robert S. Krouse, MD, FACS
 Marie Bakitas, DNSc, CRNP
 Prevention, Screening & Surveillance
 Committee Co-Chairs: Banu Arun, MD
 Jason A. Zell, DO
 Symptom Management & Survivorship
 Committee Co-Chairs: Michael J. Fisch, MD, MPH
 Norah Lynn Henry, MD, PhD
 Executive Officers: Katherine D. Crew, MD (CCD, Prevention,
 Symptom Management)
 Virginia Sun, PhD, MSN, RN (Palliative)
 Senior Advisor: Frank L. Meyskens, Jr., MD
 Statisticians: Michael LeBlanc, PhD
 Katherine Guthrie, PhD
 Cathy Tangen, DrPH
 Joseph M. Unger, PhD
 Garnet Anderson, PhD
 Phyllis Goodman, MS
 Kathryn B. Arnold, MS
 Amy K. Darke, MS
 Danika Lew, MA
 Sarah Colby, MS
 Anna Moseley, MS
 Cathee Till, MS
 Allison Hayes, BS
 Matt Chansky, BS

Administrative Lead

Statistics & Data Management Center (SDMC): Monica Yee, CCRP

Scientific Leadership

NCORP Representative: Scott Edward Delacroix, Jr. MD
 Helen Heng-Shan Moon, MD
 Radiation Oncology Committee: Eileen P. Connolly, MD, PhD (CCD,
 Prevention)
 Kiri A. Cook, MD (Symptom Mgmt & Survivorship)
 Erin F. Gillespie, MD (Symptom Management)
 Surgery Committee: Robert S. Krouse, MD, FACS
 Translational Medicine: James (Jimmy) Rae, PhD

Liaisons

Barlogie-Salmon Myeloma Committee: Charles S. Kuzma, MD
 Breast Committee: Mariya Rozenblit, MD (Survivorship)
 Helen K. Chew, MD (Symptom Management)

Dawn Hershman, MD, MS (CCD)

..... Banu Arun, MD (Prevention)
 Philip Lammers, MD
 Early Therapeutics & Rare Cancers: Lara E. Davis, MD (Survivorship)
 Jason M. Prosek, MD
 Gastrointestinal Committee: Jason A. Zell, DO (Prevention)
 Afsaneh Barzi, MD (CCD)
 Genitourinary Committee: Clara Hwang, MD
 Sarah P. Psutka, MD
 International Liaison: Kathy S. Albain, MD
 Leukemia Committee: Stephanie B. Tsai, MD
 Lung Committee: Gary E. Goodman, MD
 Lymphoma Committee: Hayder Saeed, MD
 Melanoma Committee: Sancy Leachman, MD, PhD
 Thach-Giao Truong, MD (Survivorship)
 Recruitment and Retention Committee: Allison M. Caban-Holt, PhD
 Digital Engagement: Jennifer R. Klemp, PhD (Survivorship)
 Krishna Soujanya Gunturu, MD (Survivorship)
 Mina S. Sedrak, MD (CCD)
 Katherine D. Crew, MD (Prevention)
 Michael J. Fisch, MD (Symptom Management)
 Veterans Affairs: Yeun-Hee Anna Park, MD (Symptom Management)
 Jacqueline Ann Gesek, BSN, RN (Nursing)

Designates

Oncology Research Professionals

CRAs: Amanda R. Dinsdale, MHA, CCRC
 Amy Jo Koffarnus, BS, CCRP
 Melina D. Rodriguez, BS
 Shirley S. Sui, BS
 Samantha Wright, MS, CCRP
 Nurses: Connie Szczepanek, RN, BSN
 Rachel C. Dooley, BSN, RN, OCN
 Pharmaceutical Sciences Committee: Kimberly McConnell, PharmD
 Siu-Fun Wong, PharmD
 Sun "Coco" Yang, PharmD, PhD
 Data Coordinators: Kim Carvalho, BA
 Sam Dzingle, BA
 Mathew Eng, PharmD
 Manny Kharbanda, BA
 Diane Liggett, BS, CCRP
 Roxanne Topacio, CCRP
 Monica Yee, BA, CCRP
 Recruitment and Retention Specialist: Jamie Sundstrom, BS

Cancer Control & Prevention Committees

Patient Advocates:Barbara Segarra-Vazquez, DHSc (CCD)
..... Hartley “Lee” M. Jones, MBA (Survivorship)
..... Cheryl L. Jernigan, CPA (Prevention)
..... Valerie Fraser (Palliative)
Sr. Protocol Project Manager (CCD; Prevention): Patricia O’Kane
Protocol Project Manager (Symptom Management):Megan Keim
Protocol Project Manager (Symptom Management): Justine Trevino
Protocol Project Manager (Palliative Care): Andrea Garcia
Protocol Project Manager (Palliative Care): Justine Trevino
Clinical Trials Program Manager (Palliative Care):Laura Gildner, MS
Clinical Trials Program Manager (CCD; Prevention;
Symptom Control): Mariah Norman, MS

Cancer Care Delivery (CCD) Committee

Leadership

Co-Chairs: Scott D. Ramsey, MD, PhD
 Veena Shankaran, MD, MS

Time/Location

Thursday, May 1, 2025 10:30 a.m. - 12:30 p.m.

Room: Bayview Room (Bay Level)

Agenda

NCORP Grant Renewal Updates – Dawn Hershman, Scott Ramsey, Veena Shankaran

Patient Advocate Updates – Barbara Segarra-Vazquez

Presentations

AI for Precision Oncology: Validation on Completed Clinical Trials –

Anant Madabhushi, PhD, Professor, Biomedical Engineering, Emory University and Georgia Tech

Developing Studies

S2417CD, A Pragmatic Randomized Controlled Trial to Evaluate the Effectiveness of an Intervention to Promote Guideline-Concordant Colorectal Cancer Surveillance – Dr. Christine Veenstra, MD, University of Michigan, Sarah Hawley, PhD, University of Michigan

S2424CD, Lay Health Worker-led Intervention to Promote Goals of Care Communication – Manali Patel, MD, MPH, MS, Stanford University; Ravi Parikh, MD, Emory University; Christopher Manz, MD, Dana Farber Cancer Institute

Employment and Related Outcomes in Newly Diagnosed Patients with Metastatic Breast Cancer, Claire Sathe, MD, Columbia University Irving Medical Center

Patient-centered Video Education Intervention to Improve Rural Cancer Care Delivery – Randall Holcombe, MD, MBA, Izumi Okado, PhD, University of Hawaii

Patient, Provider, and Care Delivery Impacts of Immediate Release of Radiology Reports in Advanced Cancer – Dr. Veena Shankaran, MD, University of Washington.

Active Studies

S1703, “Randomized Non-inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic

Hormone Receptor Positive HER-2 Breast Cancer,” Dr. Melissa Accordini, MD, Columbia University Irving Medical Center Activated 7/16/18.

Recently Completed Accrual Studies

S1912CD, “A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT).” Dr. Veena Shankaran, MD. Activated 7/26/21. Closed: 12/16/24.

S2108CD, “A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy.” Drs. J. Rueter, M. Trivedi, B. Symington, P. Tseng, D. Hershman, S. Ramsey. Activated: 8/22/22. Closed: 11/22/24.

Closed Studies

S1415CD, “A Pragmatic Trial To Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia - Trial Assessing CSF Prescribing, Effectiveness and Risk (TrACER).” Drs. S. Ramsey, D. Hershman, G. Lyman, et al. Activated: 10/7/16. Closed: 4/15/20.

S1417CD, “Implementation of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer.” Dr. V. Shankaran. Activated: 4/15/16. Closed: 2/1/19.

Substudies (Economic Analyses / Cost Effectiveness from NCTN trials)

S1806, Healthcare Cost Comparison of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle-invasive Bladder Cancer, Dr. R. Vaidya, Dr. J. Unger

Cancer Care Delivery (CCD) Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	S1703	S1912CD	S2108CD	A191901	A231901CD	EAQ222CD	NHLBIMDS
Banner University Medical Center - Tucson	1	-	-	-	-	-	-
Baptist Mem Health Care/Mid South Minority Underserved NCORP	-	-	-	-	1	-	3
Bay Area Tumor Institute NCORP	-	1	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	28	-	-	-	-	-	5
Cancer Research Consortium of West Michigan NCORP	-	9	-	-	1	-	-
Cancer Research for the Ozarks NCORP	-	11	44	-	-	-	-
Cancer Research of Wisconsin & N. Michigan Consortium	14	19	61	1	-	-	-
Carle Cancer Center NCI Comm Oncology Research Program	10	2	132	-	-	-	1
Columbia University Minority Underserved NCORP	26	10	-	-	-	-	24
Columbus NCI Comm Oncology Research Program	4	-	-	-	-	-	-
CommonSpirit Health Research Institute	12	2	54	-	-	-	-
Corewell Health William Beaumont University Hospital	-	-	-	-	-	-	2
Cotton O'Neil Cancer Center / Stormont Vail Health	1	-	-	-	-	-	-
Dayton NCI Comm Oncology Research Program	3	1	-	-	-	-	-
Essentia Health NCI Comm Oncology Research Program	-	-	132	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	-	-	23
Georgia Cares Minority Underserved NCORP	-	12	-	-	-	-	-
Georgia NCI Comm Oncology Research Program	3	-	31	-	-	-	-
Gulf South Minority Underserved NCORP	6	3	-	-	-	-	-
Hawaii Minority Underserved NCORP	11	14	100	-	-	4	5
Heartland Cancer Research NCORP	25	7	237	-	-	-	-
Henry Ford Health Providence Southfield Hospital	-	-	-	4	-	-	1
Kaiser Permanente NCI Comm Oncology Research Program	5	17	-	-	-	-	9
Kansas City Veterans Affairs Medical Center	-	-	-	-	-	-	4
Kansas Institute of Medicine Cancer & Blood Center	-	-	-	-	-	-	2
Lahey Hospital & Medical Center	4	-	-	-	-	-	-
Loyola University Medical Center	3	-	-	7	-	-	-
Malcom Randall Veterans Administration Medical Center	-	-	-	-	-	-	6
Massachusetts Veterans Epidemiology Research & Information Cntr	-	-	-	-	-	-	35
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	-	-	5
Michigan Cancer Research Consortium NCORP	16	21	94	-	-	-	-

Cancer Care Delivery (CCD) Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	<i>S1703</i>	<i>S1912CD</i>	<i>S2108CD</i>	<i>A191901</i>	<i>A231901CD</i>	<i>EAQ222CD</i>	<i>NHLBI/MD</i>
Moffitt Cancer Center	-	-	-	-	-	-	8
Montana Cancer Consortium NCORP	11	7	69	-	-	-	-
Mount Sinai Hospital	7	-	-	-	-	-	-
MultiCare Tacoma General Hospital	-	-	-	22	-	-	-
NCORP of the Carolinas	6	2	-	-	-	-	2
Nevada Cancer Research Foundation NCORP	2	2	-	1	-	-	-
New Mexico Minority Underserved NCORP	16	28	-	-	-	-	-
Northwell Health NCORP	-	3	-	-	-	-	18
Oregon Health & Science University	-	-	-	-	-	-	12
Pacific Cancer Research Consortium NCORP	10	30	-	-	-	-	-
Riverside Methodist Hospital	2	-	-	-	-	-	-
Salem Hospital	1	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	6	37	18	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	2	-	-	3	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	-	-	-	27
UC San Diego Moores Cancer Center	-	-	-	-	-	-	34
Universidad de la Republica - Facultad de Medicina	1	-	-	-	-	-	-
University of Arkansas for Medical Sciences	5	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	-	-	-	-	-	-	16
University of Kansas Cancer Center - MCA Rural MU NCORP	9	11	95	-	-	-	-
University of Rochester LAPS	4	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	2	-	-	-
Upstate Carolina NCORP	-	10	73	-	-	-	-
Western States Cancer Research NCORP	-	2	-	1	-	1	-
Wisconsin NCI Comm Oncology Research Program	8	4	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	49	-	-	-	-	-	7
ALLIANCE	17	19	81	-	-	-	-
ECOG-ACRIN	28	31	63	-	-	-	-
NRG	20	16	-	-	-	-	-
Total	376	331	1,284	41	2	5	249

Palliative Care Committee

Leadership

Co-Chairs: Robert S. Krouse, MD
 Marie Bakitas, DNSc, CRNP

Time/Location

Thursday, May 1, 2025 8:00 a.m. - 10:00 a.m.
 Room: Bayview Room (Bay Level)

Agenda

1. **Welcome and Introductions:** Drs. Krouse and Bakitas
2. **Committee Liaison Updates:**
 - Executive Officer: Dr. Virginia Sun
 - Patient Advocates: Valerie Fraser
Carole Seigel
 - ORP Liaison: Shriley Sui
 - GI Liaison: Discussion of the Request for Dr. Vincent Chung
 - Proposals: Advancing Palliative Care
 - Integration in Gastrointestinal Oncology Clinical Trials

3. Active Studies

- S1501**, "Prospective Observational Cohort Study of Patients with Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity." Dr. Justin Floyd. Reopened 11/1/25
- S2408**, "A Randomized Phase III Blinded Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula" Dr. Jonathan Sham. Activated on 2/14/25
- SR2204**, "A Randomized Phase III Trial of a Perioperative Physical Activity Intervention in Older Adults with Lung Cancer and their Family Caregivers.

Developing Studies

- S2424CD**, "Randomized Controlled Trial Lay Health Worker-led Intervention to Promote Goals of Care Communication." Drs. Parikh, Manz, Patel
- S2418** "Distress Screening for Family Caregivers of Persons with Advanced Cancer: The FamilySTRONG Randomized Clinical Trial." Dr. Nicholas J Odom, R01 Re-submitted in July 2024
- S2422**, "Telehealth Intervention for Personalized Self-Management (TIPS) for Eating after Gastroesophageal Cancer Surgery." Dr. Kim, R01 Submitted in November 2025

S2415 "Acupuncture to Decrease Symptom Burden in Patients with Metastatic Breast Cancer" Dr. Heather Greenlee. R01 Re-submitted in July 2024

4. Update on Proposed APP/Nursing Research Support Committee and Approved Trial

NCORP Study, WF2403: Building Capacity within the NCORP Network through an Education and Mentorship Intervention for Advanced Practice Providers (COACH-APP)

5. Secondary Studies (S1316)

6. Update on Dr. Parajuli's Projects

Development and Initial Validation of a Palliative Care Readiness Tool for Older Adults with Cancer (NIH/NIA R15 AG081886-01A1)

Participation of Older adults Belonging to Underrepresented Backgrounds in SWOG Clinical Trials (SWOG ChEER Program Project)

7. Closing Remarks and Next Steps

Final comments from committee leadership

Closed Studies

- S1820**, "A Randomized Phase II Trial of the Altering Intake, Managing Symptoms Intervention for Bowel Dysfunction in Rectal Cancer Survivors (AIMS-RC)." Dr. Virginia Sun. Activated: 12/9/19. Closed to Accrual as of 04/12/2022. Permanently Closed: 04/12/2022
- S1316**, "Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction." Dr. Robert Krouse. Activated: 3/9/15. Permanently Closed: 5/15/20

Palliative Care Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	<i>\$1501</i>
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	7
CWRU Case Comprehensive Cancer Center LAPS	15
Cancer Research for the Ozarks NCORP	11
City of Hope Comprehensive Cancer Center	49
Columbia University Minority Underserved NCORP	2
CommonSpirit Health Research Institute	1
Fred Hutchinson Cancer Research Center LAPS	4
Georgia NCI Community Oncology Research Program	13
Gulf South Minority Underserved NCORP	4
Heartland Cancer Research NCORP	15
Henry Ford Health Providence Southfield Hospital	4
Henry Ford Hospital	3
Kaiser Permanente NCI Community Oncology Research Program	1
King Faisal Specialist Hospital and Research Centre	3
Lahey Hospital and Medical Center	6
Loyola University Medical Center	8
MU Health Care Goldschmidt Cancer Center	5
Medical University of South Carolina Minority Underserved NCORP	1
Michigan Cancer Research Consortium NCORP	3
Moffitt Cancer Center	25
Montana Cancer Consortium NCORP	1
NCORP of the Carolinas (Prisma Health NCORP)	2
National Cancer Center-Korea	1
New Mexico Minority Underserved NCORP	7
Oregon Health and Science University	1
UC Davis Comprehensive Cancer Center LAPS	2
USC Norris Comprehensive Cancer Center LAPS	4
University of Kansas Cancer Center - MCA Rural MU NCORP	7
University of Michigan Comprehensive Cancer Center LAPS	10
Wayne State University - Karmanos Cancer Institute LAPS	6
Western States Cancer Research NCORP	2
ALLIANCE	23
ECOG-ACRIN	43
NRG	24
Total	313

Prevention, Screening, & Surveillance Committee

Leadership

Co-Chairs: Banu Arun, MD
 Jason A. Zell, DO

Time/Location

Thursday, May 1, 2025 4:30 p.m. - 6:30 p.m.
 Room: Bayview Room (Bay Level)

Agenda

Welcome and Opening Comments

Dr. Jason Zell & Dr. Banu Arun

Frank and Linda Meyskens Annual Endowed Lectureship on Advances in Cancer Prevention: "A Third of a Century Experience

in Design, Execution, Analysis, Reporting, and Long-Term Follow-Up of
 Pivotal Cancer Prevention Trials"

Ian M. Thompson, Jr., MD, Children's Hospital of San Antonio

Closed Studies

S0820, "A Double-Blind Placebo-Controlled Trial of Eflornithine and
 Sulindac to Prevent Recurrence of High Risk Adenomas and Second
 Primary Colorectal Cancers in Patients with Stage 0-III Colon or
 Rectal Cancer, Phase III – Preventing Adenomas of the Colon with
 Eflornithine and Sulindac (PACES)." Drs. J. Zell, P. Brown, M.P. Lance, et
 al. Activated: 3/1/13. Closed: 6/30/23.

S1823, "A Prospective Observational Cohort Study to Assess miRNA
 371 for Outcome Prediction in Patients with Newly Diagnosed Germ
 Cell Tumors". Drs. C. Nichols and L. Nappi. Activated: 6/1/20. Closed:
 5/20/24.

S1904, "Cluster Randomized Controlled Trial of Patient and Provider
 Decision Support to Increase Chemoprevention Informed Choice
 Among Women with Atypical Hyperplasia or Lobular Carcinoma In
 Situ – Making Informed Choices on Incorporating Chemoprevention
 into Care (MiCHOICE)." Drs. K. Crew, R. Kukafka, et al. Activated 9/1/20.
 Closed 6/14/24.

Concepts in Development (not yet approved by Triage)

Concept, "Randomized trial of Radiation with or without HER2 targeted
 therapy (trastuzumab) in DCIS patients identified as Residual Risk (RRt)
 by DCISionRT testing". Dr. E. Connolly.

- Concept received feedback from Patient Advocate Committee
- Concept pending drug availability through CTEP.

SWOG/Alliance Tamoxifen/Exemestane Concept, Dr. J. McGuinness.

Other Group Studies with SWOG Study Champions

CTSU A151804, "Establishment of a National Biorepository to Advance
 Studies of Immune-Related Adverse Events." Dr. G. Lyman. Activated:
 1/31/20.

CTSU A212102, "Blinded Reference Set for Multicancer Early Detection
 Blood Tests." Dr. J. McGuinness. Activated: 8/1/22.

CTSU EA1151, "Tomosynthesis Mammographic Imaging Screening Trial
 (TMIST)." Dr. B. Arun. Activated: 7/6/17.

CTSU/NHLBI-MDS, "The National Myelodysplastic Syndromes (MDS)
 Study." Drs. D. Hill and C. Arana Yi. Activated: 4/5/16. Closed: 6/24/24.

CTSU/EA8184, "A Phase II Randomized Double Blinded Study of Green
 Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for
 Prostate Cancer: Modulation of Biological and Clinical Intermediate
 Biomarkers." Dr. R. Kopp. Activated: 5/10/21.

CTSU/NRG-CC005, "FORTE (Five or Ten Year Colonoscopy for 1-2 Non-
 Advanced Adenomatous Polyps)". Dr. L. Kachnic. Activated: 10/6/21.

Prevention, Screening, and Surveillance Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	S1823	S1904	A211801	A212102	EA1151	EA2185	EA8184	NRGCC005	NRGCC008
Audie L Murphy VA Hospital	-	-	-	34	-	-	4	-	-
Banner MD Anderson Cancer Center	5	-	-	-	1	-	-	-	-
Banner University Medical Center - Tucson	14	-	-	-	56	-	-	-	-
Baptist Memorial Health Care/Mid S Minority Underserved NCORP	-	12	-	-	8	-	-	-	-
Bay Area Tumor Institute NCORP	1	-	-	-	-	-	-	-	-
Baylor College of Medicine/Duncan Comprehensive Cancer Center	-	-	-	-	-	3	-	-	4
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	2	290	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	2	-	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	5	-	-	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	6	-	-	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	5	26	-	-	2	-	-	-	-
City of Hope Comprehensive Cancer Center	-	20	-	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	42	-	-	-	-	-	-	-
Columbus NCI Community Oncology Research Program	7	-	-	-	-	-	-	-	-
Essentia Health NCI Community Oncology Research Program	5	-	-	-	100	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-	-	105	-	-	-	-
Gulf South Minority Underserved NCORP	13	-	-	-	-	-	-	-	2
Hawaii Minority Underserved NCORP	3	21	-	-	80	-	-	-	-
Heartland Cancer Research NCORP	15	11	-	-	-	-	-	-	-
Henry Ford Hospital	-	-	-	4	133	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	178	15	-	-	-	-	-	-	-
Kansas City Veterans Affairs Medical Center	-	-	-	2	-	-	-	1	-
Lahey Hospital and Medical Center	-	3	-	-	-	-	-	-	-
Loma Linda University Medical Center	8	-	-	-	-	-	-	-	-
Loyola University Medical Center	-	4	-	-	-	-	-	-	-
Malcom Randall Veterans Administration Medical Center	-	-	-	-	-	-	-	1	-
Massachusetts VetS Epidemiology Research and Information Cntr	-	-	-	26	-	8	-	16	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	1	4	-	3	-	-
Memorial Hermann Texas Medical Center	-	-	-	-	8	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	11	-	-	-	463	-	-	-	-
Nevada Cancer Research Foundation NCORP	1	-	-	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	12	-	-	-	-	-	-	-	-
Northwell Health NCORP	11	-	-	-	-	-	-	-	1
Ohio State University Comprehensive Cancer Center LAPS	8	2	-	-	-	-	-	-	-

Prevention, Screening, and Surveillance Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	S1823	S1904	A211801	A212102	EA1151	EA2185	EA8184	NRGCC005	NRGCC008
Oregon Health and Science University	17	-	-	-	-	3	2	10	3
Pacific Cancer Research Consortium NCORP	-	1	-	-	-	-	-	-	-
Riverside Methodist Hospital	3	-	-	-	-	-	-	-	-
Salem Hospital	3	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	2	-	-	-	-	-	-	-	-
The Don and Sybil Harrington Cancer Center	-	-	-	5	-	-	-	-	-
Tulane University School of Medicine	-	-	-	-	2	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-	-	-	1	1	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	4	-	-	76	-	-	-	-	-
UC San Diego Moores Cancer Center	24	-	-	-	-	1	-	-	-
UCLA / Jonsson Comprehensive Cancer Center	30	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	33	-	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	389	3	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	6	-	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	26	-	-	5	2	-	-	8	-
University of Kentucky/Markey Cancer Center	-	-	-	-	9	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	-	-	1	-	-	-	-	-	-
University of Mississippi Medical Center	6	-	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	8	-	-	-	-	-	-	-	-
University of Rochester LAPS	20	-	-	-	263	-	-	-	-
University of Texas Health Science Center at San Antonio	-	-	-	19	-	-	-	-	1
University of Utah - Huntsman Cancer Institute LAPS	-	21	-	-	-	-	-	-	-
Upstate Carolina NCORP	-	-	-	-	619	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	7	-	-	-	-	-	-	-	-
Virginia Mason Medical Center	16	-	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	8	-	-	-	-
Western States Cancer Research NCORP	5	-	-	-	73	-	-	-	-
ALLIANCE	96	106	-	-	-	-	-	-	-
CCTG	217	-	-	-	-	-	-	-	-
ECOG-ACRIN	76	43	-	-	-	-	-	-	-
NRG	55	85	-	-	-	-	-	-	-
Total	964	412	1	174	2,615	19	10	36	11

Symptom Management & Survivorship Committee

Leadership

Co-Chairs: Michael J. Fisch, MD, MPH
 Norah Lynn Henry, MD, PhD

Time/Location

Thursday, May 1, 2025 2:00 p.m. - 4:00 p.m.
 Room: Bayview Room (Bay Level)

Agenda

Plenary

Symptom Management and Survivorship from the Lens of an Oncologist and Cancer Survivor - Mark Lewis, MD, Intermountain Healthcare

Patient Advocate Update - Lee Jones

Concepts in Development

S2423, "Testing the Fatigue Diet in People with Early-Stage Breast Cancer: The GUIDE Study". Drs. S. Zick and H. Greenlee. Triage informally reviewed on 1/22/24. R01 application submitted February 8th. Scored a 38 in the 36th percentile, plan to resubmit R01 in November 2024.

S2435, "Phase III Trial of an App-Supported Sleep Coaching Intervention in Post-Treatment Survivors of Diverse Cancers and their Bedroom Partners". Drs. Rina Fox and Terry Badger. R01 submitted June 5th. Review response expected Q4 2024. Summary statements received, planning to resubmit in June 2025.

Use of GLP-1 agonists in early stage breast cancer survivors. Dr. Vidhya Nair

Weight management prior to radical prostatectomy to improve quality of life and obesity-driven prostate cancer biomarkers. Dr. Jill Hamilton-Reeves

Observational cohort study of cancer-related cognitive dysfunction in men with prostate cancer on ADT-based regimens. Dr. Clara Hwang

Exercise intervention to reduce fatigue in men with prostate cancer on ADT-based regimens. Drs. Lisa Rogers and Dennis Kerrigan

The Use of Memantine for the Prevention of Cancer-Related Cognitive Impairment (CRCI) in Young Adult (YA) Patients with Colorectal Cancer. Dr. Christopher Cann

Active Studies

S2013, "Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study." Drs. Gunturu, Hershman, Kuderer, et al. Activated: 8/16/21; Temporarily closed to accrual: 5/6/24.

S2205, "ICE COMPRESS: Randomized Trial of Limb Cryocompression Versus Continuous Compression Versus Low Cyclic Compression for the Prevention of Taxane-Induced Peripheral Neuropathy." Drs. Accordini, Pennington, Hershman, et al. Activated: 3/16/23.

Closed Studies

S1600, "A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes (SIMMune)." Drs. Hamilton-Reeves, Holzbeierlein, Kukreja, et al. Permanently closed 10/20/23.

S1614, "A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors." Drs. Hwang, Lok, Gehring, et al. Permanently closed 11/15/22.

S1714, "A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients." Drs. Trivedi, Hershman, Brannagan, et al. Activated: 3/1/19; Permanently closed 11/15/21.

S1706, "A Phase II Randomized, Double-Blinded, Placebo-Controlled Trial of Olaparib Administered Concurrently with Radiotherapy for Inflammatory Breast Cancer." Dr. Jaggi. Activated: 9/12/18; Closed to accrual: 7/1/24.

S1806, "Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer." Dr. Singh. Activated: 4/19/18; Closed to accrual: 4/1/24.

S1826, "A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma." Drs. Herrera, Friedberg. Activated: 7/19/19; Closed to accrual: 12/1/22.

S0820, "A Double-Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)." Drs. Zell, Brown, Lance, et al. Activated: 3/1/13; Closed to accrual: 6/30/23.

S1904, "Cluster Randomized Controlled Trial of Patient and Provider Decision Support To Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma in Situ - Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)." Drs. Crew, Kukafka, Hershman, et al. Activated: 9/1/20; Closed to accrual: 6/14/24.

Symptom Management & Survivorship Committee

S2010, “A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence with Endocrine Therapy in Young Women with Stage I-III Breast Cancer (ASPEN).” Drs. Henry, Hershman, and Skaar. Activated: 1/17/23; Closed to accrual: 1/15/25.

Committee Business

1. What other studies are we planning?
2. What is happening with our open studies?
3. What other updates should we know about?
 - Patient Advocate Update
 - Statistical Center Update

Other SWOG Studies with Symptom Control and QOL Component

Cancer Care Delivery

S1703, “Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (Stmddm) Versus Usual Care in Patients with Metastatic Hormone Receptor Positive Her-2 Negative Breast Cancer.” Drs. Accordino, Hershman, and Ramsey. Activated: 7/16/18.

S1912CD, “A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT).” Drs. Shankaran, Carlos, Hershman, et al. Activated: 7/26/21.

S2108CD, “A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy.” Drs. Reuter, Trivedi, Symington, et al. Activated: 8/22/22.

GU

S1802, “Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer.” Dr. Chapin. Activated: 9/17/18.

Leukemia

S1925, “Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients

with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study.” Drs. Stephens, Hill, Pagel, et. al. Activated: 12/14/20.

Lung

S1914, “A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC#783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC.” Drs. Daly, Simone, Kelly, et al. Activated: 3/25/20.

S1827, “MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK).” Drs. Rusthoven, Brown, Wefel, et al. Activated: 1/10/20.

Lymphoma

S1918, “A Phase II/III Randomized Study of R-miniCHOP with or without Oral Azacitidine (CC-486) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements.” Drs. Brem, Smith, Henry, et al. Activated: 3/19/21.

Myeloma

S1803, “Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study).” Drs. Krishnan, Chhabra, and Callander. Activated: 6/27/19.

NCTN Studies

CTSU/NRG-GI004, “Colorectal Cancer Metastatic dMMR Immunotherapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/ Bevacizumab Combination Chemotherapy with or Without Atezolizumab or Atezolizumab Monotherapy in the First Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer.” Dr. Overman. Activated: 11/7/17; Temporarily closed: 6/4/20; Reactivated: 1/29/21.

Symptom Management & Survivorship Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	S1600	S2010	S2013	S2205	A211901	A221805	A222001	A222004
Audie L Murphy VA Hospital	-	-	26	-	-	-	-	-
Banner MD Anderson Cancer Center	-	-	-	-	-	1	-	-
Banner University Medical Center - Tucson	-	-	5	-	-	-	1	-
Baptist Mem Health Care/Mid S Minority Underserved NCORP	-	-	-	-	-	-	-	-
Baylor College of Medicine/Duncan Comprehensive Cancer Center	5	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer CenterLAPS	-	-	-	-	-	4	-	-
Cancer Research Consortium of West Michigan NCORP	-	2	-	1	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	12	-	-	-	-	-
Cancer Research of Wisconsin & Northern Michigan Consortium	-	4	131	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	1	17	-	-	-	-	-
City of Hope Comprehensive Cancer Center	6	-	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	25	27	28	-	-	-	1
Columbus NCI Community Oncology Research Program	-	-	35	-	-	-	-	-
CommonSpirit Health Research Institute	-	13	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	1	-	-
Fred Hutchinson Cancer Research Center LAPS	13	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	22	-	-	-	-	-
Georgia NCI Comm Oncology Research Program	-	20	67	-	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	9	-	-	-	-	-
Gulf South Minority Underserved NCORP	1	4	25	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	9	4	12	-	-	-	-
Heartland Cancer Research NCORP	-	25	234	-	-	-	-	-
Henry Ford Health Providence Southfield Hospital	-	-	29	-	-	-	-	-
Henry Ford Hospital	8	-	-	2	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	22	13	-	-	-	-	-
Instituto Nacional de Enfermedades Neoplasicas	-	24	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	27	74	-	-	-	-	-
Lahey Hospital & Medical Center	-	12	63	-	-	-	-	-
Massachusetts Vets Epidemiology Research and Information Center	-	-	63	-	-	-	-	-
Mercy Medical Center - Des Moines	-	-	9	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	19	1	-	-	-	-	-
Moffitt Cancer Center	-	9	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	7	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	-	-	-
NCORP of the Carolinas	-	-	-	-	-	-	-	-

Symptom Management & Survivorship Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	S1600	S2010	S2013	S2205	A211901	A221805	A222001	A222004
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	-	-	3
New Mexico Minority Underserved NCORP	-	20	-	17	-	-	-	-
Northwestern University LAPS	-	7	-	-	-	-	-	-
Oregon Health & Science University	-	-	12	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	-	11	2	-	-	-	-	-
Rhode Island Hospital	-	-	-	7	-	-	-	-
STCC at DHR Health Institute for Research & Development	-	18	55	-	7	-	-	-
Saint Joseph Hospital - Cancer Centers of Colorado	-	-	3	-	-	-	-	-
Salem Hospital	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	2	148	48	-	-	-	-
Stanford Cancer Institute Palo Alto	-	-	-	-	-	-	-	-
The Don & Sybil Harrington Cancer Center	-	10	4	-	-	-	-	1
UC Davis Comprehensive Cancer Center LAPS	-	7	13	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	6	-	-	-	-	-
UC San Diego Moores Cancer Center	-	2	2	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	4	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	78	-	12	-	-	-	-	-
Universidad de la Republica - Facultad de Medicina	-	4	22	-	-	-	-	-
U of Alabama at Birmingham/Deep South Research Consortium LAPS	-	-	-	3	-	-	-	-
University of Arkansas for Medical Sciences	-	6	25	-	-	-	-	-
University of Colorado Cancer Center LAPS	14	3	38	-	-	2	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	51	18	82	17	1	2	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	-	32	-	-	-	-	-	-
University of Mississippi Medical Center	-	1	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	2	-	-	-	-	-	-
University of Rochester LAPS	16	-	-	-	-	-	-	-
University of Texas Health Science Center at San Antonio	-	17	53	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	1	3	-	5	-	1	2
Upstate Carolina Consortium Comm Oncology Research Program	-	-	-	13	-	-	-	-
Western States Cancer Research NCORP	-	-	-	4	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	8	27	-	-	-	-	-
ALLIANCE	5	39	352	49	-	-	-	-
ECOG-ACRIN	4	34	110	5	-	-	-	-
NRG	2	85	256	68	-	-	-	-
Total	203	547	2,098	274	13	10	2	7

Symptom Management & Survivorship Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	ACCL1931	EAQ202	NRGCC010	NRGCC011
Audie L Murphy VA Hospital	-	-	-	-
Banner MD Anderson Cancer Center	-	-	-	-
Banner University Medical Center - Tucson	-	-	-	-
Baptist Mem Health Care/Mid S Minority Underserved NCORP	-	-	-	1
Baylor College of Medicine/Duncan Comprehensive Cancer Cntr	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-
Cancer Research of Wisconsin & Northern Michigan Consortium	-	-	-	-
Carle Cancer Center NCI Comm Oncology Research Program	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-
Columbus NCI Comm Oncology Research Program	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-
Dayton NCI Comm Oncology Research Program	-	-	-	1
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	-
Georgia NCI Comm Oncology Research Program	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-	-
Gulf South Minority Underserved NCORP	-	-	11	-
Hawaii Minority Underserved NCORP	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-
Henry Ford Health Providence Southfield Hospital	-	-	-	-
Henry Ford Hospital	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	-
Instituto Nacional de Enfermedades Neoplasicas	-	-	-	-
Kaiser Permanente NCI Comm Oncology Research Program	-	-	-	-
Lahey Hospital & Medical Center	-	-	-	4
Massachusetts Vets Epidemiology Research & Information Cntr	-	-	-	-
Mercy Medical Center - Des Moines	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-
Moffitt Cancer Center	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-
Mount Sinai Hospital	-	-	-	1
NCORP of the Carolinas	-	39	-	-

Symptom Management & Survivorship Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	ACCL1931	EAQ202	NRGCC010	NRGCC011
Nevada Cancer Research Foundation NCORP	-	4	-	-
New Mexico Minority Underserved NCORP	-	-	-	-
Northwestern University LAPS	-	-	-	-
Oregon Health & Science University	-	-	-	-
Pacific Cancer Research Consortium NCORP	-	-	-	-
Rhode Island Hospital	-	-	-	-
STCC at DHR Health Institute for Research & Development	-	-	-	-
Saint Joseph Hospital - Cancer Centers of Colorado	-	-	-	-
Salem Hospital	-	-	-	6
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-
Stanford Cancer Institute Palo Alto	2	-	-	-
The Don & Sybil Harrington Cancer Center	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-	2
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	-
UC San Diego Moores Cancer Center	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-
Universidad de la Republica - Facultad de Medicina	-	-	-	-
U of Alabama at Birmingham/Deep S Research Consortium LAPS	-	-	-	-
U of Arkansas for Medical Sciences	-	-	-	-
U of Colorado Cancer Center LAPS	-	-	-	-
U of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	8
U of Kentucky/Markey Cancer Center	-	-	-	3
U of Michigan Comprehensive Cancer Center LAPS	-	-	-	-
U of Mississippi Medical Center	-	-	-	-
U of Oklahoma Health Sciences Center LAPS	-	-	2	-
U of Rochester LAPS	-	-	-	-
U of Texas Health Science Center at San Antonio	-	-	-	-
U of Utah - Huntsman Cancer Institute LAPS	-	-	-	-
Upstate Carolina NCORP	-	-	-	-
Western States Cancer Research NCORP	-	-	-	-
Wisconsin NCI Comm Oncology Research Program	-	-	-	-
ALLIANCE	-	-	-	-
ECOG-ACRIN	-	-	-	-
NRG	-	-	-	-
Total	2	43	13	26

Early Therapeutics & Rare Cancers Committee

Leadership

Chair: Razelle Kurzrock, MD
 Vice-Chair: Young Kwang Chae, MD, MPH
 Executive Officer: Christopher W. Ryan, MD
 Statisticians: Megan Othus, PhD
 Anna B. Moseley, MS
 Sara Threlkel, BS

Designates

Data Coordinator: Christine Magner
 Digital Engagement: Kanwal Raghav, MD, MBBS
 Veterans Affairs: Jimmy Ruiz, MD
 Oncology Research Professionals:
 CRAs: TBD
 Nurse: Adam Platt, BS
 Pharmaceutical Science: Craig Elg, PharmD
 Sun "Coco" Yang, PharmD, PhD
 Patient Advocate: Marcia K. Horn, JD
 Protocol Project Manager: Catrina De Los Santos-Mireles
 Clinical Trials Program Manager: Laura Gildner, MS

Early Therapeutics Liaisons

Breast Committee Liaison: Stephanie L. Graff, MD
 Cancer Control Liaison: Jason M. Prosek, MD
 Lara E. Davis, MD (Survivorship)
 Genitourinary Committee Liaison: Parminder Singh, MD
 Imaging: TBD
 Lung Committee Liaison: Shirish M. Gadgil, MD
 Lymphoma Committee Liaison: Nasheed Mohammad Hossain, MD
 Melanoma Committee Liaison: TBD
 Myeloma Committee Liaison: Frits van Rhee, MD, PhD

Time/Location

Thursday, May 1, 2025 9:00 a.m. - 11:00 a.m.

Room: Seaciff AB (Bay Level)

Agenda

9:00 – 9:05 am Welcome and Introduction - Razelle Kurzrock, MD
 9:05 – 9:25 am CNS Working Group and DART CNS Data -
 Manmeet Ahluwalia, MD
 9:25 – 9:45 am S2012, "Randomized Phase II/III Trial of First Line
 Platinum/Etoposide with or without Atezolizumab
 (NSC #783608) in Patients with Poorly Differentiated
 Extrapulmonary Neuroendocrine Carcinomas" -
 David Zhen, MD

9:45 – 10:05 am Translational Aspects of DART -
 Young Kwang Chae, MD, MPH
 10:05 – 10:25 am Overview of Clinical Updates of DART -
 Sandip Patel, MD
 10:25 – 10:45 am Updates from Sarcoma Working Group - Lara Davis, MD
 10:45 – 10:55 am NEC-BiTe: A phase II randomized trial of tarlatamab in
 patients with extrapulmonary neuroendocrine
 carcinoma - Junaid Arshad, MD, MS
 10:55 – 11:00 am Wrap Up - Razelle Kurzrock, MD

Active Studies

S2012, "Randomized Phase II/III Trial of First Line Platinum/Etoposide
 with or without Atezolizumab (NSC#783608) in Patients with Poorly
 Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas
 (NEC)." Drs. Zhen, Chiorean, Burgess, Swisher. Activated: 12/2/21.

CTSU/EA2183, "A Phase III Study of Consolidative Radiotherapy in
 Patients with Oligometastatic HER2 Negative Esophageal and Gastric
 Adenocarcinoma." Dr. Uboho. SWOG Champion: Dr. Saeed. Activated:
 2/6/20.

CTSU/A071401, "Phase II Trial of SMO/AKT/NF2/CDK Inhibitors in
 Progressive Meningiomas with SMO/AKT/NF2/CDK Pathway Mutations."
 Dr. Brastianos. SWOG Champion: Dr. Piccioni. Activated: 8/28/2015. New
 patient registration (Step 1) to the NF2, CDKN2A, CDK4, CDK6, CCND1,
 CCND2, CCND3, and CCNE1 Cohort (Abemaciclib Cohort) is closed to
 accrual as of 10/03/2022.

CTSU/A092001, "Phase 2 Randomized Trial of Neoadjuvant or Palliative
 Chemotherapy with or Without Immunotherapy for Peritoneal
 Mesothelioma". SWOG Champion: Dr. P.S.K. Raghav. Activated: 10/15/21.

CTSU/AGCT1531, "A Phase III Study of Active Surveillance for Low Risk
 and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk
 Pediatric and Adult Patients with Germ Cell Tumors" SWOG Champion:
 Dr. D'Souza Activated: 5/8/17. Stratum 2 is temporarily closed to accrual
 12/17/2024.

CTSU/AOST2031, "A Phase 3 Randomized Controlled Trial Comparing
 Open vs Thoracoscopic Management of Pulmonary Metastases in
 Patients with Osteosarcoma" SWOG Champion: Dr. Hofstetter. Activated:
 2/15/22

CTSU/AOST2032, "A Feasibility and Randomized Phase 2/3 Study of the
 VEGFR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic
 Chemotherapy for Newly Diagnosed Osteosarcoma" SWOG Champion:

Early Therapeutics & Rare Cancers Committee

Dr. J. A. Livingston. Activated: 2/17/23 Temporarily Closed to Accrual as of 09/06/2023

CTSU/A071702, "A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatic Hyper-mutated Recurrent Glioblastoma." SWOG Champion: Dr. M. Ahluwalia. Activated: 10/30/20. Pre-Registration is temporarily Closed to accrual 12/12/23

CTSU/ HN.11 (CCTG-HN11), "SPECT-CT Guided Elective Contralateral Neck Treatment (SELECT) for Patients with Lateralized Oropharyngeal Cancer: A Phase III Randomized Controlled Trial SWOG" Champion: Dr. Paul Swiecicki. Activated: 9/29/22

Studies in Development

S2425, "A Randomized Phase II Study of Temozolomide in Combination with Atezolizumab (Tem-Atezo) versus Temozolomide Alone in Adults with Advanced Bronchopulmonary Neuroendocrine Tumors." Dr. Sukrithan

S2426, "A Randomized Phase II Study of Amivantamab versus Cetuximab in Immunocompromised Patients with Recurrent Inoperable or Metastatic Cutaneous Squamous Cell Carcinoma". Dr. Swiecicki.

S2505, "Phase III Randomized Study Testing Non-Inferiority of Short-Course Ultra-Fractionated Radiation (UHRT-5) Versus Standard Fractionation (RT-25) for High-Risk, Resectable Soft Tissue Sarcoma. Dr. Harris

Closed Studies

CTSU/A071601, "Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas." Dr. Brastianos. SWOG Champion: Dr. Ahluwalia. Activated: 8/4/17. Temporarily Closed (Cohort A): 9/8/20. Closed: 05/10/2024

S1609, "DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors." Drs. Patel, Chae, and Kurzrock. Activated: 1/13/17. Closed: 3/15/23.

CTSU/NRG-GY006, "A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer." Dr. Leath. SWOG Champion: Dr. Robinson. Activated: 1/15/16. Closed: 9/22/22

CTSU/NRG-GY020, "A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer." Dr. Backes. SWOG Champion: Dr. Robinson. Activated: 2/7/20. Closed: 8/29/22.

NCIC0VID, "NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study." Dr. Karim. Activated: 5/21/20. Closed: 2/1/2022.

CTSU/NRG-GY009, "A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer." Dr. O'Cearbhaill. SWOG Champion: Dr. Robinson. Activated: 5/12/17. Closed 10/14/2021

CTSU/NRG-HN007, "An Open-Label, Phase III Study of Platinum-Gemcitabine with or without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma." Dr. Brigitte B. Y. Activated: 9/8/20; Closed: 10/28/21

CTSU/EAY131, "Molecular Analysis for Therapy Choice (MATCH)." Activated: 8/12/2015. Closed: 12/23/2022

CTSU/NRG-BN007, "A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab versus Temozolomide in Patients with Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma." Dr. Lassman. SWOG Champion: Dr. Ahluwalia. Activated: 8/6/20. Closed: 3/29/23.

CTSU/EA3163, "Phase II Randomized Trial of Neoadjuvant Chemotherapy Followed by Surgery and Post-Operative Radiation versus Surgery and Post-Operative Radiation for Organ Preservation of T3 and T4a (and Selected T4b) Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)." Dr. Saba. SWOG Champion: Dr. Swiecicki. Activated: 3/28/18. Closed: 11/7/23

Proposed Studies

NRG-BN1803, "NRG-COG Phase II Trial of Radiation Plus Concurrent and Adjuvant ONC201 for Newly Diagnosed, H3 K27M-Mutant Gliomas." SWOG Champion: Dr. Ahluwalia.

NRG-OV1821, "A Randomized Phase II Trial of Olaparib Versus Olaparib + Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer." Dr. Robinson.

NRG-BN1855, "A Randomized Phase II/III Open Label Study of Ipilimumab and Nivolumab Vs Temozolomide in Patients with Newly Unmethylated MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Glioblastoma." Dr. M. Ahluwalia.

Early Therapeutics & Rare Cancers Committee

NRG-HN1854, “An Open-label, Phase III Study of Platinum-Gemcitabine with or Without Nivolumab in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma.” Dr. P. Swiecicki.

NRG-UC1805, “Randomized Phase III Trial of Radiation +/- Pembrolizumab for High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer.” Dr. W. Robinson.

ComboMatch Proposed Studies

EAY191-S7, “A Phase 2 Study Investigating Safety and Efficacy of Trastuzumab Deruxtecan (DS8201/T-DXd) and ATR Inhibitor, Ceralasertib (AZD6738) in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Advanced Solid Tumors.” Dr. K. Raghav.

ComboMATCH Active Studies

EAY191-S3, “Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors.”
Study Chairs: Reva Basho, M.D., Haider Mahdi, M.

Early Therapeutics & Rare Cancers Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	EAY191-S3	S2012	A071401	AGCT1531	EAY191	EAY191A3	EAY191A6	EAY191E4
Cancer Research Consortium of West Michigan NCORP	-	1	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	1	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	1	-	-	-
CommonSpirit Health Research Institute	-	1	1	-	-	-	-	-
Duke University - Duke Cancer Institute LAPS	1	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	10	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	1	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	1	-	-	-	-	-	-
Henry Ford Hospital	-	2	-	-	-	-	-	-
Kaiser Permanente NCI Comm Oncology Research Program	-	3	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	3	-	-	-	-	-	-
Moffitt Cancer Center	-	4	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	1	-	-	-	-
Northwestern University LAPS	-	4	1	-	-	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	5	-	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	1	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	1	-	-	-	-	-	-
The Don & Sybil Harrington Cancer Center	-	-	-	1	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	1	-	4	-	1	3
UC San Diego Moores Cancer Center	-	-	2	-	-	-	-	-
University of Colorado Cancer Center LAPS	-	-	1	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	-	2	-	-	-	-	-	-
University of Texas Health Science Center at San Antonio	-	2	-	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	1	-	-	-	6	2	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	1	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	2	-	-	-	-	-	-
Wisconsin NCI Comm Oncology Research Program	-	1	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	4	2	-	-	-	-	-
ALLIANCE	1	11	-	-	-	-	-	-
ECOG-ACRIN	4	7	-	-	-	-	-	-
NRG	-	7	-	-	-	-	-	-
Total	8	74	8	2	11	2	1	3

Gastrointestinal Committee

Leadership

Chair: Philip A. Philip, MD, PhD, FRCP
 Vice-Chair: Elena Gabriela Chiorean, MD, FASCO
 Executive Officer: Christopher W. Ryan, MD
 Statisticians: Katherine A. Guthrie, PhD
 Sarah Colby, MS

Scientific Leadership

Gastroesophageal: Syma Iqbal, MD
 Zev A. Wainberg, MD
 Pancreatic: Davendra P.S. Sohal, MD
 Andrew M. Lowy, MD (Surgical representative)
 Hepatobiliary: Anthony B. El-Khoueiry, MD
 Rachna T. Shroff, MD
 Syed A. Ahmad, MD (Surgical representative)
 Colon: Marwan G. Fakih, MD
 Philip J. Gold, MD
 Sepideh Gholami, MD (Surgical representative)
 Neuroendocrine Tumors: Nageshwara Arvind Dasari, MD
 Aman Chauhan, MD
 Ano-Rectal: Lisa A. Kachnic, MD
 Hagen F. Kennecke, MD
 Imaging: Anthony F. Shields, MD, PhD
 Pathology: Mary Kay Washington, MD, PhD
 Radiation Oncology: Lisa A. Kachnic, MD
 Surgery: Stephen W. Behrman, MD
 Syed A. Ahmad, MD
 Flavio Rocha, MD
 Translational Medicine: Gabriel N. Duda, PhD, DMD
 Eric Collisson, MD
 HEARD: Rachel Safyan, MD
 Colmar Figueroa-Moseley, PhD, MPH

Designates

Cancer Control Liaisons: Jason A. Zell, DO (Prevention)
 Vincent Chung, MD (Palliative Care)
 Community Liaisons: Gary L. Buchsacher, MD, PhD (Medical Oncology)
 Mohamed E. Salem, MD
 Flavio Rocha, MD (Surgical)
 David Horowitz, MD (Radiation Oncology)
 AYA Committee: Christopher Cann, MD
 Digital Engagement: Heloisa Soares, MD, PhD
 Veterans Affairs: Rangaswamy Govindarajan, MD
 Data Coordinators: Alex Rangel, BS
 Brian Zeller
 Christine Magner

Oncology Research Professionals:

CRA: TBD
 Nurse: TBD
 Patient Advocate (Colon): Angela "Marielle" McLeod, MHA
 Patient Advocate (Pancreatic): Carole Seigel, MBA
 Pharmaceutical Science: Jane E. Rogers, PharmD
 Safae Chouraichi, PharmD
 Protocol Project Manager: Andrea Garcia
 Clinical Trials Program Manager: Laura Gildner, MS

Time/Location

Friday, May 2, 2025 4:30 p.m. - 6:30 p.m.
 Room: Garden Room (Atrium Lobby Level)

Agenda

1. Welcome
2. Announcements & Introductions Philip Philip
E. Gabriela Chiorean
3. HEARD Subcommittee Initiatives Rachel Safyan, Colmar Figueroa-Moseley, Carole Seigel, Marielle McLeod
4. SWOG Led Trials Updates

a. S1922	Michael Overman
b. S2001	Vincent Chung
c. S2104	Heloisa Soares/Syed Ahmad
d. S2107	Van Morris
e. S2012	David Zhen/E. Gabriela Chiorean
f. S2303	Anwaar Saeed/Paul Oberstein
g. S2408	J. Sham/V. Pillarisetty
h. S2433	Rachael Safyan
5. Pancreatic Subcommittee Davendra Sohal, Andrew Lowy

a. Major recent clinical results
b. NCTN trials update
c. Future SWOG plans
6. Anal and Rectal Subcommittee Hagen Kennecke, Lisa Kachnic

a. Major recent clinical results
b. NCTN trials update
c. Future SWOG plans

Gastrointestinal Committee

7. Colon Subcommittee Marwan Fakih, Philip Gold, Sepideh Gholami
 - a. Major recent clinical results
 - b. NCTN trials update
 - c. Future SWOG plans
8. Gastroesophageal Subcommittee Syma Iqbal, Zev Wainberg
 - a. Major recent clinical results
 - b. NCTN trials update
 - c. Future SWOG plans
9. Hepatobiliary Subcommittee Anthony El-Khoueiry, Rachna Shroff
 - a. Major recent clinical results
 - b. NCTN trials update
 - c. Future SWOG plans
10. Neuroendocrine Subcommittee Arvind Dasari, Aman Chauhan
 - a. Major recent clinical results
 - b. NCTN trials update
 - c. Future SWOG plans
11. Discussion / Other Business
12. Adjourn

Gastroesophageal

Active Studies

S2303, "Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ≥ 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)," Dr. Saeed, and Dr. Oberstein. Activated: 5/6/24

CTSU/A022102, "Randomized Phase III Trial of mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab for First-Line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma." Dr. Oberstein. Activated: 1/17/19.

CTSU/EA2174, "A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma." Dr. Kelly. Activated: 1/17/19. Temporarily Closed to Accrual as of 12/29/22.

EA2212, "A Randomized Phase II Study of Perioperative Atezolizumab +/- Chemotherapy in Resectable MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer" SWOG Champion: Emerson Chen. Temporarily Closed to Accrual as of 12/4/24

CTSU/EA2183, "A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)." Dr. Horowitz. Activated: 2/6/20.

Closed Studies

CTSU/A021302, Impact of Early FDG-PET Directed Intervention on Preoperative Therapy for Locally Advanced Gastric Cancer: A Random Assignment Phase II Study. S. Iqbal. Activated by SWOG: 4/1/16.

Pancreatic

Developing Studies

S2433, "Randomized Phase III Study of Second-Line Chemotherapy with or without Panitumumab for Locally Advanced or Metastatic KRAS Wild Type Pancreatic Adenocarcinoma." Drs. R. Safyan, E. Chiorean, H. Singh

Active Studies

S2408, "A Randomized Phase III Blinded Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula." Drs. J. Sham, V. Pillarisetty, R. Krouse. Activated: 2/14/25

S2001, "Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations." Dr. Chung. Activated: 12/4/20.

A022106, "A Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/ Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)." SWOG Champion: G. Botta

CTSU/A021804, "A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma." Dr. C. Lopez. Activated: 11/2/20.

CTSU/A021806, "A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer." Dr. Noel. Activated: 7/1/20.

CTSU/EA2192, "APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation." Drs. Chiorean and Philip. Activated: 4/29/21.

Gastrointestinal Committee

Closed Studies

EA2186, "A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)." Activated: 6/18/20. Dr. Zhen. Closed to Accrual as of 10/17/23

CTSU/RTOG-0848, "Gemcitabine, with and without Erlotinib, Followed by a Second Randomization with and without Chemoradiation, as Adjuvant Treatment for Pancreatic Head Cancer: A Phase III RTOG/SWOG/NCIC/EORTC Study." P. Philip. Closed to accrual as of 1/18/19

CTSU/A021501, "Preoperative Extended Chemotherapy vs Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas." S. Ahmad. Closed to accrual as of 5/6/19

EA2161, "A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET)." Closed to Accrual & Treatment: 12/27/19

Neuroendocrine

Active Studies

S2104, "Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolimide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors." Dr. Soares. Activated: 10/14/21

S2012, "Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC #783608) in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)" Drs. D. Zhen, E. Chiorean, E. Burgess, E. Swisher, L. Byers. Activated: 12/2/21

Closed Studies

CTSU/A021602, "Randomized Double-Blinded Phase III Study of CABozantinib versus Placebo IN Advanced NEuroendocrine Tumors after Progression on Prior Therapy (CABINET)." Dr. Strosberg. Activated: 7/18/18. Closed to Accrual as of 9/8/23

EA2142, "Randomized Phase II Study of Platinum and Etoposide Versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas." SWOG Champion: H. Soares. Closed to Accrual & Treatment: 4/1/21

Hepatobiliary

Active Studies

CTSU/NRG-GI003, "A Phase III Randomized Trial of Protons Versus Photons

for Hepatocellular Carcinoma." Dr. El-Khoueiry. Activated: 6/21/17.

CTSU/EA2197, "Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial." Dr. Rocha. Activated: 12/22/20.

Closed Studies

S1815, "A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers." Dr. Shroff. Activated: 12/3/18. Permanently Closed: 2/15/21.

CTSU/EA2187, "A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma." Dr. Stein. Activated: 1/31/20. Permanently Closed: 3/22/23. CTSU/RTOG-1112, Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma. L. Dawson. SWOG Champion: T. Mitin

Colorectal

Active Studies

S1922, "Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma." Dr. M. Overman

A022101, "A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)" SWOG Champion: S. Gholami Activated: 1/10/23.

EA2222, "A Randomized Phase III Study of Systemic Therapy with or Without Hepatic Arterial Infusion for Unresectable Colorectal Liver Metastases: The PUMP Trial" Activated: 10/19/23. SWOG Champion: Skye C. Mayo, MD, MPH

CTSU/NRG-GI008, "Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)." SWOG GI Committee Co-Chairs: P. Philip & C. Eng Activated: 3/10/22

CTSU/NRG-GI004/ S1610, "Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination versus Single Agent Atezolizumab in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer." Dr. Overman. Activated: 11/7/17.

Gastrointestinal Committee

Closed Studies

S2107, "Randomized Phase II Trial of Encorafenib and Cetuximab with or without Nivolumab for Patients with Microsatellite Stable, BRAFV600E Metastatic Colorectal Cancer." Dr. Morris. Study closed to accrual 10/1/24

S1613, "A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification." Dr. Raghav. Activated: 10/19/17. Step 3 permanently closed: 11/30/23

S0820, "A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)." Dr. Zell. Activated: 3/1/13. Permanently Closed: 6/30/23

CTSU/A021502, "Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair." Dr. Lieu. Activated: 9/12/17. Permanently Closed: 1/17/23

CTSU/A021703, "Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)." Dr. Cohen. Activated: 9/30/19. Permanently Closed: 12/15/22

CTSU/E7208, "A Randomized Phase II Study of Irinotecan and Cetuximab With or Without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy." H. Hochster. Accrual target: 147 / Final accrual: 136

NRG-GI005, "Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)." Dr. A. Scott. Activated: 12/16/19. Accrual target: 1408 / SWOG accrual: 35 / NCTN accrual: 635 SWOG Champion: A. Scott Closed to Accrual as of 2/12/24

Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients." Dr. Morris. Activated: 10/15/20.

CTSU/EA2182, "A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)." Dr. Murphy. Activated: 11/12/19.

CTSU/EA2201, "A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma." Dr. Cho. Activated 5/13/21.

Closed Studies

CTSU/N1048, "A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision." C. Eng. Activated: 4/15/12. Accrual target: 1120 / Final accrual: 1194

InterAACT EA2133, "An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin plus 5-Fluorouracil Versus Carboplatin plus Weekly Paclitaxel in Patients with Inoperable Locally Recurrent or Metastatic Disease." V. Morris. Activated: 2/15/16. Accrual target: 80 / Final accrual: 12

NRG-GI002, "A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer." Activated: 10/12/16. Accrual target: 348/ SWOG accrual: 12 / Final accrual: 363 SWOG Champion: L. Kachnic

EA2165, "A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer." NCTN activated: 4/13/18. Accrual target: 344 / SWOG accrual: 38 / Final accrual: 383 SWOG Champion: V. Morris

Anal

Active Studies

A022104, "The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer" Activated 11/9/22. SWOG Champion: A. Dasari

CTSU/EA2176, "Randomized Phase III Study of Immune Checkpoint

Gastrointestinal Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	S1922	S2001	S2104	S2107	S2303	A021602	A021806	A022001	A022102	A022104	CCTGC032
Banner University Medical Center - Tucson	-	-	9	-	-	3	1	-	-	-	-
Baptist Mem Health Care/Mid S Minority Underserved NCORP	-	2	-	-	-	-	-	-	-	-	-
Baylor College of Medicine/Duncan Compr Cancer Cntr	-	-	-	-	-	-	-	-	-	10	-
Boston Medical Center	-	-	-	-	-	3	1	-	3	5	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	-	2	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	2	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	1	-	-	-	-	-	-	-	-	-
Cancer Research of Wisc & Northern Mich Consort	-	-	-	-	1	-	-	-	-	-	-
Carle Cancer Center NCI Comm Oncology Research Prgm	1	1	1	2	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	6	-	-	-	1	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	1	-	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	1	3	-	-	-	-	-	-	-
Dayton NCI Comm Oncology Research Program	-	-	-	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	2	-	-	-	2	-	-	8	-
Gulf South Minority Underserved NCORP	-	-	-	3	-	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	1	1	-	3	-	-	-	-	-	-	-
Henry Ford Health Providence Southfield Hospital	-	2	-	-	-	-	-	-	-	-	-
Henry Ford Hospital	-	1	-	-	-	-	-	-	-	1	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Comm Oncology Research Prgm	1	-	-	6	-	-	-	-	-	-	-
Loma Linda University Medical Center	-	-	-	-	-	-	-	-	-	-	-
Medical U of South Carolina Minority Underserved NCORP	-	-	1	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	1	2	-	3	2	-	-	-	-	-	-
Moffitt Cancer Center	-	-	2	-	-	4	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	1	-	-	-	-	-	-	-
NCORP of the Carolinas	-	-	1	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	-	1	-	-	-	-
Northwestern University LAPS	1	-	-	-	-	-	1	-	-	-	-
Ohio State U Comprehensive Cancer Center LAPS	-	-	1	-	-	-	-	-	-	-	-
Oregon Health & Science University	-	-	1	-	1	-	1	-	-	-	-

Gastrointestinal Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	S1922	S2001	S2104	S2107	S2303	A021602	A021806	A022001	A022102	A022104	CCTGCO32
Pacific Cancer Research Consortium NCORP	-	2	3	2	-	-	-	-	-	-	1
STCC at DHR Health Institute for Research & Development	-	-	-	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	2	4	4	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	-	-	-	-	1	-	-
The Don and Sybil Harrington Cancer Center	-	-	-	-	-	-	2	-	-	1	-
The West Clinic - Wolf River	-	-	-	-	-	-	-	-	-	13	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	-	2	-
UC Irvine Health/Chao Family Comprehensive Cancer Cntr	-	2	-	4	-	-	-	-	7	5	2
UPMC Hillman Cancer Center LAPS	-	-	-	-	2	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	1	-	1	-	-	-	-	-	-
U of Alabama at Birmingham/Deep South Research Consort LAPS	-	-	-	-	-	-	-	-	1	-	-
University of Arkansas for Medical Sciences	-	-	-	-	-	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	1	-	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	-	3	-	9	-	-	-	-	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-	-	-	-	-	8	-	-
University of Kentucky/Markey Cancer Center	-	-	4	-	-	-	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	4	3	2	-	-	4	4	-	-	1	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	2	-	-	-	-	-	-	-
University of Rochester LAPS	1	-	-	-	-	8	11	-	3	19	-
University of Texas Health Science Center at San Antonio	-	-	-	-	-	-	3	-	-	5	-
University of Texas MD Anderson Cancer Center LAPS	13	-	-	10	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	1	3	-	1	-	-	1	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	4	-	1	-	-	-	-	-	8	-
Virginia Mason Medical Center	-	-	-	-	-	2	-	-	-	4	-
Wayne State University - Karmanos Cancer Institute LAPS	-	1	-	-	-	-	-	-	3	-	-
Wisconsin NCI Community Oncology Research Program	-	-	1	1	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	1	-	-	-	-	2	1	-	-	-
ALLIANCE	12	5	4	8	5	-	-	-	-	-	-
ECOG-ACRIN	2	12	6	14	-	-	-	-	-	-	-
NRG	3	7	8	10	-	-	-	-	-	-	-
Total	40	60	56	88	13	25	31	2	26	82	3

Gastrointestinal Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	CCTGNE1	EA2174	EA2176	EA2182	EA2186	EA2192	EA2197	EA2222	NRGG1004
Banner University Medical Center - Tucson	-	-	-	-	-	-	-	-	-
Baptist Mem Health Care/Mid South Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
Baylor College of Medicine/Duncan Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-
Boston Medical Center	-	2	-	2	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	2	-	4	1	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-	-	-	-	-
Cancer Research of Wisconsin & Northern Michigan Consortium	-	-	-	-	-	-	-	-	-
Carle Cancer Center NCI Comm Oncology Research Program	-	-	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	3	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	-	-	-	-	-
Dayton NCI Comm Oncology Research Program	-	-	-	-	1	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	1	-	-	-	-
Gulf South Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-	2	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-	-	-	-	-
Henry Ford Health Providence Southfield Hospital	-	-	1	2	2	-	-	-	-
Henry Ford Hospital	-	-	-	-	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-	1
Kaiser Permanente NCI Community Oncology Research Program	-	-	8	-	-	-	-	-	-
Loma Linda University Medical Center	-	-	-	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-	-	-	-
Moffitt Cancer Center	-	-	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-	-	-
NCORP of the Carolinas	-	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	1	-	-	2	-	1	-	-
Northwestern University LAPS	-	-	1	-	1	-	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	2	-	-	-	-	-	-	-	-
Oregon Health & Science University	-	-	4	1	-	3	5	-	-

Gastrointestinal Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	CCTGNE1	EA2174	EA2176	EA2182	EA2186	EA2192	EA2197	EA2222	NRGG1004
Pacific Cancer Research Consortium NCORP	-	-	-	-	-	-	-	-	-
STCC at DHR Health Institute for Research & Development	-	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	-	1	-	-	-
The Don and Sybil Harrington Cancer Center	-	-	-	-	-	-	-	-	-
The West Clinic - Wolf River	-	-	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-	-	-	-	1	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	4	1	2	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	1	3	-	-	-	-	-	-
U of Alabama at Birmingham/Deep South Res Consortium LAPS	-	-	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	2	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	1	1	-	-	-	-	-
University of Colorado Cancer Center LAPS	2	-	-	2	1	-	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-	-	-	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	-	-	1	-
University of Michigan Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	1	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	-	-	-	-	-	-
University of Rochester LAPS	-	-	-	-	7	-	-	-	1
University of Texas Health Science Center at San Antonio	-	-	-	-	3	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	10	-	-	-	-	-	13
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	-	-	1	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	1	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-	-
Total	4	6	34	14	26	4	8	2	15

Gastrointestinal Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	NRGG1005	NRGG1006	NRGG1008
Banner University Medical Center - Tucson	-	-	-
Baptist Mem Health Care/Mid South Minority Underserved NCORP	3	-	2
Baylor College of Medicine/Duncan Comprehensive Cancer Center	-	-	1
Boston Medical Center	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-
Cancer Research of Wisconsin & Northern Michigan Consortium	-	-	-
Carle Cancer Center NCI Comm Oncology Research Program	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-
Columbia University Minority Underserved NCORP	-	-	-
CommonSpirit Health Research Institute	-	-	-
Dayton NCI Comm Oncology Research Program	1	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-
Gulf South Minority Underserved NCORP	-	-	-
Hawaii Minority Underserved NCORP	-	-	-
Heartland Cancer Research NCORP	-	-	-
Henry Ford Health Providence Southfield Hospital	5	-	1
Henry Ford Hospital	1	-	-
Houston Methodist Hospital	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	11	-	-
Loma Linda University Medical Center	-	-	1
Medical University of South Carolina Minority Underserved NCORP	-	-	-
Michigan Cancer Research Consortium NCORP	1	-	-
Moffitt Cancer Center	-	-	-
Montana Cancer Consortium NCORP	-	-	-
NCORP of the Carolinas	-	-	-
Northwell Health NCORP	1	-	1
Northwestern University LAPS	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-
Oregon Health & Science University	1	-	-

Gastrointestinal Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	NRGG1005	NRGG1006	NRGG1008
Pacific Cancer Research Consortium NCORP	-	-	-
STCC at DHR Health Institute for Research & Development	1	-	1
Southeast Clinical Oncology Research Consortium NCORP	-	-	-
Sutter Cancer Research Consortium	-	-	-
The Don and Sybil Harrington Cancer Center	-	-	-
The West Clinic - Wolf River	-	-	3
UC Davis Comprehensive Cancer Center LAPS	1	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	1	-	-
UPMC Hillman Cancer Center LAPS	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-
U of Alabama at Birmingham/Deep South Research Consortium LAPS	-	-	-
University of Arkansas for Medical Sciences	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-
University of Colorado Cancer Center LAPS	-	-	6
University of Kansas Cancer Center - MCA Rural MU NCORP	2	-	-
University of Kentucky/Markey Cancer Center	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	1	1
University of Rochester LAPS	-	-	7
University of Texas Health Science Center at San Antonio	-	-	-
University of Texas MD Anderson Cancer Center LAPS	1	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	1	-	3
Virginia Mason Medical Center	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-
Yale University - Yale Cancer Center LAPS	4	-	-
ALLIANCE	-	-	-
ECOG-ACRIN	-	-	-
NRG	-	-	-
Total	35	1	27

Genitourinary Committee

Leadership

Chair: Seth P. Lerner, MD
 Vice-Chair: Daniel P. Petrylak, MD
 Chair Emeritus: Ian M. Thompson, Jr., MD
 Executive Officer: Christopher W. Ryan, MD
 Statisticians: Cathy M. Tangen, DrPH
 Melissa Plets, MS
 Sam Callis, MS
 Sara Threlkel, BS

Scientific Leadership

Translational Medicine: David J. McConkey, PhD (GU Chair)
 Joshua J. Meeks, MD, PhD
 Roger Li, MD (Bladder)
 Amir Goldkorn, MD (Prostate)
 Sumanta “Monty” K. Pal, MD (Renal)
 Radiation Oncology: James B. Yu, MD
 Daniel A. Hamstra, MD
 Imaging: Evan Y. Yu, MD
 Hiram Shaish, MD
 John D. Hazle, PhD
 Immunotherapeutics: Shuchi Gulati, MD (Medical Onc)
 Robert Svatek, MD (Urologic Onc)
 Pathology: M. Scott Lucia, MD
 Surgery: Kelly L. Stratton, MD
 Early Therapeutics: Parminder Singh, MD
 Bladder Organ Site Chairs: Siamak Daneshmand, MD (Localized)
 Thomas W. Flaig, MD (Advanced)
 Prostate Organ Site Chairs: Daniel W. Lin, MD (Localized)
 Tanya B. Dorff, MD (Advanced)
 Renal Organ Site Chairs: Brian Shuch, MD (Localized)
 Ulka N. Vaishampayan, MD (Advanced)

Designates

Cancer Control: Clara Hwang, MD
 Sarah P. Psutka, MD, MSC
 Digital Engagement: Neema Navai, MD
 NCORP: Scott Edward Delacroix, Jr., MD
 Helen Heng-Shan Moon, MD
 Veterans Affairs: Michael M. Goodman, MD
 Data Coordinators: Laura Wells, BA
 Michele Counts, BS
 Tonya Johnson, BS
 Oncology Research Professionals:
 CRAs: Abigail L. Cornette, MS
 Nurse: Gary Lee Duvall, RN

Patient Advocates: Darrell Nakagawa (Bladder)
 Tony Crispino (Emeritus, Prostate)
 Lee Henry Moultrie (Prostate)
 Laura B. Esfeller, MA (Renal)
 Pharmaceutical Science: Joyce Lee, PharmD
 Protocol Project Manager: Megan Keim
 Clinical Trials Program Manager: Mariah Norman, MS

Time/Location

Saturday, May 3, 2025 9:30 a.m. - 11:30 a.m.
 Room: Grand Ballroom A (Street Level)

Agenda

9:30 - 9:45 am: Chair’s Welcome and Opening Remarks - Seth Lerner
 9:45 - 10:10 am: Cancer Control - Clara Hwang and Sarah Psutka
 10:10 - 11:30 am: Review of open approved trials - all organ site chairs

Renal – Brian Shuch and Ulka Vaishampayan
 Bladder – Sia Daneshmand and Tom Flaig
 Prostate – Dan Lin and Tanya Dorff

Cancer Control

Liaison: Drs. Clara Hwang and Sarah Psutka

Active Studies

S1600, “A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes.” Drs. J. Hamilton-Reeves and J. Holzbeierlein. Activated: 2/21/19.

S1823, “A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Early Stage Germ Cell Tumors”, PI: Craig Nichols– Activated 6/1/2020 GU Champions: Thomas Frye & Anishka D’Souza

S1931 (Companion Study), “Examining Psychosocial and Emotional Issues for Metastatic Kidney Cancer.” PI: Cristiane Bergerot.

S1937 (Companion Study), “Assessment of Quality of Life for S1937: A Phase III Randomized Trial of Eribulin with or without Gemcitabine Versus Standard of Care (Physician’s Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy.” QoL Study Chair: Dr. Afsaneh Barzi. On hold until accrual picks up on S1937.

Genitourinary Committee

Renal

Organ Site Chairs: Dr. Ulka Vaishampayan (Advanced) and Dr. Brian Shuch (Local).

Priority Study

S1931, "Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)." Drs. H. Kim and U. Vaishampayan. Activated: 11/16/20.

Concepts in Development

S2419, "Phase III Double Blinded Trial of Immune-Based Therapy with a Live Biotherapeutic CBM588, or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma [BioFront Trial]." Drs. P. Barata and U. Vaishampayan. GUSC approval received 12/10/24. RaPID call scheduled 3/6/25.

Active Studies

S2200, "A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2)" Drs. B. Maughan and S. Pal. Activated 9/19/22.

CTSU/AREN1721, "A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups." Dr. M. Parikh. Activated: 10/9/18; Temporarily Closed: 3/24/21; Re-activated: 2/7/22.

CTSU/A031704, "PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]." Dr. T. Zhang. Activated: 5/9/19; Step 1 temporarily closed: 3/8/21; Step 1 re-activated: 3/26/21.

CTSU/A031801, "A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (Radical)." Dr. M. Parikh. Activated: 12/13/19.

CTSU/A031901, "Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A randomized Phase 3 non-Inferiority Trial." Dr. D. Vaena. Activated: 12/10/20.

Closed Studies

S1500, "A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)." Drs. S. Pal and P. Lara. Activated 4/5/16; Permanently closed: 12/15/19.

S0931, "EVEREST: Everolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study." Drs. C. Ryan, E. Heath, P. Lara, et al. Activated: 4/1/11; Permanently Closed: 9/15/16.

CTSU/E2810, "Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy." Dr. S. Pal. Activated: 8/8/12; Permanently closed: 7/25/17.

CTSU/A031501, "Phase III Randomized Adjuvant study of Pembrolizumab in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation." Dr. G. Sonpavde. Activated: 9/21/17; Permanently Closed: 8/24/21.

CTSU/EA8143, "A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)." Drs. P. Lara and B. Shuch. Activated: 2/2/17; Permanently Closed: 6/9/21.

Bladder

Organ Site Chairs: Dr. Thomas Flaig (Advanced) and Dr. Siamak Daneshmand (Local).

Priority Study

S1937, "A Phase III Trial of Eribulin (NSC #707389) with or Without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy." Drs. S. Sadeghi and P. Lara. Activated: 2/16/21. Temporary Closure: 5/30/23. Re-opened Arms 1&3 to accrual and permanently closed Arm 2 on 2/15/24. Revision #4 had Sacituzumab govitecan removed as a treatment option on 2/3/25.

Concepts in Development

S2427, "Bladder preservation with chemoradiotherapy or immunoradiotherapy after a good response to neoadjuvant chemotherapy in patients with muscle invasive bladder cancer (BRIGHT)." Dr. L. Ballas. PRC call occurred 1/29/25. Pending first submission to CTEP early March 2025.

Genitourinary Committee

Active Studies

S1806, “Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer.” Drs. P. Singh, S. Lerner, J. Efstathiou, et al. Activated: 4/19/19. Step 1 accrual closed 3/1/24. Revision #10 submission to CTEP by end of February 2025.

CTSU/A031701, “A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations.” Drs. A. Gupta and S. Gupta. Activated: 8/1/18.

CTSU/A031803, “Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer.” Drs. D. Tyson and C. Ramamurthy. Activated: 1/6/20.

CTSU/EA8185, “Phase II Study of Bladder-Sparing Chemoradiation with MEDI4736 (Durvalumab) in Clinical Stage III, Node Positive Bladder Cancer (INSPIRE).” Drs. T. Mitin and J. Meeks. Activated: 8/25/20.

CTSU/EA8192, “A Phase II/III Trial of MED14736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy” Drs. S. Psutka and A. Tripathi. Activated: 5/6/21.

Closed Studies

S1011, “A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer.” Drs. S. Lerner, A. Alva, and T. Koppie, et al. Activated: 8/1/11; Permanently Closed: 4/15/17. Listed as FDAAA/IRB Completed on 1/8/25.

S1602, “A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG Naïve High-Grade Non-Muscle Invasive Bladder Cancer.” Drs. R. Svatek, A. Alva, and S. Lerner. Activated: 2/7/17; Permanently Closed: 12/15/2020.

S1605, “Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer.” Drs. P. Black, P. Singh, and S. Lerner. Activated: 2/7/17; Permanently Closed: 7/5/19.

S2011, “Randomized Phase II Trial of Gemcitabine, Avelumab, and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery for Cisplatin Ineligible Muscle-Invasive Urothelial Carcinoma.” Drs. Sonpavde, M. Liss, and S. Lerner, et al. Activated: 10/6/21. Closed to Accrual: 11/15/23.

Prostate

Organ Site Chairs: Dr. Tonya Dorff (Advanced) and Dr. Daniel W. Lin (Local).

Priority Study

S2210, “Targeted neoadjuvant treatment for patients with localized prostate cancer and germline DNA repair deficiency.” Dr. H. Cheng. Activated 8/14/23.

Concepts in Development

None

Active Studies

S2312, “A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature.” Dr. Paul Corn. Activated 9/3/24.

S1802, “Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer.” Drs. B. Chapin, A. Aparicio, and R. Valicenti. Activated: 9/17/18. Revision #5 released 8/15/24.

CTSU/A031102, “A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors.” Dr. D. Quinn. Activated: 7/1/15.

CTSU/EA8171, “Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer.” Dr. M. Liss. Activated: 7/9/18.

CTSU/EA8184, “A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers.” Dr. R. Kopp. Activated: 5/10/21.

CTSU/NRG-GU002, “Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or Without Adjuvant Docetaxel.” Dr. D. Raben. Activated: 12/30/16.

CTSU/NRG-GU008, “Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *Intensifying Treatment for Node

Genitourinary Committee

Positive Prostate Cancer by Varying the Hormonal Therapy." Dr. D. Lin. Activated: 3/5/20; Temporarily Closed: 6/24/21; Re-activated: 12/1/21.

CTSU/NRG-GU009, "Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)." Dr. S. Zhang. Activated: 10/15/20; Temporarily Closed: 6/24/21; Re-activated: 12/15/21.

Closed Studies

S1216, "A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer." Drs. N. Agarwal, A. Goldkorn, S. Gupta, et al. Activated: 3/6/13; Permanently Closed: 7/15/17.

CTSU/NRG-GU005, "Phase III IGRT and SBRT Vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer." Dr. A. Solanki. Activated: 11/16/17; Closed to accrual: 6/8/22.

CTSU/NRG-GU006, "A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or Without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate Cancer." Dr. J. Zeng. Activated: 4/27/18; Permanently Closed: 5/19/20.

CTSU/RTOG-0924, "Androgen Deprivation Therapy and High Dose Radiotherapy with or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial. Dr. T. Marshall. Activated: 7/7/11; Permanently Closed: 6/24/19.

CTSU/NRG-GU007, "Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen Deprivation Therapy (ADT) and Radiotherapy In High Risk Prostate Cancer (With Initial Phase I)." Dr. D. VanderWeele. Activated: 6/3/19; Temporarily Closed: 5/5/21; Reactivated of dose level 2 (phase I) for 1 additional patient: 9/14/21; Temporarily closed to accrual for phase I dose level 2: 11/4/21; Re-activated to accrual for phase I/dose level 3: 12/6/21; Temporarily Closed: 7/11/2022.

CTSU/EA8153, "Cabazitaxel with Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHARTED2 Trial." Dr. P. Corn. Activated: 2/8/18; Permanently Closed: 4/2/21; Tobacco use assessment sub-study permanently closed: 10/8/21.

CTSU/AGCT1531, "A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors." Dr. A. D'Souza. Activated: 5/8/17; PRO study Temporarily Closed: 2/12/21.

Translational Medicine

Chair: Dr. David McConkey

Co-Chair: Dr. Joshua Meeks

Bladder Chair: Dr. Joshua Meeks

Prostate Chair: Dr. Amir Goldkorn

Renal Chair: Dr. Sumanta "Monty" Pal

Diverse Studies of Interest

S1609, "DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors." Drs. S. Patel, Y. Chae, R. Kurzrock, et al. Activated: 1/13/17; Permanently Closed: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 13, 14, 15, 16, 17, 18, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 39, 41, 42, 43, 44, 45, 48, 51, 52, and 53; Temporarily Closed: 38, 40, 46, and 51.

CTSU/A031702, "A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)" Dr. S. Liu. Activated: 4/12/19; Temporarily Closed: Cohort A, B, C, E, F, G, I.

CTSU/EAY 131, "Molecular Analysis for Therapy Choice (MATCH)." Dr. V. Villalobos. Activated: 8/12/15; EAY131 (MATCH) Subprotocol Z1C, EAY131-Z1C, is permanently Closed to Accrual: 5/25/21; EAY131 (MATCH) Subprotocol M, or EAY131-M, is suspended, effective immediately: 8/3/21; AY131 Subprotocols A, C1, C2, E, L, V, Z1E, and Z1G are closed to accrual: 1/31/22; Subprotocol Z1G reactivated: 2/23/22

CTSU/EA8134, "InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)." Dr. C. Pettaway. Activated: 9/8/17.

Genitourinary Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	<i>S1802</i>	<i>S1806</i>	<i>S1931</i>	<i>S1937</i>	<i>S2011</i>	<i>S2200</i>	<i>S2210</i>	<i>S2312</i>	<i>A021804</i>
Audie L Murphy VA Hospital	-	-	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	7	-	1	-	-	-	-	-	-
Banner University Medical Center - Tucson	7	-	1	-	-	-	-	-	-
Baylor College of Medicine/Duncan Comprehensive Cancer Center	3	8	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	2	8	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	1	5	-	-	-	-	-	-	-
Cancer Research of Wisconsin & Northern Michigan Consortium	1	6	-	1	-	-	-	-	-
Carle Cancer Center NCI Comm Oncology Research Program	1	1	1	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	11	4	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	5	-	3	-	-	6	-	-	-
Columbia University Minority Underserved NCORP	2	4	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	3	4	-	5	-	-	-	-	-
Dayton NCI Comm Oncology Research Program	5	2	-	-	-	-	-	-	-
Desert Regional Medical Center	2	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	23	-	-	-	-	-	2	-	-
Georgia Cares Minority Underserved NCORP	1	-	-	-	-	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	5	-	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	83	73	1	-	-	1	1	-	-
Hawaii Minority Underserved NCORP	-	4	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	11	8	1	-	4	3	-	-	-
Henry Ford Health Providence Southfield Hospital	-	-	-	-	-	-	-	-	-
Henry Ford Hospital	27	4	-	1	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia	4	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	20	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Comm Oncology Research Program	18	-	2	-	-	-	-	-	-
Lahey Hospital & Medical Center	-	-	-	-	-	-	-	-	-
Loyola University Medical Center	9	6	1	2	-	-	-	-	-
Massachusetts Veterans Epidemiology Research & Information Center	-	-	-	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	8	-	-	1	-	-	-	-	-
Mercy Medical Center - Des Moines	-	1	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	11	20	-	3	-	1	-	1	-
Montana Cancer Consortium NCORP	4	-	-	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	-	-	-	-
NCORP of the Carolinas	11	-	-	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	1	-	-	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	-	-	1	-	-	-	-	-	-
Northwell Health NCORP	-	3	-	-	-	-	-	-	-

Genitourinary Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	<i>S1802</i>	<i>S1806</i>	<i>S1931</i>	<i>S1937</i>	<i>S2011</i>	<i>S2200</i>	<i>S2210</i>	<i>S2312</i>	<i>A021804</i>
Northwestern University LAPS	-	8	1	1	-	1	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	2	3	-	-	-	-	-	-	-
Oregon Health & Science University	-	1	1	-	-	1	-	-	1
Saint Joseph Hospital - Cancer Centers of Colorado	2	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	9	1	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	3	-	-	-	-	-	-	-
The West Clinic - Wolf River	-	-	-	2	-	-	-	-	-
Tulane University School of Medicine	-	-	9	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	12	9	2	3	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	7	6	-	2	-	-	-	-	-
UC San Diego Moores Cancer Center	4	3	-	-	-	-	-	-	-
UCLA / Jonsson Comprehensive Cancer Center	-	-	3	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	8	2	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	5	-	1	12	-	-	-	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	6	-	-	-	-	-	-
University of Arkansas for Medical Sciences	7	-	-	-	-	1	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	7	6	3	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	8	6	-	7	1	-	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	7	9	-	2	-	-	-	-	-
University of Kentucky/Markey Cancer Center	1	3	-	1	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	2	-	24	-	-	-	-	-	-
University of Mississippi Medical Center	1	-	-	1	-	1	-	-	-
University of Oklahoma Health Sciences Center LAPS	38	15	4	1	-	2	-	1	-
University of Rochester LAPS	25	-	3	-	-	-	-	-	-
University of Texas Health Science Center at San Antonio	12	-	4	-	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	86	-	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	19	-	1	2	-	3	-	-	-
Upstate Carolina Consortium Comm Oncology Research Program	3	2	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	8	6	-	-	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	1	-	-	-	-	-	-	-	-
Western States Cancer Research NCORP	-	2	-	-	-	-	-	-	-
Wisconsin NCI Comm Oncology Research Program	12	6	-	-	-	-	-	-	-
Yale University- Yale Cancer Center LAPS	1	6	-	2	-	-	-	-	-
ALLIANCE	112	34	6	5	-	2	-	-	-
ECOG-ACRIN	97	44	14	8	1	4	-	-	-
NRG	108	136	12	2	-	3	-	-	-
Total	871	485	112	64	6	29	3	2	1

Genitourinary Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	A031701	A031702	A031704	A031801	A031803	A031902	A032001	A032101	A032103
Audie L Murphy VA Hospital	-	-	-	-	2	-	-	-	-
Banner MD Anderson Cancer Center	-	-	-	-	-	-	-	-	-
Banner University Medical Center - Tucson	-	-	-	-	-	-	-	-	-
Baylor College of Medicine/Duncan Comprehensive Cancer Center	-	-	-	-	6	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	10	-	-	-	-	4	12	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	1	-	-	-	-	-	-
Cancer Research of Wisconsin & Northern Michigan Consortium	-	-	-	-	-	-	-	-	-
Carle Cancer Center NCI Comm Oncology Research Program	-	-	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	-	-	-	-	-
Dayton NCI Comm Oncology Research Program	-	-	1	-	-	-	-	-	-
Desert Regional Medical Center	-	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	-	-	1	16	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	2	-	-	-	-	-	-	-	-
Henry Ford Health Providence Southfield Hospital	-	-	3	-	-	-	-	-	-
Henry Ford Hospital	-	2	6	-	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia	-	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Comm Oncology Research Program	-	-	66	-	-	-	-	-	-
Lahey Hospital & Medical Center	-	7	-	-	-	-	-	-	-
Loyola University Medical Center	-	1	2	-	-	-	-	-	-
Massachusetts Veterans Epidemiology Research & Information Center	-	-	-	-	-	1	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
Mercy Medical Center - Des Moines	-	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	1	-	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	-	-	-	-
NCORP of the Carolinas	-	-	1	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	1	-	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	-	-	1	-	-	-	-	-	-
Northwell Health NCORP	-	-	1	-	-	-	-	-	-

Genitourinary Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	A031701	A031702	A031704	A031801	A031803	A031902	A032001	A032101	A032103
Northwestern University LAPS	-	-	2	-	-	-	-	1	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	-
Oregon Health & Science University	-	5	5	-	-	-	-	-	1
Saint Joseph Hospital - Cancer Centers of Colorado	-	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	-	-	-	-	-
The West Clinic - Wolf River	-	-	-	-	-	-	-	-	-
Tulane University School of Medicine	-	-	1	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	10	-	3	7	5	-	2	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-	1	-
UCLA / Jonsson Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	5	-	-	-	-	-	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	1	-	1	12	-	-	-	-
University of Arkansas for Medical Sciences	-	-	2	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	7	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	-	-	11	-	-	-	-	2	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	1	7	-	-	-	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	12	-
University of Mississippi Medical Center	-	1	-	-	-	-	-	-	1
University of Oklahoma Health Sciences Center LAPS	-	-	-	-	-	-	-	-	1
University of Rochester LAPS	-	3	9	-	-	-	1	-	-
University of Texas Health Science Center at San Antonio	-	-	-	-	6	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	6	-	-	-	-	-
Upstate Carolina Consortium Comm Oncology Research Program	-	-	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	-	-	-	-	-
Western States Cancer Research NCORP	-	-	-	-	-	-	-	-	-
Wisconsin NCI Comm Oncology Research Program	-	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	1	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-	-
Total	23	27	130	15	47	5	15	16	3

Genitourinary Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	EA8134	EA8171	EA8185	EA8191	EA8192	EA8212
Audie L Murphy VA Hospital	-	49	-	-	-	-
Banner MD Anderson Cancer Center	-	-	-	-	-	20
Banner University Medical Center - Tucson	-	-	-	-	-	-
Baylor College of Medicine/Duncan Comprehensive Cancer Center	-	-	-	-	-	18
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-	-
Cancer Research of Wisconsin & Northern Michigan Consortium	-	-	-	-	-	-
Carle Cancer Center NCI Comm Oncology Research Program	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	-	-
Dayton NCI Comm Oncology Research Program	-	-	-	-	-	-
Desert Regional Medical Center	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	31	-	10
Georgia Cares Minority Underserved NCORP	-	-	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	11	1	-	-	61
Hawaii Minority Underserved NCORP	-	2	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-	-
Henry Ford Health Providence Southfield Hospital	-	-	-	-	-	-
Henry Ford Hospital	-	1	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	2
Instituto Nacional De Cancerologia	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	-	-	-
Kaiser Permanente NCI Comm Oncology Research Program	-	-	-	-	-	-
Lahey Hospital & Medical Center	-	-	-	-	-	-
Loyola University Medical Center	-	-	-	-	-	3
Massachusetts Veterans Epidemiology Research & Information Center	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	3	-	6
Mercy Medical Center - Des Moines	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	2	-	-
NCORP of the Carolinas	-	-	-	-	-	1
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	1	-	-

Genitourinary Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	EA8134	EA8171	EA8185	EA8191	EA8192	EA8212
Northwestern University LAPS	-	-	-	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-	-	-
Oregon Health & Science University	-	15	-	16	-	22
Saint Joseph Hospital - Cancer Centers of Colorado	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	-	-
The West Clinic - Wolf River	-	-	-	-	-	-
Tulane University School of Medicine	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	-	-	-
UC San Diego Moores Cancer Center	-	-	-	-	-	2
UCLA / Jonsson Comprehensive Cancer Center	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	12	-	-	-	-	16
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	1	-	-	-	2	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	2	8
University of Michigan Comprehensive Cancer Center LAPS	-	-	-	-	-	-
University of Mississippi Medical Center	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	5	-	7
University of Rochester LAPS	-	-	-	-	-	-
University of Texas Health Science Center at San Antonio	-	13	-	2	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-
Upstate Carolina Consortium Comm Oncology Research Program	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	-	6
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	-	-
Western States Cancer Research NCORP	-	-	-	-	-	-
Wisconsin NCI Comm Oncology Research Program	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-
NRG	-	-	-	-	-	-
Total	13	91	1	60	4	182

Genitourinary Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	NRGGU008	NRGGU009	NRGGU010	NRGGU011	NRGGU012	NRGGU013
Audie L Murphy VA Hospital	-	-	-	-	-	-
Banner MD Anderson Cancer Center	-	1	2	-	-	-
Banner University Medical Center - Tucson	-	1	-	-	-	-
Baylor College of Medicine/Duncan Comprehensive Cancer Center	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-	-
Cancer Research of Wisconsin & Northern Michigan Consortium	-	-	-	-	-	-
Carle Cancer Center NCI Comm Oncology Research Program	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	-	-
Dayton NCI Comm Oncology Research Program	-	-	-	-	-	-
Desert Regional Medical Center	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	6	16	6	5	2	-
Hawaii Minority Underserved NCORP	-	-	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-	-
Henry Ford Health Providence Southfield Hospital	-	-	-	-	-	-
Henry Ford Hospital	-	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	-
Instituto Nacional De Cancerologia	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	-	-	-
Kaiser Permanente NCI Comm Oncology Research Program	-	-	-	-	-	-
Lahey Hospital & Medical Center	-	-	-	-	-	-
Loyola University Medical Center	-	-	-	-	-	-
Massachusetts Veterans Epidemiology Research & Information Center	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	1	-	-	-
Mercy Medical Center - Des Moines	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	-
NCORP of the Carolinas	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	-	-	-	-	-	-
Northwell Health NCORP	4	20	3	-	-	-

Genitourinary Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	NRGGU008	NRGGU009	NRGGU010	NRGGU011	NRGGU012	NRGGU013
Northwestern University LAPS	-	-	4	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-	-	-
Oregon Health & Science University	-	-	-	4	-	-
Saint Joseph Hospital - Cancer Centers of Colorado	-	-	3	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	6	10	1	1	-
The West Clinic - Wolf River	-	-	-	-	-	-
Tulane University School of Medicine	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	1	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	2	-	-	-	-	-
UC San Diego Moores Cancer Center	-	-	2	-	1	-
UCLA / Jonsson Comprehensive Cancer Center	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	-	14	10	1	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	2	8	7	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	-	-	1	-	-	-
University of Mississippi Medical Center	-	2	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	4	4	-	2	5
University of Rochester LAPS	-	-	4	-	-	-
University of Texas Health Science Center at San Antonio	-	1	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-
Upstate Carolina Consortium Comm Oncology Research Program	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	-	-
Virginia Mason Medical Center	-	4	3	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	-	-
Western States Cancer Research NCORP	-	2	1	-	-	-
Wisconsin NCI Comm Oncology Research Program	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-
NRG	-	-	-	-	-	-
Total	14	80	61	11	6	5

Immunotherapeutics Committee

Leadership

Co-Chairs: Siwen Hu-Lieskovan, MD, PhD
 Katerina Politi, PhD
 Executive Officer: Anne Chiang, MD, PhD
 Statisticians: Michael LeBlanc, PhD
 Katie Minichiello, MS
 James Moon, MS
 Matt Chansky, BS

Designates

Data Coordinators: Michele Counts
 Pharmaceutical Science: Jordan P. McPherson, PharmD
 Kimberly McConnell, PharmD
 Sr. Protocol Project Manager: Chris Kippola, BS
 Clinical Trial Program Manager: Laura Gildner, MS

Time/Location

Thursday, May 1, 2025 4:00 p.m. - 6:00 p.m.
 Room: Seacliff AB (Bay Level)

Agenda

4:00 – 4:05 PM **Welcome & Introductions**
Siwen Hu-Lieskovan & Katerina Politi
SWOG Immunotherapeutics Committee Co-Chairs

4:05 – 4:20 PM **iMATCH Pilot Update: Stage II Activation**
Paul Swiecicki, Katerina Politi, Siwen Hu-Lieskovan
S2101 Study Chairs

4:20 – 4:30 PM **Q & A**

4:30 – 4:45 PM **SWOG Translational Medicine Process:
 An Overview**
James Rae, PhD
SWOG Executive Officer for Translational Medicine
Thomas H Simpson Collegiate Professor of Cancer
Research, Associate Professor of Pharmacology,
University of Michigan Medical School

4:45 – 4:55 PM **Q & A**

4:55 – 5:10 PM **Cancer Immune Monitoring and Analysis Centers
 and Cancer Immunologic Data Center
 (CIMAC-CIDC) Network: A Progress Update &
 Development of Translational Medicine Trials**
Cara Haymaker, PhD
Director, ORION Core
Associate Professor, Department of Translational
Molecular Pathology (TMP)
The University of Texas MD Anderson Cancer Center

5:10 – 5:20 PM **Q & A**

5:20 – 5:35 PM **Update: Developing Predictors of
 Immunotherapy using Big Data**
Eytan Ruppin, MD, PhD
Senior Investigator, National Cancer Institute
Chief, Cancer Data Science Laboratory

5:35 – 5:45 PM **Q & A**

5:45 – 5:55 PM **Final Comments & Closing Remarks**
Siwen Hu-Lieskovan & Katerina Politi
SWOG Immunotherapeutics Committee Co-Chairs

Active Study

S2101, “Biomarker Stratified CaboZantinib (NSC#761968) and Nivolumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study.” Drs. Hu-Lieskovan, Swiecicki and Politi. Activation: 10/14/22

Immunotherapeutics Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	SZ101
Essentia Health NCI Comm Oncology Research Program	1
Froedtert & the Medical College of Wisconsin LAPS	3
Heartland Cancer Research NCORP	1
Michigan Cancer Research Consortium NCORP	1
New Mexico Minority Underserved NCORP	1
Northwestern University LAPS	1
Pacific Cancer Research Consortium NCORP	1
University of Arkansas for Medical Sciences	2
University of Michigan Comprehensive Cancer Center LAPS	13
University of Utah - Huntsman Cancer Institute LAPS	10
ALLIANCE	8
ECOG-ACRIN	7
NRG	5
Total	54

Leukemia Committee

Leadership

Chair: Harry P. Erba, MD, PhD
 Vice-Chair: Anjali S. Advani, MD
 Executive Officer: Susan M. O'Brien, MD
 Statisticians: Megan Othus, PhD
 Anna Moseley, MS
 Allison Hayes, BS

Scientific Leadership

Translational Medicine: Jerald P. Radich, MD
 Pathology: David R. Head, MD
 Cytogenetics Liaison: Min Fang, MD, PhD

Designates

Cancer Control: Stephanie B. Tsai, MD
 Veterans Affairs: Tsewang Tashi, MD
 Data Coordinators: Louise Highleyman, BA
 Roula Bustami
 Oncology Research Professionals:
 CRA: TBD
 Nurse: TBD
 Patient Advocate: Gail Sperling, MPH
 Pharmaceutical Science: Holly O. Chan, PharmD
 Ila M. Saunders, PharmD
 Protocol Project Manager: Amy Doyle
 Sr. Protocol Project Manager: Sarah Cantu (MyeloMATCH)
 Clinical Trials Program Manager: Sharon Palmer
 Clinical Trials Program Manager: Mariah Norman, MS (MyeloMATCH)

Time/Location

Thursday, May 1, 2025 5:15 p.m. - 7:15 p.m.
 Room: Garden Room (Atrium Lobby Level)

1. Updates in Leukemia Translational Medicine
2. Updates in MyeloMATCH
3. Updates in Acute Lymphoblastic Leukemia
4. Updates in MPN
5. Updates in CLL

AML/MDS Studies

Active Studies

CTSU/A041701, "A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy." Dr. L. Liesveld. Activated: 1/16/19. Closed: 9/16/24.

Closed Studies

S1612, "A Randomized Phase II/III Trial of "Novel Therapeutics" Versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older." Drs. L. Michaelis, R. Walter, S. Assouline, et al. Activated: 12/22/17; Complete: 6/26/24.

S0919, "A Phase II Study of Idarubicin and Ara-C in Combination with Pravastatin for Poor-Risk Acute Myelogenous Leukemia (AML)." Dr. A. Advani. Re-Activated: 4/1/13; Closed: 9/15/17; Complete: 10/21/21.

S1203, "A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (NSC-701852) (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)." Drs. Garcia-Manero and Pagel. Activated: 12/15/12; Closed: 11/4/15; Complete: 03/29/22.

ALL Studies

Active Studies

S1905, "A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) / T-Cell Lymphoblastic Lymphoma (T-LBL)." Drs. A. Advani, N. Papadantonakis, and C. Yeung. Activated: 8/17/20.

CTSU/A041501, "A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL." Dr. A. Advani. Activated: 6/1/17. Temporarily closed to accrual: 05/24/22.

Developing Studies

S2507, "A Phase II Randomized Study of Blinatumomab with or without Revumenib for Patients with KMT2Ar B-ALL with persistent measurable residual disease (MRD)." Drs. I. Aldoss, A. Advani, W. Stock, J. McNeer, and C. Saygin.

Leukemia Committee

Closed Studies

S0333, "A Phase II Study of Double Induction Chemotherapy for Newly Diagnosed Non-L3 Adult Acute Lymphoblastic Leukemia with Investigation of Minimal Residual Disease and Risk of Relapse Following Maintenance Chemotherapy." Drs. Forman and O'Donnell. Activated: 4/15/05; Closed: 11/01/09.

S1312, "A Phase I Study of Inotuzumab Ozogamicin in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients with Relapsed/Refractory CD22-Positive Acute Leukemia (Including B-ALL, Mixed Phenotypic Leukemia, and Burkitt's Leukemia)." Drs. A. Advani and Liedtke. Activated: 4/1/14; Closed: 8/2/19.

S1318, "A Phase II Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients \geq 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphocytic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients \geq 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL and Philadelphia-Chromosome-Like Signature (Ph-like) ALL (Newly Diagnosed or Relapsed/Refractory) with Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)." Drs. A. Advani and K. O'Dwyer. Activated: 1/12/15; Closed: 9/29/21.

CLL Studies

Active Studies

S1925, "Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL): EVOLVE CLL/SLL Study." Drs. D. Stephens, B. Hill, J. Pagel, et al. Activated: 12/14/20.

Developing Studies

S2504, "A Randomized Phase II Study of Pirtobrutinib Plus R-CHOP vs. R-CHOP for Patients with Previously Untreated Richter Transformation (RT)." Drs. M. Shadman, D. Stephens, and A. Danilov.

Closed Studies

CTSU/EA9161, "A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)." Dr. M. Shadman. Activated: 1/3/19. Closed: 4/30/21.

CTSU/A041702, "A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (\geq 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)." Dr. B. Hill. Activation: 1/4/19. Closed: 7/15/22.

CML Studies

Closed Studies

S1712, "A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease." Drs. K. Sweet and J. Radich. Activated: 7/20/18. Closed: 10/20/22.

MDS/MPN Studies

Developing Studies

S2502, "A Phase I/II study of Nuvisertib (TP-3654) in Combination with oral decitabine plus cedazuridine for Myelodysplastic syndrome/ myeloproliferative neoplasm overlap syndromes (MDS/MPNs) and Accelerated- or Blast-Phase MPNs (MPN-AP/BP)." Drs. A. Coltoff, A. Gerds, and U. Borate.

MyeloMATCH

Active Studies

MYELOMATCH, "Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MyeloMATCH Clinical Trials." Drs. J. Radich and S. Jiwani. Activated: 05/16/24.

MM1YA-S01, "A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7+3) vs. (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger who are Considered High-Risk (Adverse) Acute Myeloid Leukemia as Determined by myeloMATCH; A myeloMATCH Clinical Trial." Drs. P. Shami and T. Lin. Activated: 05/16/24.

Developing Studies

MM1OA-S03, "A Randomized Phase II trial of C-DEC, Venetoclax, and Enasidenib Compared with Azacitidine and Venetoclax for Newly Diagnosed Older Adults with IDH2 mutant AML: A myeloMATCH Substudy." Drs. U. Borate and E. Huselton.

Leukemia Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	MM1YA-S01	MYELOMATCH	S1905	S1925	A041501	A041701	A041703	A042001
Banner University Medical Center - Tucson	-	2	-	-	-	-	-	-
Baptist Mem Health Care/Mid South Minority Underserved NCORP	-	2	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	2	7	4	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	1	-	-	-	-
Carle Cancer Center NCI Comm Oncology Research Program	-	-	-	1	-	-	-	-
Cedars-Sinai Medical Center	-	1	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	3	1	-	-	-	-
Duke University - Duke Cancer Institute LAPS	-	-	-	1	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	4	2	-	-	-	-
Froedtert & the Medical College of Wisconsin LAPS	-	4	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	1	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	-	1	-	-	-	-	-	-
Henry Ford Hospital	-	-	-	3	-	4	-	-
Intermountain Medical Center	-	-	-	-	2	-	-	-
Kaiser Permanente NCI Comm Oncology Research Program	-	-	-	1	-	-	-	-
Loyola University Medical Center	-	-	-	1	-	-	-	-
Massachusetts Vets Epidemiology Research & Information Center	-	1	-	-	-	-	-	-
Medical U of South Carolina Minority Underserved NCORP	-	-	-	3	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	8	-	7	-	-	-	-
Montana Cancer Consortium NCORP	-	1	-	-	-	-	-	-
NCORP of the Carolinas	-	1	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	2	-	-
Northwestern University LAPS	-	3	-	1	3	1	-	1
Oregon Health & Science University	1	3	1	-	8	-	-	-
Pacific Cancer Research Consortium NCORP	-	4	-	-	-	-	-	-
STCC at DHR Health Institute for Research & Development	-	-	-	1	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	1	-	-	-	-
Stanford Cancer Institute Palo Alto	-	-	-	-	8	-	-	2
UC Davis Comprehensive Cancer Center LAPS	-	-	-	4	2	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	2	3	-	1	-
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-	-
U of Alabama at Birmingham/Deep South Research Consortium LAPS	-	-	-	-	1	-	-	2
University of Arkansas for Medical Sciences	-	-	-	-	-	4	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	2	-	-	-	1	-
University of Kansas Cancer Center- MCA Rural MU NCORP	1	15	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	3	-	-	-	-	-	-
University of Rochester LAPS	1	24	2	12	7	27	3	3
University of Utah - Huntsman Cancer Institute LAPS	-	3	-	18	1	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	-	-	-	-
Western States Cancer Research NCORP	-	-	-	-	-	-	-	-
Wisconsin NCI Comm Oncology Research Program	-	2	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	5	-	-	5	-	-	-
ALLIANCE	1	56	2	30	-	-	-	-
CCTG	-	5	-	11	-	-	-	-
ECOG-ACRIN	1	50	2	14	-	-	-	-
NRG	-	2	-	4	-	-	-	-
Total	5	197	18	126	44	38	5	8

Leukemia Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	EA9152	EA9171	EA9181	EA9213	MM10AEA02	MM1YACTG01
Banner University Medical Center - Tucson	-	-	-	-	-	-
Baptist Mem Health Care/Mid South Minority Underserved NCORP	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-	-
Carle Cancer Center NCI Comm Oncology Research Program	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-	-
Duke University - Duke Cancer Institute LAPS	-	-	3	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	3	-	-
Froedtert & the Medical College of Wisconsin LAPS	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	4	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-	-
Henry Ford Hospital	-	-	-	-	-	-
Intermountain Medical Center	-	-	-	-	-	-
Kaiser Permanente NCI Comm Oncology Research Program	-	-	-	-	-	-
Loyola University Medical Center	-	-	2	-	-	-
Massachusetts Vets Epidemiology Research & Information Center	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-
NCORP of the Carolinas	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	-
Northwestern University LAPS	-	-	4	-	-	-
Oregon Health & Science University	-	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	-	-	-	-	-	-
STCC at DHR Health Institute for Research & Development	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-
Stanford Cancer Institute Palo Alto	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	11	-	-	-
UC San Diego Moores Cancer Center	-	-	1	-	-	-
U of Alabama at Birmingham/Deep South Research Consortium LAPS	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	4	-	-	-
University of Kansas Cancer Center- MCA Rural MU NCORP	-	-	-	-	-	2
University of Oklahoma Health Sciences Center LAPS	-	-	-	-	-	-
University of Rochester LAPS	-	-	8	-	1	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	3	-	-	-
Western States Cancer Research NCORP	-	2	-	-	-	-
Wisconsin NCI Comm Oncology Research Program	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	3	2	1	-	1	-
ALLIANCE	-	-	-	-	-	-
CCTG	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-
NRG	-	-	-	-	-	-
Total	3	4	41	3	2	2

Lung Committee

Leadership

Chair: Jhanelle E. Gray, MD
 Vice-Chair: Roy S. Herbst, MD, PhD
 Executive Officer: Anne Chiang, MD, PhD
 Statisticians: Mary Redman, PhD
 Yingqi Zhao, PhD
 Katie Minichiello, MS
 Sara Threlkel, BS

Scientific Leadership

Translational Medicine:
 Biology/Pathology: Philip C. Mack, PhD
 Fred R. Hirsch, MD, PhD
 Ignacio I. Wistuba MD
 Imaging: Chadwick L. Wright MD, PhD
 Myrna C. Godoy, MD, PhD
 Radiation Oncology: Henry Park, MD
 Surgery: Wayne L. Hofstetter, MD
 Subcommittee Chairs:
 Early Stage Disease: Raymond Osarogiagbon, MD
 Eric Miguel Toloza, MD, PhD
 Locally Advanced Disease: Mary B. Daly, MD
 Tina Cascone, MD, PhD
 Shirish Gadgil, MD (Early Therapeutics)
 Metastatic Disease: Rachel E. Sanborn, MD
 Sarah B. Goldberg, MD
 Community Engagement: Paul J. Hesketh, MD
 Suzanne Cole, MD

Designates

Cancer Control Liaison: Gary E. Goodman, MD
 Veterans Affairs: Chao H. Huang, MD
 Data Coordinators: Amy Johnson, CCRP
 Kevin Moralda, BS
 Larry Kaye
 Louise Highleyman, BA
 Pasarlai Ahmadzai, MD, MPH
 Clinical Research Project Manager: TBD
 Oncology Research Professionals:
 CRA: TBD
 Nurses: Rosalie Zablocki, RN
 Lisa G. Davis, RN
 Patient Advocate: Judy Johnson, MBA
 Pharmaceutical Science: Joyce Lee, PharmD
 Safae Ghouraihi, PharmD

Protocol Project Managers: Justine Trevino
 Gabe Chadwell (Lung-MAP)
 Sr. Protocol Project Manager: Jennifer Beeler (Lung-MAP)
 Clinical Trials Program Manager: Mariah Norman, MS
 Crystal Miwa (Lung-MAP)

Time/Location

Saturday, May 3, 2025 9:30 a.m. - 12:30 p.m.
 Room: Seacliff BCD (Bay Level)

Agenda

General Update & Accruals: Jhanelle E. Gray, MD

Patient Advocate Update: Judy Johnson, MBA

Thoracic Surgery Session: Eric Toloza, MD, PhD

Thoracic Radiation Session: Henry Park, MD

Translational Medicine Session: Philip C. Mack, PhD

Community Engagement Core: Paul J. Hesketh, MD

Community Engagement Champion: Lucy Gansauer, MSN, RN

Dr. Robert B. Livingston Translational Breast and Lung Cancer

Lecture: Liquid Biopsy for Minimal Residual Disease in Lung Cancer: A Unique Opportunity for Early Intervention and Improved Outcomes - Christian Rolfo, MD, PhD, Professor, Department of Internal Medicine at The Ohio State University College of Medicine, Associate Director for Early Phase Clinical Trials, and Director of the Division of Medical Oncology at The Ohio State University Comprehensive Cancer Center

Thoracic Medical Oncology: Jhanelle Gray, MD

S2414, "A randomized phase III trial incorporating pathologic response in participants with early stage non-small cell lung cancer to optimize immunotherapy in the adjuvant setting (INSIGHT)." Dr. Jeremy Cetnar

S2409, "PRISM: A Multicohort PREcision SCLC Subtype Maintenance Phase II Trial of Durvalumab Versus Biomarker-Directed Novel Agents in Combination with Durvalumab in Extensive Stage Small Cell Lung Cancer (ES-SCLC)." Dr. Anne Chiang and Dr. Alberto Chiappori (SWOG)

CTIU2317/S2402, "Perioperative versus Adjuvant Systemic Therapy in Patients with Resectable Non-Small Cell Lung Cancer (PROSPECT LUNG)." Dr. Raid Aljumaily and Dr. Raymond Osarogiagbon (SWOG)

Lung Committee

S1933, "A Pilot Trial of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status." Activated: 6/15/20; Accrual Goal: 47; Accrual: 43. Dr. Raid Aljumaily

S1827, "MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)." Activated: 1/10/20; Accrual Goal: 668; Accrual: 269. Dr. Chad Rusthoven

LUNGMAP, "A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)." Activated: 1/28/19; Accrual Goal: 6000; Accrual: 3594. Dr. Karen Reckamp and Dr. David R. Gandara (SWOG)

S1900J, "A Phase II Study of Amivantamab SC in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with High MET Amplification (Lung-MAP Sub-Study)." Activated: 9/27/24; Accrual: 11. Dr. Shirish Gadgil (SWOG) and Dr. Christian Rolfo

S1900G, "A Randomized Phase II Study of Capmatinib plus Osimertinib (Tagrisso) with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Activated: 4/3/23; Accrual Goal: 66 (60 eligible); Accrual: 28. Dr. Sarah Goldberg and Dr. Ross Camidge (SWOG)

S1900K, "A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Activated: 12/18/2023; Accrual Goal: 56; Accrual: 9. Dr. Paul Paik (ECOG-ACRIN) and Xiuning Le (SWOG)

Open Discussion

Active Studies

LUNGMAP, "A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)." Drs. Borghaei, Reckamp, Gandara, et al. Activation: 1/28/19.

S1900G, "A Randomized Phase II Study of INC280 (Capmatinib) plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Goldberg and Camidge. Activation: 4/3/23.

S1900K, "A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Paik and Le. Activation: 12/18/23.

S1900J, "A Phase II Study of Amivantamab SC (subcutaneous) in Participants with MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Rolfo and Gadgil. Activation: 9/27/24.

S1827, "MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)." Drs. Rusthoven, Brown, Wefel, et al. Activation: 1/10/20.

S1914, "A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC." Drs. Daly, Simone, Kelly, et al. Activation: 3/25/20.

S1933, "A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status." Drs. Aljumaily, Mitin, and Wozniak. Activation: 6/15/20.

CTSU/A081801, "Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)." Dr. Gray. Activation: 6/3/20.

CTSU/A151216, "Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)." Dr. Gandara. Activation: 8/18/14.

CTSU/EA5182, "Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)." Dr. Goldberg. Activated: 10/22/20.

CTSU/NRG-LU007, "Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial." Dr. Park. Activated: 8/17/20.

Closed Studies

CTSU/NRG-CC003, "Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer." Dr. Gaspar. Activation: 12/7/15; Temporary closure: 5/28/20; Reactivation: 7/27/20; Permanent closure: 6/21/22.

S1800A, "A Phase II Randomized Study of Ramucirumab Plus Pembrolizumab (MK-3475) Versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent

Lung Committee

Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)." Drs. Reckamp and Dragnev. Activation: 5/17/19. Permanently closed: 10/20/20.

S1800D, "A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)." Drs. Wrangle and Husain. Activation: 2/15/22. Permanently closed: 3/10/23.

S1900A, "A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)." Drs. Riess and Wheatley-Price. Activation: 1/28/19. Permanently closed: 2/2/21.

S1900B, "A Phase II Study of Selpercatinib (LOXO-292) in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)." Drs. Elamin and Gray. Activation: 2/10/20. Permanently closed: 5/1/21.

S1900C, "A Phase II Study of Talazoparib Plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)." Drs. Skoulidis and Suga. Activation: 1/16/20. Permanently closed: 12/18/20.

S1900E, "A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN Lung-MAP Sub-Study)." Drs. Padda and Gerber. Activation: 4/2/21. Permanently closed: 12/27/24.

S1900F, "A Randomized Phase II Study of Carboplatin and Pemetrexed with or Without Selpercatinib (LY3527723) in Participants with Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy (Lung-MAP Sub-Study)." Drs. Gray and Elamin. Activation: 7/25/22. Permanently closed: 6/27/23.

S1929, "Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)." Drs. Karim, Reckamp, Gay, et al. Activation: 6/15/20; Step 1 Registration Permanently Closed 8/15/22; Step 2 Permanently Closed 10/15/22.

S1934, "NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small

Cell Lung Cancer." Drs. Osarogiagbon, Huang, Decker, et al. Activation: 9/9/21; Temporary closure: 11/5/21; Reactivation: 2/15/22; Permanently closed 3/1/23.

CTSU/EA5163/S1709, "INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis." Dr. Chiang. Activation: 2/28/19. ; Closed to accrual: 3/1/24.

S1701, "A Randomized Phase II Trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma." Drs. Tsao and Koczywas. Activation: 8/9/18; Closed to accrual: 10/15/22.

S2302, "PRAGMATICA: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer" Drs. Reckamp and Dragnev. Activation: 3/6/23; Closed to accrual: 12/20/24.

CTSU/E4512, "A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein." Dr. Li. Activation: 8/18/14; Closed to accrual: 5/10/24.

CTSU/EA5181, "Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC." Dr. Harkenrider. Activation: 4/9/20; Closed to accrual: 11/20/23.

CTSU/NRG-LU002, "Maintenance Systemic Therapy versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial." Dr. Gomez. Activation: 4/7/17; Temporary closure: 11/12/21; Closed to accrual: 12/06/23.

CTSU/NRG-LU005, "Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab." Dr. Hsu. Activation: 5/28/19; Closed to US and Canadian sites 6/23/22; Closed to accrual: 12/31/23.

CTSU/EA5191, "A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC." Dr. Massarelli. Activated: 5/22/20; Closed to accrual: 10/13/23.

Lung Committee

NCI-Approved Concepts

S1800E, “A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or without Cemiplimab for Participants Previously Treated with Platinum-based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study).” Drs. Waqar and Li.

S2404, “Accelerating Drug Efficacy Evaluation thru Growth Rate and Overall Survival Correlations” Dr. Lawrence Schwartz and Dr. Karen Reckamp.

Concepts in Development

S1800G, “A Randomized Phase II Study of Casdozokitug with or without Toripalimab in Participants with Previously Treated Relapsed or Refractory Advanced Lung Squamous Cell Carcinoma (NRG Lung-MAP Non-match Sub-Study).” Drs. Henick and Marron.

S1900N, “A Randomized Phase II Study of Sacituzumab Govitecan alone, Ivonescimab alone, or Sacituzumab Govitecan and Ivonescimab in Participants with Previously-Treated Actionable Genomic Alteration Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study).” Drs. Scott and Riess.

S2409, “PRISM: PReclision in SCLC via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)” Drs. Chiang, Chiappori, Kim, et al.

S2414, “Incorporating Pathologic Response in Patients with Early Stage Lung Cancer to Optimize Immunotherapy in the Adjuvant Setting (INSIGHT).” Drs. Cetnar and Osarogiagbon.

Lung Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	LUNGMAP	S1827	S1900E	S1900G	S1900J	S1900K	S1914	S1933	S2302	A081801
Ascension Via Christi Hospitals Wichita	1	-	-	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	-	1	-	-	-	-	1	-	-	1
Banner University Medical Center - Tucson	-	-	-	-	-	-	-	-	2	-
Baptist Mem Health Care/Mid S Minority Underserved NCORP	36	3	2	-	-	-	10	1	16	4
Baylor College of Medicine/Duncan Comprehensive Cancer Cntr	-	5	-	-	-	-	-	-	-	-
Boston Medical Center	-	6	-	-	-	-	-	-	2	-
CWRU Case Comprehensive Cancer Center LAPS	11	2	2	-	-	-	-	-	18	15
Cancer Research Consortium of West Michigan NCORP	3	-	-	-	-	-	7	-	3	-
Cancer Research for the Ozarks NCORP	44	-	-	-	-	-	9	4	5	-
Cancer Research of Wisconsin & Northern Michigan Consortium	34	5	4	-	-	-	8	-	8	-
Carle Cancer Center NCI Comm Oncology Research Program	3	1	1	-	-	-	6	-	8	-
Cedars-Sinai Medical Center	21	-	1	1	-	-	4	-	9	-
City of Hope Comprehensive Cancer Center	5	1	-	-	-	-	-	-	3	-
Columbia University Minority Underserved NCORP	13	-	-	-	-	-	-	1	7	-
Columbus NCI Comm Oncology Research Program	28	5	-	-	-	-	-	-	4	-
CommonSpirit Health Research Institute	39	1	-	-	-	-	1	-	1	-
Corewell Health William Beaumont University Hospital	-	-	-	-	-	-	-	-	-	-
Cotton O'Neil Cancer Center / Stormont Vail Health	-	-	-	-	-	-	-	-	-	-
Dayton NCI Comm Oncology Research Program	2	-	-	-	-	-	-	-	-	1
Duke University - Duke Cancer Institute LAPS	-	-	-	-	-	-	-	-	2	-
Essentia Health NCI Comm Oncology Research Program	16	-	-	-	-	-	3	-	-	-
Fred Hutchinson Cancer Research Center LAPS	4	-	-	-	-	-	-	-	10	-
Froedtert & the Medical College of Wisconsin LAPS	2	-	-	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	6	1	-	-	-	-	2	1	-	-
Georgia NCI Comm Oncology Research Program	65	3	1	-	-	-	9	-	18	-
Grupo Oncologico Cooperativo de Investigacion	-	1	-	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	24	1	-	-	-	-	3	-	7	1
Hartford Hospital	1	-	-	-	-	-	-	-	4	-
Hawaii Minority Underserved NCORP	27	2	-	-	-	-	-	-	7	-
Heartland Cancer Research NCORP	149	9	6	-	-	-	40	5	52	-
Henry Ford Health Providence Southfield Hospital	13	-	-	-	-	-	-	-	-	-
Henry Ford Hospital	7	-	-	-	-	-	-	-	-	2
Houston Methodist Hospital	-	-	-	-	-	-	-	-	2	-
Instituto Nacional De Cancerologia de Mexico	-	5	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Comm Oncology Research Program	90	-	8	-	-	-	3	-	27	5
Kansas City Veterans Affairs Medical Center	3	-	-	-	-	-	-	-	1	-
Lahey Hospital & Medical Center	32	-	-	-	-	-	4	2	12	-
Loma Linda University Medical Center	6	-	-	-	-	-	-	-	-	-
Loyola University Medical Center	25	-	-	-	-	-	1	-	8	-
Malcom Randall Veterans Administration Medical Center	18	-	-	-	-	-	-	-	4	-
Massachusetts Vets Epidemiology Research & Information Cntr	65	4	1	-	-	-	-	-	9	12
Medical U of South Carolina Minority Underserved NCORP	22	-	2	1	-	-	-	-	19	-
Mercy Medical Center - Des Moines	8	-	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	111	2	7	2	-	-	12	-	18	-
Mission Hospital	1	-	-	-	-	-	-	-	-	-
Moffitt Cancer Center	18	1	1	1	-	-	-	-	52	25

Lung Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	LUNGMAP	S1827	S1900E	S1900G	S1900J	S1900K	S1914	S1933	S2302	A081801
Montana Cancer Consortium NCORP	25	-	1	-	-	-	1	1	1	-
Mount Sinai Hospital	-	-	-	-	-	-	9	-	2	-
MultiCare Tacoma General Hospital	-	-	-	-	-	-	-	-	3	-
NCORP of the Carolinas	20	-	1	-	-	-	-	-	-	-
National Cancer Center-Korea	-	1	-	-	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	14	-	-	-	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	99	1	2	-	-	-	8	1	3	-
Northwell Health NCORP	-	-	-	-	-	-	1	-	-	1
Northwestern University LAPS	27	1	-	1	-	-	-	-	18	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	6	-
Oregon Health & Science University	11	-	-	1	-	-	1	-	3	8
Pacific Cancer Research Consortium NCORP	21	-	-	-	-	-	-	-	1	-
Saint Joseph Hospital - Cancer Centers of Colorado	1	-	-	-	-	-	1	-	-	1
Salem Hospital	7	-	2	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	52	7	1	-	-	-	14	-	7	-
Sutter Cancer Research Consortium	48	-	1	-	-	-	-	-	1	-
The Don & Sybil Harrington Cancer Center	13	-	1	-	-	-	-	-	-	-
The James Graham Brown Cancer Center at U of Louisville	-	-	-	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	40	1	2	1	-	-	11	-	15	1
UC Irvine Health/Chao Family Comprehensive Cancer Center	30	1	-	-	-	-	5	-	1	-
UC San Diego Moores Cancer Center	16	-	1	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	74	11	7	-	-	-	2	4	10	-
USC Norris Comprehensive Cancer Center LAPS	-	5	-	-	-	-	7	-	3	-
U of Alabama at Birmingham / Deep S Research Consortium LAPS	-	-	-	-	-	-	-	-	12	-
University of Arkansas for Medical Sciences	11	-	-	-	-	-	17	-	12	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	14	4	-	1	-	-	6	-	3	2
University of Kansas Cancer Center - MCA Rural MU NCORP	98	1	1	-	-	-	-	-	5	1
University of Kentucky/Markey Cancer Center	53	1	-	-	-	-	-	-	9	-
University of Michigan Comprehensive Cancer Center LAPS	1	-	-	-	-	-	-	-	6	-
University of Mississippi Medical Center	1	-	-	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	33	1	-	-	-	-	6	15	10	-
University of Rochester LAPS	67	-	6	-	-	-	3	-	14	-
University of Texas Health Science Center at San Antonio	-	2	-	-	-	-	-	-	22	-
University of Texas MD Anderson Cancer Center LAPS	3	6	-	-	-	-	6	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	4	-	-	-	-	5	-	4	-
Upstate Carolina NCORP	41	3	-	-	-	-	3	-	1	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	-	-	-	-	10	-
Wayne State University - Karmanos Cancer Institute LAPS	1	-	-	-	-	-	-	-	-	-
Western States Cancer Research NCORP	2	-	-	-	-	-	-	-	-	-
Wisconsin NCI Comm Oncology Research Program	41	1	1	-	-	-	13	-	5	-
Yale University - Yale Cancer Center LAPS	26	5	3	2	-	-	11	-	14	7
ALLIANCE	858	22	21	3	1	1	42	5	154	-
CCTG	-	33	-	-	-	-	-	-	-	-
ECOG-ACRIN	363	10	19	-	-	2	31	-	90	-
NRG	479	71	12	3	-	-	91	1	55	-
Total	3,543	251	118	17	1	3	417	41	838	87

Lung Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	A082002	A151216	E4512	EA5162	EA5163	EA5181	EA5182	EA5191	EA5221	NRGLU002
Ascension Via Christi Hospitals Wichita	-	-	-	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	-	1	-	-	-	-	-	-	-	-
Banner University Medical Center - Tucson	-	7	2	-	-	10	-	-	-	-
Baptist Mem Health Care/Mid S Minority Underserved NCORP	-	26	-	-	1	1	2	-	-	1
Baylor College of Medicine/Duncan Comprehensive Cancer Cntr	-	-	-	-	-	-	-	-	-	-
Boston Medical Center	-	3	-	-	-	2	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	59	-	-	17	21	1	4	-	-
Cancer Research Consortium of West Michigan NCORP	-	1	-	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	1	-	-	-	-	-	-	-	-
Cancer Research of Wisconsin & Northern Michigan Consortium	-	-	-	-	-	-	-	-	-	-
Carle Cancer Center NCI Comm Oncology Research Program	-	-	-	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	5	-	-	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-	-	1	-	-	-	-
Columbus NCI Comm Oncology Research Program	-	-	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	2	-	-	-	-	-	-	-	-
Corewell Health William Beaumont University Hospital	-	2	-	-	-	-	-	-	-	-
Cotton O'Neil Cancer Center / Stormont Vail Health	-	3	-	-	-	-	-	-	-	-
Dayton NCI Comm Oncology Research Program	-	8	-	-	-	-	-	-	-	-
Duke University - Duke Cancer Institute LAPS	-	-	-	-	-	-	-	-	-	-
Essentia Health NCI Comm Oncology Research Program	-	-	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	15	-	-	-	4	-	-	-	-
Froedtert & the Medical College of Wisconsin LAPS	-	-	-	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	-	-	-	-	-	-	-
Georgia NCI Comm Oncology Research Program	-	10	-	-	1	-	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	1	-	-	3	-	-	-	-	-
Hartford Hospital	-	-	-	-	-	-	1	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-	-	1	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-	-	-	-	-	-
Henry Ford Health Providence Southfield Hospital	-	15	2	1	2	3	-	1	-	-
Henry Ford Hospital	-	29	-	-	-	-	-	-	-	-
Houston Methodist Hospital	-	8	-	-	1	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Comm Oncology Research Program	-	206	6	-	8	-	6	-	-	-
Kansas City Veterans Affairs Medical Center	-	-	-	-	-	-	-	-	1	-
Lahey Hospital & Medical Center	-	30	-	-	2	-	-	-	-	-
Loma Linda University Medical Center	-	10	-	-	-	-	-	-	-	-
Loyola University Medical Center	-	26	-	-	2	2	-	-	-	-
Malcom Randall Veterans Administration Medical Center	-	-	-	-	-	-	-	-	-	-
Massachusetts Vets Epidemiology Research & Information Cntr	-	34	-	-	3	-	-	2	-	-
Medical U of South Carolina Minority Underserved NCORP	-	-	-	-	-	-	-	-	-	-
Mercy Medical Center - Des Moines	-	-	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-	-	-	-	-
Mission Hospital	-	-	-	-	-	-	-	-	-	-
Moffitt Cancer Center	-	83	1	-	5	-	-	-	-	-

Lung Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	A082002	A151216	E4512	EA5162	EA5163	EA5181	EA5182	EA5191	EA5221	NRGLU00
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	1	8	-	-	-
MultiCare Tacoma General Hospital	-	-	-	-	-	-	-	-	-	-
NCORP of the Carolinas	-	1	-	-	-	-	-	-	-	-
National Cancer Center-Korea	-	-	-	-	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	-	-	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	3	-	-	-	-	-	-	-	-
Northwestern University LAPS	-	-	-	-	-	-	-	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-
Oregon Health & Science University	-	24	-	-	-	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	-	4	-	-	-	-	-	-	-	-
Saint Joseph Hospital - Cancer Centers of Colorado	-	3	-	-	-	-	-	-	-	-
Salem Hospital	-	-	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	1	11	-	-	-	3	-	-	-	-
The Don & Sybil Harrington Cancer Center	-	-	-	-	-	-	-	-	-	-
The James Graham Brown Cancer Center at U of Louisville	-	5	-	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	2	46	1	-	6	-	1	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	15	1	-	-	-	-	-	-	-
UC San Diego Moores Cancer Center	-	5	-	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	12	-	-	-	-	-	-	-	-
U of Alabama at Birmingham / Deep S Research Consortium LAPS	-	-	-	-	-	-	-	-	-	-
U of Arkansas for Medical Sciences	-	3	1	-	1	3	-	-	-	-
U of Cincinnati Cancer Center-UC Medical Center	-	24	1	-	2	-	1	-	-	-
U of Colorado Cancer Center LAPS	-	58	2	-	-	-	-	1	-	-
U of Kansas Cancer Center - MCA Rural MU NCORP	-	31	-	-	7	-	-	3	-	-
U of Kentucky/Markey Cancer Center	1	5	-	-	-	-	-	-	-	-
U of Michigan Comprehensive Cancer Center LAPS	-	62	-	-	-	-	-	-	-	-
U of Mississippi Medical Center	-	26	-	-	-	-	-	-	-	-
U of Oklahoma Health Sciences Center LAPS	-	-	-	-	-	1	-	-	-	-
U of Rochester LAPS	-	-	-	-	6	19	-	-	-	-
U of Texas Health Science Center at San Antonio	-	-	-	-	2	-	-	-	-	-
U of Texas MD Anderson Cancer Center LAPS	-	2	1	-	-	-	-	-	-	-
U of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	1	-	-	-	-	-
Upstate Carolina NCORP	-	-	-	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	1	-	-	-	-	-	-	-	1
Western States Cancer Research NCORP	-	1	-	-	-	-	1	-	-	-
Wisconsin NCI Comm Oncology Research Program	-	-	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	57	4	-	14	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-	-	-
CCTG	-	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-	-	-
Total	4	984	22	1	84	72	21	11	1	2

Lung Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	NRGLU005	NRGLU006	NRGLU008	R1308
Ascension Via Christi Hospitals Wichita	-	-	-	-
Banner MD Anderson Cancer Center	2	-	-	-
Banner U Medical Center - Tucson	1	-	-	-
Baptist Mem Health Care/Mid S Minority Underserved NCORP	4	-	1	-
Baylor College of Medicine/Duncan Comprehensive Cancer Cntr	-	3	-	-
Boston Medical Center	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-
Cancer Research of Wisconsin & Northern Michigan Consortium	-	-	-	-
Carle Cancer Center NCI Comm Oncology Research Program	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-
Columbia U Minority Underserved NCORP	-	-	-	-
Columbus NCI Comm Oncology Research Program	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-
Corewell Health William Beaumont University Hospital	-	-	-	-
Cotton O'Neil Cancer Center / Stormont Vail Health	-	-	-	-
Dayton NCI Comm Oncology Research Program	-	-	-	-
Duke U - Duke Cancer Institute LAPS	-	-	-	-
Essentia Health NCI Comm Oncology Research Program	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-
Froedtert & the Medical College of Wisconsin LAPS	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	-
Georgia NCI Comm Oncology Research Program	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-	-
Gulf South Minority Underserved NCORP	-	-	-	-
Hartford Hospital	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-
Henry Ford Health Providence Southfield Hospital	-	-	-	-
Henry Ford Hospital	-	-	-	-
Houston Methodist Hospital	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	-
Kaiser Permanente NCI Comm Oncology Research Program	-	-	-	-
Kansas City Veterans Affairs Medical Center	-	-	-	-
Lahey Hospital & Medical Center	-	-	-	-
Loma Linda U Medical Center	-	-	-	1
Loyola U Medical Center	-	-	-	-
Malcom Randall Veterans Administration Medical Center	-	-	-	-
Massachusetts Vets Epidemiology Research & Information Cntr	-	-	-	-
Medical U of South Carolina Minority Underserved NCORP	-	-	-	-
Mercy Medical Center - Des Moines	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-
Mission Hospital	-	-	-	-
Moffitt Cancer Center	-	-	-	-

Lung Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	NRGLU005	NRGLU006	NRGLU008	R1308
Montana Cancer Consortium NCORP	-	-	-	-
Mount Sinai Hospital	1	-	-	-
MultiCare Tacoma General Hospital	-	-	-	-
NCORP of the Carolinas	-	-	-	-
National Cancer Center-Korea	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-
New Mexico Minority Underserved NCORP	-	-	-	-
Northwell Health NCORP	-	-	-	-
Northwestern University LAPS	-	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-
Oregon Health & Science University	-	-	-	-
Pacific Cancer Research Consortium NCORP	-	-	-	-
Saint Joseph Hospital - Cancer Centers of Colorado	-	-	-	-
Salem Hospital	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-
Sutter Cancer Research Consortium	-	-	1	-
The Don & Sybil Harrington Cancer Center	-	-	-	-
The James Graham Brown Cancer Center at University of Louisville	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	-
UC San Diego Moores Cancer Center	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-
U of Alabama at Birmingham / Deep S Research Consortium LAPS	-	-	-	-
U of Arkansas for Medical Sciences	1	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-
University of Colorado Cancer Center LAPS	1	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	2	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	-	-	-	-
University of Mississippi Medical Center	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	-
University of Rochester LAPS	1	-	-	-
University of Texas Health Science Center at San Antonio	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-
Upstate Carolina Consortium Comm Oncology Research Program	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-
Western States Cancer Research NCORP	-	-	-	-
Wisconsin NCI Comm Oncology Research Program	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-
ALLIANCE	-	-	-	-
CCTG	-	-	-	-
ECOG-ACRIN	-	-	-	-
NRG	-	-	-	-
Total	13	3	2	1

Lymphoma Committee

Leadership

Chair: Jonathan W. Friedberg, MD
 Vice-Chair: Sonali M. Smith, MD
 Executive Officer: Susan M. O'Brien, MD
 Statisticians: Michael LeBlanc, PhD
 Hongli Li, MS
 Shay Bellasea, MS
 Matt Chansky, BS

Scientific Leadership

Translational Medicine: Alexey Danilov, MD, PhD
 Radiation Oncology: Nicholas Burden Figura, MD
 Imaging: Lawrence H. Schwartz, MD
 Immunotherapeutics: Sweetha Kambhampati, MD
 Pathology: Joo Y. Song, MD
 Early Therapeutics: Nasheed Mohammad Hossain, MD

Designates

Cancer Control: Hayder Saeed, MD
 Digital Engagement: Elizabeth A. G. Brem, MD
 Veterans Affairs: Helen Ma, MD
 Data Coordinators: Alex Rangel, BS
 Gabi Herbert, MS, BS
 Laura Wells, BA
 Daria Chugina, MD, CCRPS
 Oncology Research Professionals:
 CRA: Erin M. Cebula, MPH
 Jacob Kedroske, BA
 Nurse: TBD
 Patient Advocate: Tricia Hernandez, MS
 Pharmaceutical Science: Martina Fraga, PharmD
 Protocol Project Manager: Erin Rogers
 Clinical Trials Program Manager: Laura Gildner, MS

Time/Location

Saturday, May 3, 2025 12:00 p.m. - 2:00 p.m.

Room: Garden Room (Atrium Lobby Level)

Agenda

1. **Welcome & Introductions** - Dr. Jonathan Friedberg & Dr. Sonali Smith
2. **High Risk/Transformed Indolent Lymphomas Mini-Symposium**
 - a. Overview of high risk follicular lymphoma - Dr. Swetha Thiruvengadam
 - b. Richter Transformation - Dr. Mazzyar Shadman
 - c. Relapsed high risk follicular lymphoma: early results of S1608 - Dr. Paul Barr
 - d. Discussion and questions from audience - Panel Discussion

3. S1826 ctDNA Update - Dr. Herrera

4. Patient Advocacy Report - Tricia Hernandez

5. New Trials

- a. EA4232 - Dr. Hoffman

6. Ongoing Trials

- | | | |
|----|----------|--------------------------|
| a. | S2308 | Dr. Ghosh |
| b. | S2114 | Dr. Hess |
| c. | S1925 | Dr. Stephens |
| d. | S2207 | Drs. Amengual and Reagan |
| e. | AHOD2131 | Dr. Hu |
| f. | AO51902 | Dr. Amengual |
| g. | AO52101 | Dr. Phillips |
| h. | ANHL1931 | Dr. Kamdar |
| i. | S1918 | Dr. Brem |

Developing Studies

S2506, "MOZART MZL: A Randomized 3-Arm Phase II Study Evaluating Mosunetuzumab Alone and In Combination with Either Zanubrutinib or Polatuzumab Vedotin for The Treatment of Patients with Relapsed/Refractory Marginal Zone Lymphoma." Drs. Hu and Smith.

Open Studies

S1918, "A Phase II/III Randomized Study of R-miniCHOP With or Without CC-486 (Oral Azacytidine) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements." Drs. Brem and Smith. Activated: 3/19/21.

S2114, "A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma." Drs. Hess and Hossain. Activated: 2/23/2023.

S2207, "Randomized phase II study of the addition of Targeted therapeutic agents to tafasitamab-based therapy in non-transplant-eligible patients with Relapsed/refractory Large B-cell Lymphoma." Drs. Amengual, Reagan, and Smith. Activated: 6/30/2023

S2308, "Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma." Drs. Ghosh and Friedberg. Activated: 8/1/2024

Lymphoma Committee

CTSU/EA4151, "A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission." Dr. Fenske. SWOG Champion: Dr. Till. Activated: 8/29/17.

CTSU/ANHL1931, "A Randomized Phase 3 trial of Nivolumab in Combination with Chemo immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B cell Lymphoma." Dr. Roth. SWOG Champion: Dr. Kamdar. Activated 6/7/2021.

CTSU/A051902, "A Randomized Phase II Study of CHO(E)P vs Oral Azacitidine-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-cell Lymphomas." Dr. Mehta-Shah. SWOG Champion: Dr. Amengual. Activated 7/30/2021.

CTSU/A052101, "A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients with Mantle Cell Lymphoma (INTERCON)." Dr. Beaven. SWOG Champion: Dr. Tycel. Activated 09/08/2023.

CTSU/AHOS2131, "A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma." Dr. Henderson. SWOG Champion: Dr. Hu. Activated 04/28/2023.

Closed Studies

S1608, "Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma." Drs. Barr and Burack. Activated: 8/10/17. Closed: 7/15/2024

CTSU/A051701, "Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas." Dr. Abramson. SWOG Champion: Dr. Vallurupalli. Activated: 8/7/19. Closed: 12/14/2023.

CTSU/EA4181, "A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CA-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients \leq 70 years Old with Untreated Mantle Cell Lymphoma." Dr. Wagner-Johnson. SWOG Champion: Dr. Spurgeon. Activated: 10/3/19. Closed: 4/7/2023

Open Leukemia Studies

S1925, "A Randomized, Phase III Study of Early Intervention with

Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study." Dr. Stephens. Activated: 12/14/20.

S1905, "A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)." Drs. Advani and Papadantonakis. Activated: 8/17/20.

Developing Leukemia Studies

S2504, "A Randomized Phase II Study of Pirtobrutinib Plus R-CHOP vs. R-CHOP for Patients with Previously Untreated Richter Transformation (RT)." Drs. M. Shadman, D. Stephens, and A. Danilov.

Open Cancer Care Delivery Study

S1912CD, "A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)." Dr. Shankaran. Activated 7/26/2021.

Lymphoma Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	S1608	S1918	S2114	S2207	S2308	A051701	A051902
Banner University Medical Center - Tucson	2	-	-	-	-	-	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	1	2	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	3	-	-	-	8	-
Cancer Research Consortium of West Michigan NCORP	3	-	5	-	-	-	-
Cancer Research for the Ozarks NCORP	1	1	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	1	2	-	3	-	-	-
Cedars-Sinai Medical Center	-	1	-	4	-	-	-
City of Hope Comprehensive Cancer Center	8	10	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	6	5	1	-	-	1
Columbus NCI Community Oncology Research Program	1	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	-	-	7
Froedtert and the Medical College of Wisconsin LAPS	-	-	3	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	2	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	2	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	1	-	-	-	-	-
Heartland Cancer Research NCORP	1	-	-	-	-	-	-
Henry Ford Hospital	-	-	-	-	-	2	-
Kaiser Permanente NCI Community Oncology Research Program	3	3	-	-	-	-	-
Loyola University Medical Center	-	-	2	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	2	3	19	-	-	3	-
Michigan Cancer Research Consortium NCORP	1	8	-	1	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	1	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	1	-
Northwestern University LAPS	1	-	-	-	-	-	-
Oregon Health and Science University	-	-	2	-	-	2	-
Pacific Cancer Research Consortium NCORP	-	-	6	1	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-	-	-	4	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	7	-	-	-	-	-
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-
University of Alabama at Birmingham/Deep South Research Consortium LAPS	-	-	-	-	-	3	-
University of Arkansas for Medical Sciences	-	-	5	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	-	1
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	1	-	3	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	1	-	-	-	-
University of Rochester LAPS	16	-	7	7	1	11	3
University of Texas Health Science Center at San Antonio	-	-	9	1	4	-	-
University of Texas MD Anderson Cancer Center LAPS	3	-	-	-	1	-	-
University of Utah - Huntsman Cancer Institute LAPS	1	11	-	-	-	-	-
Upstate Carolina Consortium Community Oncology Research Program	1	1	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	1	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	1	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	-	-
ALLIANCE	17	37	17	5	5	-	-
ECOG-ACRIN	5	17	7	-	1	-	-
NRG	11	7	5	4	-	-	-
Total	78	124	98	27	15	34	12

Lymphoma Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	A052101	AH02131	ANHL1931	E4412	EA4151
Banner University Medical Center - Tucson	-	-	-	-	1
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	23
Cancer Research Consortium of West Michigan NCORP	-	1	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-	-	-
Cedars-Sinai Medical Center	-	3	1	-	-
City of Hope Comprehensive Cancer Center	-	9	11	-	18
Columbia University Minority Underserved NCORP	-	1	3	1	-
Columbus NCI Community Oncology Research Program	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	15
Froedtert and the Medical College of Wisconsin LAPS	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-
Henry Ford Hospital	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	3	-	11	-
Loyola University Medical Center	-	-	-	-	5
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	2
Michigan Cancer Research Consortium NCORP	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	1	-	2
Nevada Cancer Research Foundation NCORP	-	-	-	1	-
Northwell Health NCORP	-	-	-	-	-
Northwestern University LAPS	-	-	1	-	-
Oregon Health and Science University	-	3	-	-	7
Pacific Cancer Research Consortium NCORP	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	2	-	-
UC San Diego Moores Cancer Center	-	-	-	-	1
University of Alabama at Birmingham/Deep South Research Consortium LAPS	-	-	-	7	5
University of Arkansas for Medical Sciences	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	2
University of Kansas Cancer Center - MCA Rural MU NCORP	2	-	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	3
University of Oklahoma Health Sciences Center LAPS	-	-	-	-	-
University of Rochester LAPS	11	7	10	-	11
University of Texas Health Science Center at San Antonio	-	1	-	-	14
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	4	-	-	20
Upstate Carolina Consortium Community Oncology Research Program	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	1
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	1	-	-	-	5
ALLIANCE	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-
NRG	-	-	-	-	-
Total	14	32	29	20	135

Melanoma Committee

Leadership

Chair: Sapna P. Patel, MD
 Vice-Chair: Roger S. Lo, MD, PhD
 Executive Officer: Christopher W. Ryan, MD
 Statisticians: Michael Wu, PhD
 James Moon, MS
 Allison Hayes, BS

Scientific Leadership

Translational Medicine: William E. Carson, III, MD
 Radiation Oncology: TBD
 Surgery: John Robert Hyngstrom, MD
 Dermatology: TBD
 Imaging: TBD
 Medical Oncology: TBD
 Pathology: TBD
 Non-Melanoma Skin Cancer: Nikhil I. Khushalani, MD
 Early Therapeutics: TBD
 SWOG's ECOG Liaisons: Thach-Giao Truong, MD
 ECOG's SWOG Liaisons: David H. Lawson, MD
 Michael Lowe, MD
 Digital Engagement: Zeynep Eroglu, MD

Designates

Prevention: Sancy Leachman, MD, PhD
 Data Coordinator: Cassie Villasin, BA
 Michele Counts, BS, CCRP
 Tonya Johnson, BA
 Oncology Research Professionals:
 CRA: Kathryn Allen, BA, CCRP
 Nurse: TBD
 Patient Advocate: TBD
 Pharmaceutical Science: Sun "Coco" Yang, PharmD, PhD
 Kimberly McConnell, PharmD
 Protocol Project Manager: Catrina De Los Santos-Mireles
 Clinical Trials Program Manager: Laura Gildner, MS

Time/Location

Saturday, May 3, 2025 12:30 p.m. - 2:30 p.m.
 Room: Grand Ballroom B (Street Level)

Keynote Speaker

The Sex-Specific Shield: Chromosomes, Hormones, and CD8 T Cell Immunity in Cancer - Zihai Li, MD, PhD, Klotz Memorial Chair in Cancer Research, Professor and Founding Director, Pelotonia Institute for Immuno-Oncology, Deputy Director for Translational Research, The Ohio State University Comprehensive Cancer Center

Presentations

Artificial intelligence-powered pathology biomarkers for prognosis and prediction of treatment response in stage III and IV cutaneous melanoma, Anirudh Joshi, Valar Labs

Hope Foundation Impact Award Grant Update, Roi Weiser, MD, Assistant Professor, Department of Surgical Oncology, MD Anderson Cancer Center

Active Studies

S2015, "Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma." Dr. Mammen. Activated: 04/08/22.

CTSU/EA6141, "Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma." SWOG Champion: Dr. K. Kim. Activated: 09/10/2015.

CTSU/EA6192, "The BMM2 (BRAF, Autophagy, MEK Inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib with or Without Hydroxychloroquine in Advanced BRAF V600E/K Melanoma with Elevated LDH". SWOG Champion: Dr. Truong. Activated: 10/23/2020.

A091903, A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal Melanoma. SWOG Champion: K. Tsai, MD (SWOG) Activated 06/01/2022. Temporarily Closed to Accrual as of 10/10/2023

Studies in Development

S2431, "Randomized, open-label, phase III study of anti-PD-1, anti-CTLA-4, and anti-LAG-3 antibodies in patients with previously untreated unresectable or metastatic melanoma". Dr. Chandra

Melanoma Committee

Closed Studies

CTSU/EA6174, "STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab, a Phase III Trial." SWOG Champion: Dr. Hsu. Activated: 10/01/2018. Closed to Accrual as of 07/01/2024.

S2000, "A Randomized Phase II Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases." Dr. Eroglu. Activated: 09/23/2020. Closed: 6/18/2024

S1801, "A Phase II Randomized Study of Adjuvant Versus Neoadjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High Risk Melanoma." Dr. Patel. Activated: 12/06/18. Closed: 05/05/2022.

S1512, "A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM)." Drs. Kendra and Hu-Lieskovan. Activated: 10/20/16. Closed: 06/04/2021.

S1607, "A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (Pembrolizumab) in Patients with Advanced Melanoma who have Progressed on Anti-PD1/L1 Based Therapy." Dr. Hu-Lieskovan. Activated: 10/02/17. Closed: 11/1/20.

S1616, "A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent." Dr. VanderWalde. Activated: 07/17/2017. Closed: 07/15/2020.

S1404, "A Phase III Randomized Study of MK3475 versus High-Dose Interferon a-2b for Resected High-Risk Melanoma." Dr. Patel. Activated: 10/15/2015. Closed: 11/02/2017.

CTSU/EA6134, "DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial." SWOG Champion: Dr. Chmielowski. Activated: 7/13/15. Closed: 9/30/2021.

CTSU/EA6183, A Phase II Neoadjuvant Study of Encorafenib with Binimetinib in Patients with Resectable Locoregional Metastases from Cutaneous or Unknown Primary Melanoma (Stages III N1B/C/D). SWOG Champion: C. D. Lao, MD, MPH Activated: 02/18/2020. Closed: 09/23/2022.

Melanoma Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	S2000	S2015	A091903	EA6141	EA6174	EA6192	EA6194
Banner MD Anderson Cancer Center	-	25	-	-	-	-	-
Banner University Medical Center - Tucson	-	-	-	-	3	-	1
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	16	-	-
Cancer Research Consortium of West Michigan NCORP	-	90	-	-	-	-	-
Cancer Research for the Ozarks NCORP	1	-	-	1	-	-	-
Carle Cancer Center NCI Comm Oncology Research Program	1	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	23	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	3	-	-	-
Columbia University Minority Underserved NCORP	-	6	-	-	-	-	-
Dayton NCI Comm Oncology Research Program	1	-	-	2	-	-	-
Duke University - Duke Cancer Institute LAPS	-	10	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	1	-	-
Froedtert & the Medical College of Wisconsin LAPS	-	10	-	-	-	-	-
Georgia NCI Comm Oncology Research Program	-	10	-	-	-	-	-
Intermountain Medical Center	-	30	-	-	-	-	-
Kaiser Permanente NCI Comm Oncology Research Program	-	3	-	29	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	15	-	-	-	-	-
Moffitt Cancer Center	20	51	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	1	-	-
New Mexico Minority Underserved NCORP	-	3	-	-	-	-	-
Northwell Health NCORP	-	7	-	-	-	-	-
Northwestern University LAPS	-	33	-	1	1	5	-
Ohio State University Comprehensive Cancer Center LAPS	3	31	-	-	3	3	-
Saint Joseph Hospital - Cancer Centers of Colorado	-	-	-	-	1	-	-
Sutter Cancer Research Consortium	-	-	-	7	1	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	13	-	4	8	-	3
UPMC Hillman Cancer Center LAPS	1	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	2	1	-	3	-	-
University of Arkansas for Medical Sciences	-	6	-	-	-	1	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	2	4	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	45	-	2	1	-	-
University of Kentucky/Markey Cancer Center	-	7	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	2	17	-	-	-	-	-
University of Nebraska Medical Center	-	2	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	1	-	-	-	-	-
University of Rochester LAPS	-	6	-	8	1	-	-
University of Texas Health Science Center at San Antonio	-	3	-	1	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	18	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	28	-	-	8	-	-
Western States Cancer Research NCORP	-	-	-	1	-	-	-
Wisconsin NCI Comm Oncology Research Program	-	13	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	23	-	8	1	-	-
ALLIANCE	1	89	-	-	-	-	-
ECOG-ACRIN	6	188	-	-	-	-	-
NRG	1	83	-	-	-	-	-
Total	37	891	1	69	53	9	4

Radiation Oncology Committee

Leadership

Chair: Chul Ha, MD
 Vice-Chair: Lisa Kachnic, MD
 Executive Officer: Lisa Kachnic, MD
 Statisticians: Sam Callis, MS

Designates

Breast Committee Liaison: Reshma Jagsi, MD, DPhil
 BMT Committee Liaison: Austin Sim, MD
 Cancer Care Delivery Committee Liaison: Eileen Connolly, MD
 Prevention, Screening, & Surveillance
 Committee Liaison: Eileen Connolly, MD
 CNS Working Group Liaison: Tony Wang, MD
 Genitourinary Committee Liaison: James Yu, MD
 Gastrointestinal Committee Liaison: David Horowitz, MD
 Immunotherapeutics Committee Liaison: Robert Samstein, MD, PhD
 Lung Committee Liaison: Henry Park, MD
 Lymphoma Committee Liaison: Nick Figura, MD
 Melanoma Committee Liaison: Evan Wuthrick, MD
 Myeloma Committee Liaison: Chelsea Pinnix, MD, PhD
 Sarcoma Working Group Liaison: Jeremy Harris, MD
 Symptom Management & Survivorship
 Committee liaison: Erin Gillespie, MD, MPH
 Theranostics Subcommittee Chair: Jeffrey Wong, MD
 Theranostics Subcommittee Vice-Chair: Jeremie Calais, MD, PhD
 Theranostics Subcommittee Vice-Chair: Tanya Dorff, MD
 Data Coordinator: Larry Kaye

Time/Location

Thursday, May 1, 2025 3:00 p.m. - 5:00 p.m.
 Room: Seacliff CD (Bay Level)

3:32 - 3:47 pm	Phase II trial of response-adapted neoadjuvant therapy vs. total neoadjuvant therapy for locally advanced rectal cancer. - David Horowitz, MD
3:47 - 4:02 pm	CD8 T cell PET imaging before and after radiotherapy - Savita Dandapani, MD, PhD
4:02 - 4:17 pm	FES PET in breast cancer - Joanne Mortimer, MD
4:17 - 4:32 pm	Phase II randomized study of comparing total marrow and lymphoid irradiation (TMLI) with fractionated total body irradiation (FTBI) as conditioning for allogeneic peripheral blood stem cell hematopoietic cell transplantation (PBSC-HCT) in patients with acute lymphoblastic leukemia - Monzr Al Malki, MD and Jeffrey Wong, MD
4:32 - 4:47 pm	Addition of prostate directed external beam radiation to standard of care Lu-177 PSMA-617 therapy in patients with previously unirradiated PSMA avid prostatic disease - Ravi Patel, MD, PhD
4:47 - 4:52 pm	Follow up on: Phase III randomized study testing non-inferiority of short-course ultra-fractionated radiation (UHRT-5) versus standard fractionation (RT-25) for high-risk, resectable soft tissue sarcoma (S2505) - Jeremy Harris, MD
4:52 - 4:57 pm	Follow up on: Phase II study of Atezolizumab and Tocilizumab with radiotherapy in patients with newly diagnosed MGMT unmethylated GBM - Tony Wang, MD
4:57 - 5:00 pm	Closing Remarks - Chul S. Ha, MD

Agenda

3:00- 3:02 pm	Welcome - Chul S. Ha, MD
3:02 - 3:07 pm	Report from Executive Officer - Lisa Kachnic, MD
3:07 - 3:12pm	Update from IROC - Koren Smith, MS, MBA
3:12 - 3:17 pm	Update from NCI - Jacek Capala, Ph.D., DSc
3:17 - 3:32 pm	Early salvage vs. deferred image-guided salvage radiation therapy for recurrent prostate cancer post-prostatectomy in the PSMA-PET era - Martin Ma, MD, PhD

Publication List by Committee

The publications listed below were received by the Group Chair's Office as published (including online), accepted, or submitted since the SWOG Fall 2024 Group Meeting. Conference abstracts are not included.

Because of journal embargo policies, journal names are omitted for submitted or accepted manuscripts

ADOLESCENT AND YOUNG ADULT (AYA) COMMITTEE

Published/Accepted Manuscripts

None this cycle

Submitted Manuscripts

None this cycle

BARLOGIE-SALMON MYELOMA COMMITTEE

Published/Accepted Manuscripts

S0777/S1211 Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis.

Banerjee R, Sexton R, Cowan A, Rosenberg A, Ailawadhi S, Rajkumar V, Kumar S, Lonial S, Durie B, Richardson P, Usmani S, Hoering A, Orlowski R. Blood. Jan 2;145(1):75-84, 2025.

<https://pubmed.ncbi.nlm.nih.gov/39321347/>

Submitted Manuscripts

S1702 Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial. Parker T, Rosenthal A, Sancherawala V, Landau H, Campagnaro E, Kapoor P, Neparidze N, Girnius S, Hagen P, Scott E, Hoering A, Durie B, Orlowski R. (SWOG S1702). Submitted.

BREAST COMMITTEE

Published/Accepted Manuscripts

S0307/Other Augmenting Insufficiently Accruing Oncology Clinical Trials Using Generative Models: Validation Study. El Kababji S, Mitsakakis N, Jonker E, Beltran-Bless AA, Pond G, Vandermeer L, Radhakrishnan D, Mosquera L, Paterson A, Shepherd L, Chen B, Barlow W, Gralow J, Savard MF, Fesl C, Hlauschek D, Balic M, Rinnerthaler G, Greil R, Gnatt M, Clemons M, El Emam K. J Med Internet Res. Mar 5;27:e66821, 2025

<https://pubmed.ncbi.nlm.nih.gov/40053790/>

S1007 Race and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Positive BC in the Phase III RxPONDER Trial (SWOG S1007). Abdou Y, Barlow W, Gralow J, Meric-Bernstam F, Albain K, Hayes D, Lin N, Perez E, Goldstein L, Chia S, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Schott A, Shak S, Sharma P, Lew D, Miao J, Unger J, Tripathy D, Puztai L, Hortobagyi G, Kalinsky K. J Natl Cancer Inst Dec 5:Online ahead of print. <https://pubmed.ncbi.nlm.nih.gov/39656951/>

S1007/S8814 Development and validation of the RSclinN+ tool that integrates the 21-gene recurrence score and clinical variables to predict prognosis and chemotherapy benefit for hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive breast cancer. Puztai L, Hoag J, Albain K, Barlow W, Stemmer S, Meisner A, Hortobagyi G, Shak S, Rae J, Baehner R, Sharma P, Kalinsky K. J Clin Oncol. Mar 10;43(8):919-928, 2025. <https://pubmed.ncbi.nlm.nih.gov/39621968/>

C40603 Prognostic and molecular multi-platform analysis of CALGB 40603 (Alliance) and public triple-negative breast cancer datasets. Felsheim B, Fernandez Martinez A, Fan C, Pfefferle A, Hayward M, Hoadley K, Somlo G, Carey L, Sikov W, Perou C. NPJ Breast Cancer Mar 8;11(1):24, 2025. <https://pubmed.ncbi.nlm.nih.gov/40057511/>

Submitted Manuscripts

None this cycle

CANCER CONTROL AND PREVENTION

CANCER CARE DELIVERY COMMITTEE

Published/Accepted Manuscripts

S1415CD/Other Intraclass Correlation Coefficients from Cluster Randomized Trials Conducted within the NCI Community Oncology Research Program (NCORP). Snavey A, Gunn H, Lee J-W, Pugh S, Barlow W, Culakova E, Arnold K, Kittel C, Smith S, Hanlon B, Tan A, Dockter T, Zahrieh D, Dressler E. JNCI Monographs Mar 1;2025(68):65-72. 2025. <https://pubmed.ncbi.nlm.nih.gov/39989039/>

Multiple Studies Smoking prevalence and association with sociodemographic variables in cancer clinical trial participants. Presant C, Vaidya R, Till C, Ashing K, Warren G, Hershtman D, Sun V, Salgia R, Massarelli E, Mortimer J, Idos G, Pal S, Dorff T, Amini A, Erhunmwunsee L, Phillips T, Johnson A, Adesunloye B, Bedell F, Tergas A, Amanam I, Rosen S, Unger J. Cancer Jan 1;131(1):e35560, 2025. <https://pubmed.ncbi.nlm.nih.gov/39283236/>

Multiple Studies When to Adjust for Multiplicity in Cancer Clinical Trials. Unger J, Mazza G, Elsaid M, Duan F, Dressler E, Snavey A, Enserro D, Pugh S. JNCI Monographs, Mar 1;2025(68):3-9, 2025. <https://pubmed.ncbi.nlm.nih.gov/39989044/>

Multiple Studies Best practices and pragmatic approaches for PRO/QOL measures in cancer clinical trials. Bandos H, Torres-Saavedra P, Culacova

Publication List by Committee

E, Gunn H, Lee M, Duan F, Cecchini R, Unger J, Dueck A, Steingrimsson. JNCI Monographs, Mar 1;2025(68):14-21, 2025.

<https://pubmed.ncbi.nlm.nih.gov/39989038/>

Multiple Studies* Neighborhood Socioeconomic Deprivation and Patient-Reported Outcomes in Symptom Management Trials for Breast Cancer Patients. Vaidya R, Till C, Henry NL, Fisch M, Hershman D, Unger J. Breast Cancer Res Treat Feb;209(3):603-611, 2025. [*S0927,S1200,S1202]<https://pubmed.ncbi.nlm.nih.gov/39560823/>

Multiple Studies Practical design considerations for cluster randomized controlled trials: lessons learned in community oncology research. Dressler E, Pugh S, Unger J, Gunn H, Zahrieh D, Snaveley A. JNCI Monographs, Mar 1;2025(68):56-64, 2025. <https://pubmed.ncbi.nlm.nih.gov/39989035/>

Multiple Studies Health Care Contact Days for Older Adults Enrolled in Cancer Clinical Trials. Gupta A, Till C, Vaidya R, Hershman DL, Unger JM. JAMA Netw Open. Mar 3;8(3):e250778, 2025. <https://pubmed.ncbi.nlm.nih.gov/40080017/>

Multiple Studies Design and Analysis Considerations for Investigating Patient Subgroups of Interest Within Cancer Clinical Trials. Mazza G, Culacova E, Enserro D, Dignam J, Unger J. JNCI Monographs Mar 1;2025(68):22-29, 2025. <https://pubmed.ncbi.nlm.nih.gov/39989043/>

Submitted Manuscripts

None this cycle

PALLIATIVE CARE COMMITTEE

Published/Accepted Manuscripts

S1316 Intake and Nutritional Adequacy in Cancer Patients Diagnosed with Malignant Bowel Obstruction: A secondary analysis of a randomized trial. Thomson CA, Arnold KB, Anderson G, Sun V, Secord A, Yung A, Al-Kaspoles M, Nfonsam V, Grant M, Deutsch G, Deneve J, Krouse R. J Acad Nutr Diet Nov 26;S2212-2672(24)00988-2, 2024. <https://pubmed.ncbi.nlm.nih.gov/39603592/>

Submitted Manuscripts

S1316 Optimizing Palliative Cancer Surgery Trial Completion: Lessons Learned from S1316 –Comparative Effectiveness Trial for Malignant Bowel Obstruction. Farooq F, Amini N, Sun V, Deutsch G, Deneve J, Grant M, Arnold K, Alvarez Secord A, Krouse R. Submitted.

PREVENTION, SCREENING, AND SUREILLANCE COMMITTEE

Published/Accepted Manuscripts

S9217/S0000 Long-term side effects and complications after prostate cancer treatment.Unger J, Till C, Tangen C, Hershman D, Goodman P, Leblanc M, Barlow W, Vaidya R, Minasian L, Parnes H, Thompson IM. JAMA Oncology Nov 7;10(12):1654-1662, 2024. <https://pubmed.ncbi.nlm.nih.gov/39509091/>

Multiple Studies* Stern M, Sanchez Mendez J, Kim A, Obon-Santacana M, Moratalla-Navarro F, Martin V, Moreno V, Lin Y, Bien S, Qu C, Su Y, White E, Harrison T, Huyghe J, Tangen C, Newcomb P, Phipps A, Thomas C, Kawaguchi E, Lewinger J, Morrison J, Conti D, Wang J, Thomas D, Platz E, Visvanathan K, Keku T, Newton C, Um C, Kundaje A, Shcherbina A, Murphy N, Gunter M, Dimou N, Papadimitriou N, Bezieau S, van Duijnhoven F, Mannisto S, Rennert G, Wolk A, Hoffmeister M, Brenner H, Chang-Claude J, Tian Y, LeMarchand L, Cotterchio M, Tsilidis K, Bishop D, Melaku Y, Lynch B, Buchanan D, Ulrich C, Ose J, Peoples A, Pellatt A, Devall M, Campbell P, Albanes D, Weinstein S, Berndt S, Gruber S, Ruiz-Narvaez E, SongM, Joshi A, Drew D, Petrick J, Chan A, Giannakis M, Peters U, Hsu L, Gauderman W. Genome-Wide Gene-Environment Interaction Analyses to Understand the Relationship between Red Meat and Processed Meat Intake and Colorectal Cancer Risk. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION Mar 1;33(3):400-410, 2024. [*S9217,OTHER] <https://pubmed.ncbi.nlm.nih.gov/38112776/>

Submitted Manuscripts

None this cycle

SYMPTOM MANAGEMENT AND SURVIVORSHIP COMMITTEE

Published/Accepted Manuscripts

S2010 Active symptom monitoring for premenopausal women with breast cancer initiating adjuvant endocrine therapy: Protocol for the SWOG S2010 randomized controlled efficacy trial. Henry NL, Unger J, Darke A, Skaar T, Fisch M, Hershman D. Contemp Clin Trials. Dec;147:107712, 2024. <https://pubmed.ncbi.nlm.nih.gov/39395534/>

Multiple Studies* Neighborhood Socioeconomic Deprivation and Patient-Reported Outcomes in Symptom Management Trials for Breast Cancer Patients. Vaidya R, Till C, Henry NL, Fisch M, Hershman D, Unger J. Breast Cancer Res Treat Feb;209(3):603-611, 2025. [*S0927,S1200,S1202] <https://pubmed.ncbi.nlm.nih.gov/39560823/>

Submitted Manuscripts

S1714 A Prospective Observational Cohort Study to Develop a Predictive Model of TaxaneInduced Peripheral Neuropathy in Patients

Publication List by Committee

with Cancer: SWOG S1714. Trivedi M, Unger J, Darke A, Hertz D, Brannagan T, Smith S, Hershman D, Henry NL, Fisch M. Submitted.

DIGITAL ENGAGEMENT COMMITTEE

Published/Accepted Manuscripts

None this cycle

Submitted Manuscripts

None this cycle

EARLY THERAPEUTICS AND RARE CANCERS COMMITTEE

Published/Accepted Manuscripts

S1609 A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: The Desmoid Tumors. Chae Y, Othus M, Patel S, Powers B, Hsueh C, Govindarajan R, Bucur S, Kim H, Il-Young Chung L, McLeod C, Chen H, Sharon E, Streicher H, Ryan C, Blanke CD, Kurzrock R. J Immunother Cancer Sep 28;12(9):e009128, 2024. <https://pubmed.ncbi.nlm.nih.gov/39343510/>

S1609 A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors SWOG S1609: Vulvar Cancers. Chae YK, Corthell L, Patel SP, Edwards R, Scalici JM, Kim HS, Chung LI, Othus M, McLeod CM, Chen HX, Sharon E, Streicher H, Ryan CW, Blanke CD, Kurzrock R. Clin Cancer Res. Jan 17;31(2):308-315, 2025. <https://pubmed.ncbi.nlm.nih.gov/39561273/>

S1609 Phase II Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG/NCI Experience: Invasive Mucinous or Non-mucinous Lepidic Adenocarcinoma of the Lung (Formerly Bronchioloalveolar Carcinoma). Chae Y, Othus M, Patel S, Gerber D, Tanvetyanon T, Il-Young Chung L, Kim H, McLeod C, Lopez G, Chen H, Sharon E, Streicher H, Ryan C, Blanke C, Kurzrock R. Ther Adv Med Oncol. Nov 22;16:17588359241293401, 2024. <https://pubmed.ncbi.nlm.nih.gov/39583952/>

S1609 SWOG/NCI S1609 Phase II Basket Trial Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART): Non-Epithelial Ovarian Cancer. Chae Y, Othus M, Patel S, Wilkinson K, Whitman-Purves E, Lea J, Schallenkamp J, Adra N, Appleman L, Alden M, Thomes Pepin J, Ellerton J, Poklepovic A, Walter A, Rampurwala M, Robinson W, Il-Young Chung L, Kim H, McLeod C, Lopez G, Chen H, Sharon E, Streicher H, Ryan C, Blanke C, Kurzrock R. Clin Cancer Res. Dec 16;30(24):5593-5600, 2024. <https://pubmed.ncbi.nlm.nih.gov/39417692/>

S1609 First Cycle Toxicity and Survival in Patients with Rare Cancers Treated with Checkpoint Inhibitors Othus M, Patel S, Chae YK, Deitrich E,

Streicher H, Sharon E, Kurzrock R. J Natl Cancer Inst. 2024 Nov 20:djae297. <https://pubmed.ncbi.nlm.nih.gov/39565908/>

S1609 Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma. Patel SP, Cano-Linson E, Chae YK, Schokrpur S, Lao CD, Powers BC, Victor AI, Onitilo AA, Shin S, Takebe N, Threlkel S, McLeod CM, Chen HX, Sharon E, Othus M, Ryan CW, Blanke CD, Kurzrock R. NPJ Precis Oncol. 2025 Jan 24;9(1):24. <https://pubmed.ncbi.nlm.nih.gov/39856213/>

S1609 A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort. Chae YK, Othus M, Patel SP, Aljumaily R, Win K, Pejovic T, Thomas S, Robinson W, Kim H, Chung L, McLeod C, Chen H, Sharon E, Streicher H, Ryan C, Blanke C, Kurzrock R. Accepted.

Submitted Manuscripts

S1609 A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: The Salivary Gland Tumor Cohort. Chae Y, Sun R, Patel S, Giles F, Ohr J, Worden F, Suga J, Naing A, Cohen E, Wallace J, Fenton S, Il-Young Chung L, Kang H, McLeod C, Chen H, Sharon E, Streicher H, Ryan C, Othus M, Blanke CD, Kurzrock R. Submitted.

S1609 DART/SWOG/NCI Phase II Anti-CTLA-4/PD-1 Trial: Clear Cell Carcinomas of Ovary, Endometrium, Cervix. Chae Y, Othus M, Patel S, Backes F, O'Malley D, Cristea M, Naing A, Kurnit K, Eskander R, Goodrich S, Robinson W, Kim H, Il-Young Chung L, McLeod C, Chen H, Sharon E, Streicher H, Ryan C, Blanke CD, Kurzrock R. Submitted.

GASTROINTESTINAL COMMITTEE

Published/Accepted Manuscripts

S1505 Chemotherapy Dose Density is Prognostic for Overall Survival in Patients with Resectable Pancreas Cancer: A Landmark Analysis of SWOG 1505. Patel S, Colby S, Sohal D, Guthrie K, Kachnic L, Chiorean EG, Lowy A, Rocha F, Hochster H, Philip P, Ahmad S. Cancer Feb 15;131(4):e35759, 2025. <https://pubmed.ncbi.nlm.nih.gov/39932777/>

S1613 Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patient with RAS/BRAF wild-type, HER2-positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase 2 Trial. Raghav K, Guthrie K, Tan B, Denlinger C, Fakih M, Overman M, Dasari NA, Corum L, Hicks L, Patel M, Esparaz B, Kazmi S, Alluri N, Colby S, Gholami S, Gold P, Chiorean EG, Kopetz ES, Hochster H, Philip PA. Journal of Clinical Oncology Jan 6;JCO2401710. doi: 10.1200/JCO-24-01710. Online ahead of print, 2025. <https://pubmed.ncbi.nlm.nih.gov/39761503/>

Publication List by Committee

S1815 SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers (SWOG S1815; NCT#03768414). Shroff R, King G, Colby S, Scott A, Borad M, Matin K, Mahipal A, Kalyan A, Javle M, El Dika I, Tan B, Cheema P, Patel A, Iyer R, Kelley R, Thumar J, El-Khoueiry A, Guthrie K, Chiorean EG, Hochster H, Philip P. Journal of Clinical Oncology J Clin Oncol. Feb 10;43(5):536-544, 2025. <https://pubmed.ncbi.nlm.nih.gov/39671534/>

A021602 Phase 3 Trial of Cabozantinib in Previously Treated Advanced Neuroendocrine Tumors. Chan J, Geyer S, Zemla T, Knopp M, Behr S, Pulsipher S, Lou F, Acoba J, Shergill A, Wolin E, Halfdanarson T, Konda B, Trikalinos N, Shaheen S, Vijayvergia N, Dasari A, Strosberg J, Kohn E, Kulke M, O'Reilly E, Meyerhardt J. New England Journal of Medicine Feb 13;392(7):653-665, 2025. <https://pubmed.ncbi.nlm.nih.gov/39282913/>

C80405 Plant-Based Diet and Survival Among Patients with Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance). Cheng E, Ou F, Gatten C, Ma C, Venook A, Lenz H, O'Reilly E, Campbell P, Kuang C, Caan B, Blanke C, Ng K, Meyerhardt J. J Natl Cancer Inst. Jan 1;117(1):169-179, 2025. <https://pubmed.ncbi.nlm.nih.gov/39212617/>

C80405 Gene signatures derived from transcriptomic-causal networks stratify colorectal cancer patients for effective targeted therapy. Yazdani A, Lenz H, Pilonetto G, Mendez-Giraldez R, Yazdani A, Sanoff H, Hadi R, Samiei E, Venook A, Ratain M, Vincent R, Qu B, Wen Y, Kosorok M, Symmans W, Shen J, Lee M, Kopetz S, Nixon A, Bertagnolli M, Perou C, Innocenti F. Commun Med (Lond) Jan 8;5(1):9, 2025. <https://pubmed.ncbi.nlm.nih.gov/39779996/>

C80702 The association of physical activity with survival in colon cancer versus a matched general population: Data from Cancer and Leukemia Group B 89803 and 80702 (Alliance). Brown J, Ma C, Shi Q, Zemla T, Couture F, Kuebler P, Kumar P, Tan B, Krishnamurthi S, Goldberg R, Venook A, Blanke CD, O'Reilly E, Shields A, Meyerhardt J. Cancer Mar 1;131(5):e35727, 2025. <https://pubmed.ncbi.nlm.nih.gov/39989023/>

C80702 Inflammation, Physical Activity, and Disease-Free Survival in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance). Brown J, Ma C, Shi Q, Couture F, Kuebler P, Kumar P, Tan B, Krishnamurthi S, Chang V, Goldberg R, O'Reilly E, Shields A, Meyerhardt J. J Natl Cancer Inst. Dec 1;116(12):2032-2039, 2024. <https://pubmed.ncbi.nlm.nih.gov/39180477/>

EA2186 The GIANT trial (ECOG-ACRIN EA2186) methods paper: A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer - defining a

new treatment option for older vulnerable patients. Dotan E, Catalano P, Lenchik L, Boutin R, Yao X, Marques H, Ioffe D, Zhen D, Li D, Wagner L, Simon M, Wong T, O'Dwyer P. J Geriatr Oncol Apr;14(3):101474, 2023. <https://pubmed.ncbi.nlm.nih.gov/36963200/>

Multiple Studies Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group. Rajdev L, King GG, Lieu CH, Cohen SA, Pant S, Uboha NV, Deming D, Malla M, Kasi A, Klute K, Spencer KR, Dasari A, Morris VK, Botta G, Lowy AM, O'Hara MH, Eads J, King D, Shah MA, Hong TS, Parikh A, Klempner SJ, Jabbour SK, Chawla A, Molena D, George TJ, Gibson MK, Allegra C, Goodman K, Eng C, Philip PA. JCO Precis Oncol. Mar;9:e2400489, 2025. <https://pubmed.ncbi.nlm.nih.gov/?term=rajdev+I+2025&sort=date>

Submitted Manuscripts

S2303 S2303: Phase II/III Trial of Paclitaxel + Ramucirumab +/- Nivolumab in Gastric and Esophageal Adenocarcinoma (PARAMUNE). Saeed A, Colby S, Oberstein P, Duda D, Park R, Agarwal R, Figueroa-Moseley C, Vaidya R, Unger J, Guthrie K, Rocha F, Senthil M, Safyan R, Wainberg Z, Iqbal S, Chiorean G, Philip PA. Submitted.

S0809 The Effect of Radiation Modality on Outcomes of Patients Receiving Adjuvant Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma: A Secondary Analysis of SWOG S0809. Horowitz D, Colby S, Gholami S, Guthrie KA, Ben-Josef E, El-Khoueiry A, Blanke CD, Philip P, Chiorean E, Rocha F, Ahmad S, Kachnic L. Submitted/in revision.

N0147 Cetuximab reduces patient quality of life when administered with mFOLFOX6 as adjuvant treatment following complete resection of KRAS wild-type tumors for stage III colorectal cancer (N0147 Alliance). Mahoney MR, Sloan JA, Hubbard JM, Tan AD, Liu H, Goldberg RM, Nair SG, Shields AF, Gill S, Jahagirdar B, Benson A, Sargent DJ, Alberts SR. Submitted.

GENITOURINARY COMMITTEE

Note: All PCPT and SELECT publications are listed under Cancer Control & Prevention Committees

Published/Accepted Manuscripts

S1011 Standard vs. Extended Lymphadenectomy for Muscle Invasive Bladder Cancer. Lerner S, Tangen C, Svatek R, Daneshmand S, Pohar K, Skinner E, Schuckman A, Sagalowsky A, Smith N, Kamat A, Kassouf mW, Plets M, Bangs R, Koppie T, Alva A, La Rosa F, Pal S, Kibel A, Canter D, Thompson I. N Engl J Med Oct 3;391(13):1206-1216, 2024. <https://pubmed.ncbi.nlm.nih.gov/39589370/>

Publication List by Committee

S1216 Circulating tumor cell (CTC) count is prognostic of overall survival in metastatic hormone sensitive prostate cancer (mHSPC). Goldkorn A, Tangen C, Plets M, Bsteh D, Xu T, Pinski J, Ingles S, Triche T, MacVicar G, Vaena D, Crispino A, McConkey D, Lara P, Jr., Hussain M, Quinn D, Dorff T, Thompson I, Jr, Agarwal N. JAMA Network Open Oct 1;7(10):e2437871, 2024. PMID39374015; PMC11581504.
<https://pubmed.ncbi.nlm.nih.gov/39374015/>

S1216 Correlation of body mass index with overall survival in patients with metastatic hormone-sensitive prostate cancer: Analysis of patient-level data from SWOG-1216 study. Swami U, Jo Y, Narang A, Plets M, Chehade C, Gebrael G, Gupta S, Myint Z, Tangen C, Lara P, Thompson I, Hussain M, Dorff T, Lerner S, Agarwal N. Eur Urol Oncol. Nov 8;S2588-9311(24)00241-4, 2024. <https://pubmed.ncbi.nlm.nih.gov/39521639/>

S1314 DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial, Iyer G, Tangen C, Sarfaty M, Regazzi A, Lee I, Fong M, Choi W, Dinney C, Flaig T, Thompson I, Lerner S, McConkey D, Rosenberg J. JCO Precis Oncol. Nov;8:e2400287,2024.
<https://pubmed.ncbi.nlm.nih.gov/39565908/>

S1314 Predicting Clinical Outcomes in the S1314-Coxen Trial Using a Multimodal Deep Learning Model Integrating Histopathology, Cell Types, and Gene Expression. Bai Z, Osman M, Brendel M, Tangen CM, Flaig TW, Thompson I, Plets M, Lucia S, Theodorescu D, Gustafson D, Daneshmand S, Meeks J, Choi W, Dinney C, Elemento O, Lerner SP, McConkey DJ, Faltas BM, Wang F. Accepted.

S1500 Final overall survival analysis of S1500: A randomized, phase II study comparing sunitinib to cabozantinib, crizotinib and savolitinib in advanced papillary renal cell carcinoma. Barata P, Tangen C, Plets M, Thompson I, Narayan V, George D, Heng D, Shuch B, Stein M, Gulati S, Tripathi A, Bjarnason G, Vaishampayan U, Alva A, Zhang T, Cole S, Lara P, Balzer-Haas N, Lerner S, Pal S. Clin Oncol Nov 20;42(33):3911-3916.
<https://pubmed.ncbi.nlm.nih.gov/39255440/>

S1806 Eligibility and endpoints for clinical trials in trimodality therapy for bladder cancer. Singh P, Ballas L, Sonpavde G, Chen R, Bangs R, Bauman B, Nagar H, Delacroix S, Lerner S, Efstathiou J. Bladder Cancer Oct 23;10(3):199-213, 2024. <https://pubmed.ncbi.nlm.nih.gov/39493817/>

Submitted Manuscripts

E3805 Effect of Metformin and Body Mass Index on Quality of Life and Survival in the E3805 CHARTED Trial. Jerrard D, Chen Y, Morgans A, Carducci M, Liu G, Eisenberger M, Wong Y-N, Hahn N, Bryce A, Cooney M, Dreicer R, Vogelzang N, Picus J, Shevrin D, Hussain M, Garcia J, DiPaola R, Sweeney C. Submitted 2024.

IMMUNOTHERAPEUTICS COMMITTEE

Published/Accepted Manuscripts

None this cycle

Submitted Manuscripts

None this cycle

LEUKEMIA COMMITTEE

Published/Accepted Manuscripts

S1203 Probability of remission with reinduction with 7+3 versus high-dose ara-C: Analysis of SWOG Trial S1203. Othus M, Garcia-Manero G, Appelbaum F, Erba H, Estey E, Percival M. Leukemia Mar;39(3):752-754, 2025. <https://pubmed.ncbi.nlm.nih.gov/39870766/>

myeloMATCH Evaluating the impact of stratification on the power and cross-arm balance of randomized Phase 2 clinical trials. Moseley A, LeBlanc M, Freidlin B, Shallis R, Zeidan A, Sallman D, Erba H, Little R, Othus M. Clin Trials Jan 15;17407745241304065, 2025.
<https://pubmed.ncbi.nlm.nih.gov/39815460/>

E1912 Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912. Shanafelt TD, Wang XV, Hanson CA, Paietta E, O'Brien S, Barrientos J, Jelinek DF, Braggio E, Leis JF, Zhang CC, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba H, Stone RM, Litzow M, Tallman M, Kay NE. Blood Adv Jan 14;9(1):224-228, 2025.
<https://pubmed.ncbi.nlm.nih.gov/39163612/>

Submitted Manuscripts

None this cycle

LUNG COMMITTEE

Published/Accepted Manuscripts

S1701 S1701 A randomized phase II trial of carboplatin-paclitaxel with and without ramucirumab in patients with locally advanced, recurrent, or metastatic thymic carcinoma. Tsao A, Hsieh M, Koczywas M, Tu J, Riess J, Tanvetyanon T, Ma B, Zhao Y, Redman M, Edelman M, Gandara D, Gray

Publication List by Committee

J, Kelly K. JTO Clin Res Rep Oct 16;5(12):100738, 2024.

<https://pubmed.ncbi.nlm.nih.gov/39619274/>

S1929 Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer. S1929. Abdel Karim N, Miao J, Reckamp K, Gay C, Byers L, Zhao Y, Redman M, Carrizosa D, Wang W, Petty W, Mehta K, Faller B, Agamah E, Kasbari S, Maliseti R, Kumar A, Schallenkamp J, Alluri K, Gray J, Kelly K. J Thorac Oncol Mar;20(3):383-394, 2025. <https://pubmed.ncbi.nlm.nih.gov/39505259/>

S1400 Lung-MAP Next Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400). Kozono D, Hua X, Wu M, Tolba K, Waqar S, Dragnev K, Cheng H, Hirsch FR, Mack P, Gray JE, Kelly K, Borghaei H, Herbst RS, Gandara DR, Redman M. J Thorac Oncol Dec;19(12):1618-1629, 2024. <https://pubmed.ncbi.nlm.nih.gov/39111731/>

Submitted Manuscripts

S0819 External validation of a novel computed tomography-based prognostic radiomic signature in patients with metastatic non-small cell lung cancer:correlative analysis of SWOG S0819 phase III randomized trial. Dercle L, Gomez D, Zhao B, Hama J, Kelly K, Redman M, Gandara D, Schwartz L, Gray JE. Submitted.

LYMPHOMA COMMITTEE

Published/Accepted Manuscripts

S1826 Nivolumab-AVD or Standard of Care in Advanced Stage Classic Hodgkin Lymphoma. Herrera A, LeBlanc M, Castellino S, Li H Rutherford S, Evens A, Davison K, Punnett A, Parsons S, Ahmed S, Casulo C, Bartlett N, Tuscano J, Mei M, Hess B, Jacobs R, Saeed H, Torka P, Hu B, Moskowitz C, Kaur S, Goyal G, Forlenza C, Doan A, Lambale A, Kumar P, Chowdury S, Brinker B, Sharma N, Singh A, Blum K, Perry A, Kovach A, Hodgson D, Constine L, Kostakoglu Shields L, Prica A, Dillon H, Little R, Shipp M, Crump M, Kahl B, Leonard J, Smith S, Song J, Kelly K, Friedberg JW. New England Journal of Medicine Oct 17;391(15):1379-1389, 2024. <https://pubmed.ncbi.nlm.nih.gov/39413375/>

S1826 Pediatric and Adolescent Hodgkin Lymphoma: Paving the Way for Standards of Care and Shared Decision Making.Kahn J, Mauz-Korholz C, Hernandez T, Milgrom S, Castellino S. ASCO Educational Book, 2024. https://ascopubs.org/doi/10.1200/EDBK_432420

S2308 SWOG 2308: Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma. Ghosh N, Bellasea S, Li H, Olszewski A, Bryan L, Danilov A, Smith S, LeBlanc M,

Friedberg JW. Accepted.

A51101 Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101. Batchelor TT, Giri S, Ruppert AS, Geyer SM, Smith SE, Mohile N, Swinnen LJ, Friedberg JW, Kahl BS, Bartlett NL, Hsi ED, Cheson BD, Wagner-Johnston N, Nayak L, Leonard JP, Rubenstein JL.Blood Adv Jun 25;8(12):3189-3199, 2024. <https://pubmed.ncbi.nlm.nih.gov/38598710/>

Multiple Studies Radiation target nomenclature for lymphoma trials: consensus recommendations from the National Clinical Trials Network groups. Saifi O, Pinnix C, Ballas L, Kelsey C, Milgrom S, Terezakis S, Figura N, Parikh R, Grecula J, lampouri S, Ha C, Lo A, Plastaras J, Hodgson D, Hoppe. Lancet Haematol Dec;11(12):e951-e958, 2024. <https://pubmed.ncbi.nlm.nih.gov/39362223/>

Submitted Manuscripts

S1826 Castellino S, Li H, Herrera A, Punnett A, LeBlanc M, Parsons S, Hodgson D, Keller F, Drachtman R, Lambale A, Forlenza C, Doan A, Rutherford S, Evens A, Little R, Smith M, Hoppe B, Song J, Smith S, Friedberg J, Kelly K. Nivolumab-AVD is superior to Brentuximab Vedotin-AVD with 2-year follow-up of S1826 in Adolescent Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL). Submitted.

S1826 Rutherford S, Li H, Herrera A, LeBlanc M, Ahmed S, Davison K, Parsons S, Unger J, Perry A, Casulo C, Bartlett N, Tuscano J, Hess B, Torka P, Kumar P, Jacobs R, Song J, Castellino S, Kahl B, Leonard J, Smith S, Friedberg J, Evens A. Nivolumab-AVD versus brentuximab vedotin-AVD in older patients with advanced stage classic Hodgkin lymphoma. Submitted.

A051301 Ibrutinib With Autologous Transplant In Relapsed/Refractory Activated B-Cell Type Diffuse Large B-Cell Lymphoma (ABC DLBCL). Andreadis C, Bobek O, His E Fenske T, Stiff P, Hill B, Geyer S, Horwitz M, Khimani F, Little R, Dinner S, Friedberg JW, Kahl B, Perales M, DevineS, Leonard J, Bartlett N. Submitted.

MELANOMA COMMITTEE

Published/Accepted Manuscripts

S0826 Southwest Oncology Group S0826: A phase 2 trial of SCH 727965 (NSC 727135, dinaciclib) in patients with stage IV melanoma. .Lao CD, Moon J, Ma VT, Fruehauf JP, Flaherty LE, Bury MJ, Martin WG, Gross H, Akerley W, Hopkins JO, Patel SP, Sondak VK, Ribas A. Cancer.Jan 1;131(1):e35587, 2025. <https://pubmed.ncbi.nlm.nih.gov/39342463/>

Publication List by Committee

Submitted Manuscripts

S1512 Neoadjuvant PD-1 blockade in patients with surgically resectable desmoplastic 3 melanoma (SWOG S1512 cohort A).. Kendra K, Bellasea S, Eroglu Z, Hu-Lieskovan S, Campbell K, Carson W, Wada D, Plaza J, In G, Ikeguchi A, Hyngstrom J, Brohl A, Bartosz Chmielowski, Nikhil I. Khushalani, Joseph Markowitz, Marcus Monroe, Carlo Contreras, Egmidio Medina, Gonzalez C, Baselga-Carretero I, Garcilazo I, Vega-Crespo A, Chen J, Al-Deen N, Patel S, Grossmann K, Sondak V, Sharon E, Moon J, Wu M, Ribas A. Submitted.

S1512 High response rate with single agent anti-PD-1 therapy in patients with unresectable desmoplastic melanoma (SWOG S1512 cohort B). Kendra K, Bellasea S, Eroglu Z, Hu-Lieskovan S, Campbell K, Carson W, Wada D, Plaza J, Sosman J, In G, Ikeguchi A, Hyngstrom J, Brohl A, Khushalani N, Markowitz J, Negrea G, Kasbari S, Doolittle G, Swami U, Roberts T, Medina E, Baselga-Carretero I, Gonzalez C, Garcilazo I, Vega-Crespo A, JChen J, Al-Deen N, Patel S, Sharon E, Moon J, Wu M, Ribas A. Submitted.

S1801 Endpoint and design considerations for a randomized comparison of neoadjuvant-adjuvant versus adjuvant-only cancer immunotherapy (SWOG S1801). Othus M, Sharon E, Wu M, Sondak V, Ribas A, Patel S. Submitted.

PHARMACEUTICAL SCIENCES COMMITTEE

Published/Accepted Manuscripts

S0221 Pre-treatment Amino Acids and Risk of Paclitaxel-induced Peripheral Neuropathy in SWOGS0221. Chen C, Zirpoli G, Barlow W, Budd GT, Pusztai L, Hortobagyi G, Albain K, Godwin A, Thompson A, Henry NL, Ambrosone C, Stringer K, Hertz D. Cancer Chemotherapy and Pharmacology Nov 20:djae297, 2024.
<https://pubmed.ncbi.nlm.nih.gov/38814343/>

Submitted Manuscripts

None this cycle

